Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Liver Diseases

  Free Subscription


Articles published in Hepatology

Retrieve available abstracts of 811 articles:
HTML format



Single Articles


    July 2022
  1. RYDELL GE, Ringlander J, Larsson SB, Hellstrand K, et al
    Letter to the editor: Alu-PCR design may have compromised detection of integrated core HBV DNA.
    Hepatology. 2022;76:E23.
    PubMed    


  2. DANAN G, Teschke R
    Letter to the editor: Electronic RUCAM: Major pitfalls call for caution and proper validation.
    Hepatology. 2022;76:E27.
    PubMed    


  3. RASCHI E, Caraceni P
    Letter to the editor: RECAM for the diagnosis of DILI-Is it time to incorporate additional pharmacological criteria?
    Hepatology. 2022;76:E25-E26.
    PubMed    


  4. KIVLIGHN S, Schuur E, Gish RG, Cryer D, et al
    Letter to the editor: Beneath the surface of the pandemic: Persons with alcohol-associated liver disease need our attention.
    Hepatology. 2022;76:E7-E8.
    PubMed    


  5. TAO X, Zhao Y, Chen L, Zeng M, et al
    Letter to the editor: Prediction of biochemical nonresolution in patients with chronic drug-induced liver injury: A large multicenter study.
    Hepatology. 2022;76:E13-E14.
    PubMed    


  6. KAPPUS MR, Patel YA, Duarte-Rojo A
    Improving the fitness of the NASH clinical trial: Standardizing the standard-of-care intervention.
    Hepatology. 2022;76:12-14.
    PubMed    


  7. PISCAGLIA F
    Microwave ablation in skilled hands. A treatment opportunity gaining room in the field of single HCC 3-5 cm.
    Hepatology. 2022;76:6-8.
    PubMed    


  8. HAYASHI PH, Lucena MI, Fontana RJ, Bjornsson ES, et al
    A revised electronic version of RUCAM for the diagnosis of DILI.
    Hepatology. 2022;76:18-31.
    PubMed     Abstract available


  9. SERPER M, Parikh ND, Thiele G, Ovchinsky N, et al
    Patient-reported outcomes in HCC: A scoping review by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.
    Hepatology. 2022;76:251-274.
    PubMed     Abstract available


  10. LEWIS JH
    Digitizing DILI: Who can? RUCAM? RECAM?
    Hepatology. 2022;76:3-5.
    PubMed    


  11. KAWAMURA N, Imajo K, Kalutkiewicz KJ, Nagai K, et al
    Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease.
    Hepatology. 2022;76:186-195.
    PubMed     Abstract available


  12. STINE JG, Schreibman IR, Faust AJ, Dahmus J, et al
    NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH.
    Hepatology. 2022;76:172-185.
    PubMed     Abstract available


  13. DEVARAJ E, Perumal E, Subramaniyan R, Mustapha N, et al
    Liver fibrosis: Extracellular vesicles mediated intercellular communication in perisinusoidal space.
    Hepatology. 2022;76:275-285.
    PubMed    


  14. POVERO D, Ahn JC, Arnold J, Udompap P, et al
    Hepatology Highlights.
    Hepatology. 2022;76:1-2.
    PubMed    


    June 2022
  15. ZHAO K, Guo F, Wang J, Zhong Y, et al
    Limited disassembly of cytoplasmic hepatitis B virus nucleocapsids restricts viral infection in murine hepatic cells.
    Hepatology. 2022 Jun 19. doi: 10.1002/hep.32622.
    PubMed     Abstract available


  16. YUAN T, Zhou T, Qian M, Du J, et al
    SDHA/B reduction promotes hepatocellular carcinoma by facilitating the deNEDDylation of cullin1 and stabilizing YAP/TAZ.
    Hepatology. 2022 Jun 17. doi: 10.1002/hep.32621.
    PubMed     Abstract available


  17. JOHN BV, Doshi A, Ferreira RD, Taddei TH, et al
    Comparison of Infection-induced and Vaccine-induced Immunity Against Coronavirus 2019 in Patients with Cirrhosis.
    Hepatology. 2022 Jun 16. doi: 10.1002/hep.32619.
    PubMed     Abstract available


  18. LI B, Yu D
    Is the intratumor steatosis a novel biomarker for predicting the efficacy of immunotherapy in hepatocellular carcinoma?
    Hepatology. 2022 Jun 15. doi: 10.1002/hep.32616.
    PubMed    


  19. XU C, Fan J, Liu D, Tuerdi A, et al
    Alpha-kinase 1 (ALPK1) Agonist, DF-006 Demonstrates Potent Efficacy in Murine and Primary Human Hepatocyte Models of Hepatitis B.
    Hepatology. 2022 Jun 14. doi: 10.1002/hep.32614.
    PubMed     Abstract available


  20. LIAO J, Yi Y, Yue X, Wu X, et al
    METTL1 is required for non-homologous end joining repair and renders hepatocellular carcinoma resistant to radiotherapy.
    Hepatology. 2022 Jun 14. doi: 10.1002/hep.32615.
    PubMed     Abstract available


  21. MA X, Chen A, Melo L, Clemente-Sanchez A, et al
    Loss of hepatic DRP1 exacerbates alcoholic hepatitis by inducing megamitochondria and mitochondrial maladaptation.
    Hepatology. 2022 Jun 13. doi: 10.1002/hep.32604.
    PubMed     Abstract available


  22. HOLMAN A, Parikh N, Clauw DJ, Williams DA, et al
    Rethinking the management of pain in cirrhosis: toward precision therapy for pain.
    Hepatology. 2022 Jun 5. doi: 10.1002/hep.32598.
    PubMed     Abstract available


  23. DELTENRE P, Zanetto A, Saltini D, Moreno C, et al
    The role of TIPS in patients with cirrhosis and ascites: recent evolution and open questions.
    Hepatology. 2022 Jun 4. doi: 10.1002/hep.32596.
    PubMed     Abstract available


  24. TESTINO G
    Letter to the editor: Chronic liver disease among adolescents and young adults: Alcohol use disorder identification.
    Hepatology. 2022;75:1662-1663.
    PubMed    


  25. JULIEN J, Ayer T, Tapper EB, Barbosa C, et al
    Effect of increased alcohol consumption during COVID-19 pandemic on alcohol-associated liver disease: A modeling study.
    Hepatology. 2022;75:1480-1490.
    PubMed     Abstract available


  26. SANDAHL TD, Gormsen LC, Kjaergaard K, Vendelbo MH, et al
    The pathophysiology of Wilson's disease visualized: A human (64) Cu PET study.
    Hepatology. 2022;75:1461-1470.
    PubMed     Abstract available


  27. QIAN Q, Li Y, Fu J, Leng D, et al
    Switch-associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1.
    Hepatology. 2022;75:1507-1522.
    PubMed     Abstract available


  28. VILAR-GOMEZ E, Nephew LD, Vuppalanchi R, Gawrieh S, et al
    High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population.
    Hepatology. 2022;75:1491-1506.
    PubMed     Abstract available


  29. PSARAKI A, Ntari L, Karakostas C, Korrou-Karava D, et al
    Extracellular vesicles derived from mesenchymal stem/stromal cells: The regenerative impact in liver diseases.
    Hepatology. 2022;75:1590-1603.
    PubMed     Abstract available


  30. ALVA-RUIZ R, Wu T, Idalsoaga F, Ramkissoon R, et al
    Hepatology highlights.
    Hepatology. 2022;75:1363-1364.
    PubMed    


    May 2022
  31. ZHANG JW, Fang J, Xun Z, Xu Y, et al
    Letter to the Editor: Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in the Real World.
    Hepatology. 2022 May 23. doi: 10.1002/hep.32588.
    PubMed    


  32. KIMURA Y, Koyama Y, Taura K, Kudoh A, et al
    Characterization and role of collagen gene expressing hepatic cells following partial hepatectomy in mice.
    Hepatology. 2022 May 23. doi: 10.1002/hep.32586.
    PubMed     Abstract available


  33. JALAN-SAKRIKAR N, Brevini T, Huebert RC, Sampaziotis F, et al
    Organoids and Regenerative Hepatology.
    Hepatology. 2022 May 21. doi: 10.1002/hep.32583.
    PubMed     Abstract available


  34. LI L, Zhang Y, Zhou Y, Hu H, et al
    Quaternary Nanoparticles Enable Sustained Release of Bortezomib for Hepatocellular Carcinoma.
    Hepatology. 2022 May 21. doi: 10.1002/hep.32584.
    PubMed     Abstract available


  35. XU W, Cui C, Cui C, Chen Z, et al
    Hepatocellular Cystathionine gamma lyase/Hydrogen sulfide Attenuates Non-Alcoholic Fatty Liver Disease by Activating Farnesoid X Receptor.
    Hepatology. 2022 May 19. doi: 10.1002/hep.32577.
    PubMed     Abstract available


  36. PILLING LC, Atkins JL, Melzer D
    Genetic modifiers of penetrance to liver endpoints in HFE hemochromatosis: associations in a large community cohort.
    Hepatology. 2022 May 14. doi: 10.1002/hep.32575.
    PubMed     Abstract available


  37. MURAI H, Kodama T, Maesaka K, Tange S, et al
    Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma.
    Hepatology. 2022 May 14. doi: 10.1002/hep.32573.
    PubMed     Abstract available


  38. BAJAJ JS, Rodriguez MP, Fagan A, McGeorge S, et al
    Impact of Bacterial Infections and SBP Prophylaxis on Phage-Bacterial Dynamics in Cirrhosis.
    Hepatology. 2022 May 13. doi: 10.1002/hep.32571.
    PubMed     Abstract available


  39. KIM KE, Lee J, Shin HJ, Jeong EA, et al
    Lipocalin-2 Activates Hepatic stellate cells and Promotes Non-alcoholic Steatohepatitis in High-Fat Diet-Fed ob/ob mice.
    Hepatology. 2022 May 13. doi: 10.1002/hep.32569.
    PubMed     Abstract available


  40. MEHTA S, Asrani SK
    The computer will see you now: Prediction of long-term survival in patients with cirrhosis.
    Hepatology. 2022 May 5. doi: 10.1002/hep.32559.
    PubMed    


  41. ANDERSEN JB
    Stromal yin-yang of myofibroblasts and endothelial cells in the progression of intrahepatic cholangiocarcinoma.
    Hepatology. 2022 May 3. doi: 10.1002/hep.32558.
    PubMed    


  42. GULATI P, Taneja S, Duseja A, Singh V, et al
    Letter to Editor-Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study- Should we extend the boundaries?
    Hepatology. 2022 May 3. doi: 10.1002/hep.32554.
    PubMed    


  43. LIU JJ, Xin B, Du L, Chen L, et al
    Pharmaceutical Shp2 inhibition suppresses primary and metastasized liver tumors by provoking hepatic innate immunity.
    Hepatology. 2022 May 3. doi: 10.1002/hep.32555.
    PubMed     Abstract available


  44. HILSCHER MB, Wells ML, Venkatesh SK, Cetta F, et al
    Fontan-associated liver disease.
    Hepatology. 2022;75:1300-1321.
    PubMed    


  45. LEE CH, Lui DTW, Lam KSL
    Letter to the editor: Circulating thrombospondin-2 as a biomarker in patients with NAFLD with and without diabetes-Are we convinced yet?
    Hepatology. 2022;75:1340.
    PubMed    


  46. CHUNG HH
    Letter to the editor: The multiple mechanisms of fructose disrupt gut-liver axis and metabolic regulation.
    Hepatology. 2022;75:1338-1339.
    PubMed    


  47. ASRANI SK, Ghabril MS, Kuo A, Merriman RB, et al
    Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.
    Hepatology. 2022;75:1289-1299.
    PubMed     Abstract available


  48. PAIK JM, Kabbara K, Eberly KE, Younossi Y, et al
    Global burden of NAFLD and chronic liver disease among adolescents and young adults.
    Hepatology. 2022;75:1204-1217.
    PubMed     Abstract available


  49. KUREBAYASHI Y, Matsuda K, Ueno A, Tsujikawa H, et al
    Immunovascular classification of HCC reflects reciprocal interaction between immune and angiogenic tumor microenvironments.
    Hepatology. 2022;75:1139-1153.
    PubMed     Abstract available


  50. ZHANG JL, Du BB, Zhang DH, Li H, et al
    OTUB1 alleviates NASH through inhibition of the TRAF6-ASK1 signaling pathways.
    Hepatology. 2022;75:1218-1234.
    PubMed     Abstract available


  51. SONG J, Song H, Wei H, Sun R, et al
    Requirement of RORalpha for maintenance and antitumor immunity of liver-resident natural killer cells/ILC1s.
    Hepatology. 2022;75:1181-1193.
    PubMed     Abstract available


  52. REN QN, Zhang H, Sun CY, Zhou YF, et al
    Phosphorylation of androgen receptor by mTORC1 promotes liver steatosis and tumorigenesis.
    Hepatology. 2022;75:1123-1138.
    PubMed     Abstract available


  53. CONBOY CB, Penrice DD, Watkins R, Diaz LA, et al
    Hepatology highlights.
    Hepatology. 2022;75:1071-1072.
    PubMed    


  54. QIN Y, Li A, Liu B, Gao M, et al
    Comment on "Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD".
    Hepatology. 2022 May 1. doi: 10.1002/hep.32551.
    PubMed    


  55. SANGRO B, Argemi J
    Immunotherapy in hepatocellular carcinoma - No rush despite the hype.
    Hepatology. 2022 May 1. doi: 10.1002/hep.32550.
    PubMed    


    April 2022
  56. SHAH PA, Patil R, Harrison SA
    NAFLD-related hepatocellular carcinoma: The growing challenge.
    Hepatology. 2022 Apr 28. doi: 10.1002/hep.32542.
    PubMed     Abstract available


  57. KUMAR A, Rajani D, Kumar S
    Letter to the editor: HBV genotype: a significant risk factor in determining which patients with chronic HBV infection should undergo surveillance for HCC: The hepatitis B Alaska study.
    Hepatology. 2022 Apr 28. doi: 10.1002/hep.32544.
    PubMed    


  58. YAN T, Luo Y, Yan N, Hamada K, et al
    Intestinal Peroxisome Proliferator-Activated Receptor alpha-Fatty Acid Binding Protein 1 Axis Modulates Nonalcoholic Steatohepatitis.
    Hepatology. 2022 Apr 23. doi: 10.1002/hep.32538.
    PubMed     Abstract available


  59. CHEN L, Dong J, Meng Q, Song Z, et al
    Reply to the comment on "Loss of Sam50 in hepatocytes induces cardiolipin-dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury".
    Hepatology. 2022 Apr 19. doi: 10.1002/hep.32530.
    PubMed    


  60. IVANICS T, Claasen MP, Patel MS, Hansen BE, et al
    Reply to: Letter to the editor: Cautious use of multistate modeling in prognosis analysis of hepatocellular carcinoma.
    Hepatology. 2022 Apr 18. doi: 10.1002/hep.32532.
    PubMed    


  61. JIANG ST, Zhang JW, Lu X, Xu YY, et al
    Letter to the editor: Cautious use of multistate modeling in prognosis analysis of hepatocellular carcinoma.
    Hepatology. 2022 Apr 17. doi: 10.1002/hep.32533.
    PubMed    


  62. RAO Z, Li F, Guan Z, Zhou H, et al
    Comment on "Loss of Sam50 in hepatocytes induces cardiolipin-dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury".
    Hepatology. 2022 Apr 16. doi: 10.1002/hep.32529.
    PubMed    


  63. XU MX, Tan J, Ge CX, Dong W, et al
    TRIM31 confers protection against nonalcoholic steatohepatitis by deactivating MAP3K7.
    Hepatology. 2022 Apr 16. doi: 10.1002/hep.32526.
    PubMed     Abstract available


  64. AHN JC, Lauzon M, Luu M, Noureddin M, et al
    Racial and ethnic disparities in early treatment with immunotherapy for advanced hepatocellular carcinoma in the United States.
    Hepatology. 2022 Apr 16. doi: 10.1002/hep.32527.
    PubMed     Abstract available


  65. TRIPATHI D, Bureau C
    Prophylactic embolization of large spontaneous portosystemic shunts with TIPS: A panacea for post TIPS hepatic encephalopathy?
    Hepatology. 2022 Apr 16. doi: 10.1002/hep.32525.
    PubMed    


  66. ZHU Y, Gu L, Lin X, Zhou X, et al
    P53 deficiency affects cholesterol esterification to exacerbate hepatocarcinogenesis.
    Hepatology. 2022 Apr 10. doi: 10.1002/hep.32518.
    PubMed     Abstract available


  67. DEFFIEU MS, Clement CMH, Dorobantu CM, Partiot E, et al
    Occludin stalls HCV particle dynamics apart from hepatocyte tight junctions, promoting virion internalization.
    Hepatology. 2022 Apr 7. doi: 10.1002/hep.32514.
    PubMed     Abstract available


  68. KHADERI S, Kanwal F
    Changing Epidemiology of Hepatocellular Cancer in the United States: winning the battle but it is not over yet.
    Hepatology. 2022 Apr 7. doi: 10.1002/hep.32512.
    PubMed    


  69. TCHORZ JS
    Re-tuning hepatocytes improves their functional engraftment.
    Hepatology. 2022 Apr 7. doi: 10.1002/hep.32513.
    PubMed    


  70. GOEPPERT B, Roessler S
    New kid on the block: Netrin-1 as a novel player in the delicate molecular network of hepatic inflammation.
    Hepatology. 2022 Apr 6. doi: 10.1002/hep.32509.
    PubMed    


  71. MANDATO C, Vajro P
    Letter to the Editor: The burgeoning field of Progressive Familial Intrahepatic Cholestasis.
    Hepatology. 2022 Apr 5. doi: 10.1002/hep.32489.
    PubMed    


  72. KRAMER JR, Natarajan Y, Dai J, Yu X, et al
    Response to letter to the editor from Zhou et al (Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease).
    Hepatology. 2022 Apr 2. doi: 10.1002/hep.32503.
    PubMed    


  73. ZHOU Y, Chu W, Wu X, Zhou H, et al
    Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease.
    Hepatology. 2022 Apr 2. doi: 10.1002/hep.32504.
    PubMed    


  74. TOMLINSON JL, Ahn JC, Povero D, Ramkissoon R, et al
    Hepatology Highlights.
    Hepatology. 2022;75:775-776.
    PubMed    


  75. AHUJA P, Bi X, Ng CF, Tse MCL, et al
    Src homology 3 domain binding kinase 1 protects against hepatic steatosis and insulin resistance through the Nur77- fibroblast growth factor 21 pathway.
    Hepatology. 2022 Apr 1. doi: 10.1002/hep.32501.
    PubMed     Abstract available


  76. SINGAL AK, Kwo P, Kwong A, Liangpunsakul S, et al
    Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease.
    Hepatology. 2022;75:1026-1037.
    PubMed     Abstract available


  77. SINGH SA, Madan K, Gupta S, Indrayan A, et al
    Letter to the editor: Relevance of population-based cutoffs to define frailty in clinical studies.
    Hepatology. 2022;75:1067-1068.
    PubMed    


  78. WANG S, Whitlock R, Lai JC, Taneja S, et al
    Reply.
    Hepatology. 2022;75:1068-1069.
    PubMed    


  79. JAIN A, Sharma BC
    Reply.
    Hepatology. 2022;75:1066-1067.
    PubMed    


  80. COLASANTI T, Di Giamberardino A, Grimaldi A, Cardinale V, et al
    Letter to the editor: Serum thrombospondin-2 as biomarker in liver diseases, a look beyond NASH.
    Hepatology. 2022;75:1056-1057.
    PubMed    


  81. PAILHORIES H, Boursier J, Diehl AM
    Determinants of the severity of fatty liver diseases: Need all the pieces to solve the puzzle.
    Hepatology. 2022;75:782-784.
    PubMed    


  82. NEIL DAH, Minervini M, Smith ML, Hubscher SG, et al
    Banff consensus recommendations for steatosis assessment in donor livers.
    Hepatology. 2022;75:1014-1025.
    PubMed     Abstract available


  83. KWAN SY, Jiao J, Joon A, Wei P, et al
    Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease.
    Hepatology. 2022;75:955-967.
    PubMed     Abstract available


  84. ZHOU HZ, Li F, Cheng ST, Xu Y, et al
    DDX17-regulated alternative splicing that produced an oncogenic isoform of PXN-AS1 to promote HCC metastasis.
    Hepatology. 2022;75:847-865.
    PubMed     Abstract available


  85. SUBRAMANIAN P, Gargani S, Palladini A, Chatzimike M, et al
    The RNA binding protein human antigen R is a gatekeeper of liver homeostasis.
    Hepatology. 2022;75:881-897.
    PubMed     Abstract available


    March 2022
  86. CULLARO G, Hsu CY, Lai JC
    Variability in Serum Creatinine is Associated with Waitlist and Post-Liver Transplant Mortality in Cirrhosis Patients.
    Hepatology. 2022 Mar 31. doi: 10.1002/hep.32497.
    PubMed     Abstract available


  87. LEE SH, Yim SY, Jeong YS, Li QX, et al
    Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes.
    Hepatology. 2022 Mar 29. doi: 10.1002/hep.32490.
    PubMed     Abstract available


  88. JAVITT NB
    Letter to the Editor: Hyperosmolarity during hepatic bile formation:Overlooked significance.
    Hepatology. 2022 Mar 29. doi: 10.1002/hep.32482.
    PubMed    


  89. CAI HX, Xin C, Wang XP
    ATP7B gene therapy of autologous reprogrammed hepatocytes alleviates copper accumulation in a murine model of Wilson's disease.
    Hepatology. 2022 Mar 27. doi: 10.1002/hep.32484.
    PubMed     Abstract available


  90. WANG T, Xu C, Zhang Z, Wu H, et al
    Cellular heterogeneity and transcriptomic profiles during intrahepatic cholangiocarcinoma initiation and progression.
    Hepatology. 2022 Mar 27. doi: 10.1002/hep.32483.
    PubMed     Abstract available


  91. D'ALESSIO A, Fulgenzi CAM, Nishida N, Schonlein M, et al
    Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study.
    Hepatology. 2022 Mar 21. doi: 10.1002/hep.32468.
    PubMed     Abstract available


  92. CHEN L, Dong J, Liao S, Wang S, et al
    Loss of Sam50 in hepatocytes induces cardiolipin-dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury.
    Hepatology. 2022 Mar 21. doi: 10.1002/hep.32471.
    PubMed     Abstract available


  93. FLEMMING JA, Muaddi H, Djerboua M, Neves P, et al
    Association between social determinants of health and rates of liver transplantation in individuals with cirrhosis.
    Hepatology. 2022 Mar 21. doi: 10.1002/hep.32469.
    PubMed     Abstract available


  94. CREEDEN JF, Kipp ZA, Xu M, Flight RM, et al
    Hepatic Kinome Atlas: An In-Depth Identification of Kinase Pathways in Liver Fibrosis of Humans and Rodents.
    Hepatology. 2022 Mar 21. doi: 10.1002/hep.32467.
    PubMed     Abstract available


  95. HOU J
    Drinking vinegar, a potential adjuvant for immunotherapy of hepatocellular carcinoma?
    Hepatology. 2022 Mar 18. doi: 10.1002/hep.32463.
    PubMed    


  96. GOLDBERG D, Mantero A, Kaplan D, Delgado C, et al
    Accurate Long-Term Prediction of Death for Patients with Cirrhosis.
    Hepatology. 2022 Mar 12. doi: 10.1002/hep.32457.
    PubMed     Abstract available


  97. LV Y, Chen H, Luo B, Bai W, et al
    Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: A randomized controlled trial.
    Hepatology. 2022 Mar 10. doi: 10.1002/hep.32453.
    PubMed     Abstract available


  98. HU C, Xu B, Wang X, Wan WH, et al
    Gut microbiota-derived short-chain fatty acids regulates group 3 innate lymphoid cells in hepatocellular carcinoma.
    Hepatology. 2022 Mar 9. doi: 10.1002/hep.32449.
    PubMed     Abstract available


  99. FOERSTER F, Gairing SJ, Ilyas SI, Galle PR, et al
    Emerging Immunotherapy for Hepatocellular Carcinoma: A Guide for Hepatologists.
    Hepatology. 2022 Mar 7. doi: 10.1002/hep.32447.
    PubMed     Abstract available


  100. BARNAULT R, Verzeroli C, Fournier C, Michelet M, et al
    Hepatic inflammation elicits production of proinflammatory netrin-1 through exclusive activation of translation.
    Hepatology. 2022 Mar 7. doi: 10.1002/hep.32446.
    PubMed     Abstract available


  101. HE Y, Luo J, Zhang G, Jin Y, et al
    Single-cell profiling of human CD127(+) innate lymphoid cells reveals diverse immune phenotypes in hepatocellular carcinoma.
    Hepatology. 2022 Mar 4. doi: 10.1002/hep.32444.
    PubMed     Abstract available


  102. NIE YZ, Zheng YW, Taniguchi H
    Improving the repopulation capacity of elderly human hepatocytes by decoding aging-associated hepatocyte plasticity.
    Hepatology. 2022 Mar 4. doi: 10.1002/hep.32443.
    PubMed     Abstract available


  103. LU Z, Liu R, Wang Y, Jiao M, et al
    TET2 Inactivation Restrains IL-10-producing Regulatory B cells to Enable Anti-tumor Immunity in Hepatocellular Carcinoma.
    Hepatology. 2022 Mar 4. doi: 10.1002/hep.32442.
    PubMed     Abstract available


  104. PLAZ TORRES MC, Jaffe A, Perry R, Marabotto E, et al
    Diabetes Medications and Risk of Hepatocellular Carcinoma.
    Hepatology. 2022 Mar 3. doi: 10.1002/hep.32439.
    PubMed     Abstract available



  105. Hepato Liver Cancer logy highlights.
    Hepatology. 2022;75:503-504.
    PubMed    


  106. HILSCHER MB, Shah VH
    A NET gain in our understanding of acute liver failure.
    Hepatology. 2022;75:511-513.
    PubMed    


  107. LUO MS, Huang GJ
    Letter to the editor: The addition of C-reactive protein and von Willebrand factor to Model for End-Stage Liver Disease-Sodium.
    Hepatology. 2022;75:763-764.
    PubMed    


  108. WU JW, Tseng TC, Kao JH
    Letter to the editor: New kid in the playground: HBcrAg and risk of HCC.
    Hepatology. 2022;75:760-761.
    PubMed    


  109. BEKKI Y, Fenig Y
    Letter to the editor: The impact of donor liver fibrosis on early allograft dysfunction and ischemia-reperfusion injury.
    Hepatology. 2022;75:754.
    PubMed    



  110. Seeking Editor for Clinical Liver Disease.
    Hepatology. 2022;75:i.
    PubMed    


  111. VON MEIJENFELDT FA, Stravitz RT, Zhang J, Adelmeijer J, et al
    Generation of neutrophil extracellular traps in patients with acute liver failure is associated with poor outcome.
    Hepatology. 2022;75:623-633.
    PubMed     Abstract available


  112. GOIKOETXEA-USANDIZAGA N, Serrano-Macia M, Delgado TC, Simon J, et al
    Mitochondrial bioenergetics boost macrophage activation, promoting liver regeneration in metabolically compromised animals.
    Hepatology. 2022;75:550-566.
    PubMed     Abstract available


  113. REN R, He Y, Ding D, Cui A, et al
    Aging exaggerates acute-on-chronic alcohol-induced liver injury in mice and humans by inhibiting neutrophilic sirtuin 1-C/EBPalpha-miRNA-223 axis.
    Hepatology. 2022;75:646-660.
    PubMed     Abstract available


  114. TAMAKI N, Imajo K, Sharpton S, Jung J, et al
    Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis.
    Hepatology. 2022;75:661-672.
    PubMed     Abstract available


  115. WANG C, Zhang L, Sun Z, Yuan X, et al
    Dedifferentiation-associated inflammatory factors of long-term expanded human hepatocytes exacerbate their elimination by macrophages during liver engraftment.
    Hepatology. 2022 Mar 1. doi: 10.1002/hep.32436.
    PubMed     Abstract available


  116. KANWAL F, Khaderi S, Singal AG, Marrero JA, et al
    Risk Factors for Hepatocellular Cancer in Contemporary Cohorts of Patients with Cirrhosis.
    Hepatology. 2022 Mar 1. doi: 10.1002/hep.32434.
    PubMed     Abstract available


  117. IBRAHIM SH, Kamath BM, Loomes KM, Karpen SJ, et al
    Cholestatic Liver Diseases of Genetic Etiology: Advances and Controversies.
    Hepatology. 2022 Mar 1. doi: 10.1002/hep.32437.
    PubMed     Abstract available


    February 2022
  118. SUTHEN SD, Lim CJ, Nguyen PHD, Dutertre CA, et al
    Hypoxia-driven immunosuppression by Treg and type-2 conventional dendritic cells in hepatocellular carcinoma.
    Hepatology. 2022 Feb 20. doi: 10.1002/hep.32419.
    PubMed     Abstract available


  119. FAN L, Pan Q, Yang W, Koo SC, et al
    A Developmentally Prometastatic Niche to Hepatoblastoma in Neonatal Liver mediated by the Cxcl1/Cxcr2 Axis.
    Hepatology. 2022 Feb 18. doi: 10.1002/hep.32412.
    PubMed     Abstract available


  120. IVANICS T, Murillo Perez CF, Claasen MP, Patel MS, et al
    Dynamic risk profiling of hepatocellular carcinoma recurrence after curative intent liver resection.
    Hepatology. 2022 Feb 18. doi: 10.1002/hep.32411.
    PubMed     Abstract available


  121. EFE C, Harputluoglu M, Karadag Soylu N, Yilmaz S, et al
    Liver transplantation following SARS-CoV-2 vaccination-induced liver failure.
    Hepatology. 2022 Feb 17. doi: 10.1002/hep.32409.
    PubMed    


  122. WANG Z, Yu J, Liang P
    Reply to "Treatment options for 3-5 cm solitary hepatocellular carcinoma-Need a closer look!"
    Hepatology. 2022 Feb 9. doi: 10.1002/hep.32402.
    PubMed    


  123. JINDAL A, Mukund A
    Treatment options for 3-5 cm solitary hepatocellular carcinoma-Need a closer look!
    Hepatology. 2022 Feb 9. doi: 10.1002/hep.32401.
    PubMed    


  124. NOUREDDIN M, Abdelmalek MF
    ACE inhibitors: The Secret to Prevent Cirrhosis Complications and Hepatocellular Carcinoma in NAFLD?
    Hepatology. 2022 Feb 6. doi: 10.1002/hep.32399.
    PubMed    


  125. YAKOVCHENKO V, Morgan TR, Miech EJ, Neely B, et al
    Core implementation strategies for improving cirrhosis care in the Veterans Health Administration.
    Hepatology. 2022 Feb 6. doi: 10.1002/hep.32395.
    PubMed     Abstract available


  126. ALVAREZ CS, Petrick JL, Parisi D, McMahon BJ, et al
    Racial/ethnic disparities in hepatocellular carcinoma incidence and mortality rates in the United States, 1992-2018.
    Hepatology. 2022 Feb 5. doi: 10.1002/hep.32394.
    PubMed     Abstract available


  127. JEON Y, Kwon SM, Rhee H, Yoo JE, et al
    Molecular and radio-pathologic spectrum between hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Hepatology. 2022 Feb 5. doi: 10.1002/hep.32397.
    PubMed     Abstract available


  128. ZANETTO A, Campello E, Spiezia L, Burra P, et al
    Letter to the Editor: is PAI-1 a thrombotic biomarker in NASH cirrhosis?
    Hepatology. 2022 Feb 3. doi: 10.1002/hep.32392.
    PubMed    


  129. LEMOINE CP, Superina R
    Letter to the Editor: Is TIPS the best treatment for non-cirrhotic adults with EPHVO and portal hypertension?
    Hepatology. 2022 Feb 2. doi: 10.1002/hep.32386.
    PubMed    


  130. LUO C, Xin H, Zhou Z, Hu Z, et al
    Tumor-Derived Exosomes Induce Immunosuppressive Macrophages to Foster Intrahepatic Cholangiocarcinoma Progression.
    Hepatology. 2022 Feb 2. doi: 10.1002/hep.32387.
    PubMed     Abstract available


  131. LEE V, Wong TC
    Reply to "prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant".
    Hepatology. 2022 Feb 2. doi: 10.1002/hep.32379.
    PubMed    


  132. WATKINS R, Ilyas SI, Penrice DD, Conboy CB, et al
    Hepatology Highlights.
    Hepatology. 2022;75:241-242.
    PubMed    


  133. ROGAL S, Hansen L, Patel A, Ufere NN, et al
    AASLD Practice Guidance: Palliative care and symptom-based management in decompensated cirrhosis.
    Hepatology. 2022 Feb 1. doi: 10.1002/hep.32378.
    PubMed    


  134. KARATAYLI E, Lammert F
    Vulnerability to alcohol-associated liver disease: A tale of two systems.
    Hepatology. 2022;75:246-247.
    PubMed    


  135. HEY P, Gow P
    Letter to the Editor: Rethinking public health measures to reduce liver injury from therapeutic acetaminophen ingestion.
    Hepatology. 2022;75:495-496.
    PubMed    


  136. GIDENER T, Yin M, Dierkhising RA, Allen AM, et al
    Magnetic resonance elastography for prediction of long-term progression and outcome in chronic liver disease: A retrospective study.
    Hepatology. 2022;75:379-390.
    PubMed     Abstract available


  137. VAN KLEEF LA, Ayada I, Alferink LJM, Pan Q, et al
    Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
    Hepatology. 2022;75:419-429.
    PubMed     Abstract available


  138. RAMANI K, Robinson AE, Berlind J, Fan W, et al
    S-adenosylmethionine inhibits la ribonucleoprotein domain family member 1 in murine liver and human liver cancer cells.
    Hepatology. 2022;75:280-296.
    PubMed     Abstract available


  139. LIN T, Wang S, Munker S, Jung K, et al
    Follistatin-controlled activin-HNF4alpha-coagulation factor axis in liver progenitor cells determines outcome of acute liver failure.
    Hepatology. 2022;75:322-337.
    PubMed     Abstract available


  140. KIM KY, Kim JO, Kim YS, Choi JE, et al
    Genome-wide association of individual vulnerability with alcohol-associated liver disease: A Korean genome and epidemiology study.
    Hepatology. 2022;75:391-402.
    PubMed     Abstract available


    January 2022
  141. JIANG SY, Yang X, Yang Z, Li JW, et al
    Discovery of a INSIG binding compound that ameliorates nonalcoholic steatohepatitis by inhibiting SREBP-mediated lipogenesis.
    Hepatology. 2022 Jan 31. doi: 10.1002/hep.32381.
    PubMed     Abstract available


  142. DE A, Keisham A, Duseja A
    Spontaneous regression of cirrhosis: a paradigm shift in our understanding of the natural history of non-alcoholic steatohepatitis (NASH).
    Hepatology. 2022 Jan 31. doi: 10.1002/hep.32374.
    PubMed    


  143. JANG H, Lee YB, Moon H, Chung JW, et al
    Aspirin Use and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B With or Without Cirrhosis.
    Hepatology. 2022 Jan 31. doi: 10.1002/hep.32380.
    PubMed     Abstract available


  144. KUMAR A, Sharma P, Arora A
    Letter to the Editor: In patients with established NASH cirrhosis, is there no role of weight reduction in reversing fibrosis?
    Hepatology. 2022 Jan 29. doi: 10.1002/hep.32375.
    PubMed    


  145. LIU F, Zhang W, Liu H
    Letter to the Editor: Hepatocyte Proliferation Peak and beta-Oxidation in Liver Regeneration after Partial Hepatectomy.
    Hepatology. 2022 Jan 26. doi: 10.1002/hep.32357.
    PubMed    


  146. PAIK JM, Henry L, Younossi ZM
    Response to: Chronic Liver Disease Among Adolescent and Young Adult: Alcohol Use Disorder Identification- Letter to the Editor. Hepatology 2022.
    Hepatology. 2022 Jan 25. doi: 10.1002/hep.32362.
    PubMed    


  147. SAHAI P, Jindal A, Mukund A
    Letter to the Editor: Prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant.
    Hepatology. 2022 Jan 25. doi: 10.1002/hep.32354.
    PubMed    


  148. LI YT, Liu CJ, Kao JH, Lin LF, et al
    Metastatic Tumor Antigen 1 Contributes to Hepatocarcinogenesis Posttranscriptionally Through Novel RNA Binding Function.
    Hepatology. 2022 Jan 24. doi: 10.1002/hep.32356.
    PubMed     Abstract available


  149. HAN J, Wang B, Liu W, Wang S, et al
    Declining disease burden of hepatocellular carcinoma in the US, 1992-2017: A population-based analysis.
    Hepatology. 2022 Jan 24. doi: 10.1002/hep.32355.
    PubMed     Abstract available


  150. FANG Y, Liu W, Tang Z, Ji X, et al
    MCT4 inhibition potentiates hepatocellular carcinoma immunotherapy via enhancing T cell infiltration and immune attack.
    Hepatology. 2022 Jan 19. doi: 10.1002/hep.32348.
    PubMed     Abstract available


  151. KHATIB SA, Ma L, Dang H, Forgues M, et al
    Single-cell biology uncovers apoptotic cell death and its spatial organization as a potential modifier of tumor diversity in hepatocellular carcinoma.
    Hepatology. 2022 Jan 16. doi: 10.1002/hep.32345.
    PubMed     Abstract available


  152. LOCKART I, Yeo MGH, Hajarizadeh B, Dore GJ, et al
    Hepatocellular carcinoma incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis.
    Hepatology. 2022 Jan 14. doi: 10.1002/hep.32341.
    PubMed     Abstract available


  153. WU T, Simonetto DA, Halamka JD, Shah VH, et al
    The Digital Transformation of Hepatology: The Patient is Logged In.
    Hepatology. 2022 Jan 13. doi: 10.1002/hep.32329.
    PubMed     Abstract available


  154. JOHN BV, Deng Y, Schwartz KB, Taddei TH, et al
    Post-Vaccination COVID-19 Infection is Associated with Reduced Mortality in Patients With Cirrhosis.
    Hepatology. 2022 Jan 12. doi: 10.1002/hep.32337.
    PubMed     Abstract available


  155. RAMADORI P, Kam S, Heikenwalder M
    T Cells: Friends and Foes in NASH Pathogenesis and Hepatocarcinogenesis.
    Hepatology. 2022 Jan 12. doi: 10.1002/hep.32336.
    PubMed     Abstract available


  156. SANDMANN L, Cornberg M
    Hepatocellular carcinoma and hepatitis B virus reactivation - a preventable condition not to be missed.
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32333.
    PubMed    


  157. WANG Z, Liu M, Zhang DZ, Wu SS, et al
    Microwave Ablation versus Laparoscopic Resection as First-line Therapy for Solitary 3-5 cm Hepatocellular Carcinoma.
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32323.
    PubMed     Abstract available


  158. FANG ZQ, Ruan B, Liu JJ, Duan JL, et al
    Notch-triggered maladaptation of liver sinusoidal endothelium aggravates nonalcoholic steatohepatitis through eNOS.
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32332.
    PubMed     Abstract available


  159. MA H, Kang Z, Foo TK, Shen Z, et al
    Disrupted BRCA1-PALB2 Interaction Induces Tumor Immunosuppression and T-Lymphocyte Infiltration in Hepatocellular Carcinoma Through cGAS-STING Pathway.
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32335.
    PubMed     Abstract available


  160. ANDERSSON ER
    Outside influence: the extrahepatic duct as a source for bile duct regeneration.
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32334.
    PubMed    


  161. MOORE MP, Cunningham RP, Meers GM, Johnson SA, et al
    Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD.
    Hepatology. 2022 Jan 9. doi: 10.1002/hep.32324.
    PubMed     Abstract available


  162. TRANAH TH, Shawcross DL
    The rise and fall and rise again of ammonia as a therapeutic target in hepatic encephalopathy.
    Hepatology. 2022 Jan 7. doi: 10.1002/hep.32319.
    PubMed    


  163. SHIODE Y, Kodama T, Shigeno S, Murai K, et al
    Traf3 inactivation promotes the development of intrahepatic cholangiocarcinoma via NIK-mediated hepatocyte transdifferentiation.
    Hepatology. 2022 Jan 7. doi: 10.1002/hep.32317.
    PubMed     Abstract available


  164. NG CH, Xiao J, Lim WH, Chin YH, et al
    Placebo Effect on Progression and Regression in Non-Alcoholic Steatohepatitis. Evidence from a Meta-Analysis.
    Hepatology. 2022 Jan 6. doi: 10.1002/hep.32315.
    PubMed     Abstract available


  165. WU H, Li Y, Shi G, Du S, et al
    Hepatic IRF8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti-PD-1 therapy.
    Hepatology. 2022 Jan 6. doi: 10.1002/hep.32316.
    PubMed     Abstract available



  166. Hepatology Highlights.
    Hepatology. 2022;75:1-2.
    PubMed    


  167. PHAM L, Kennedy L, Baiocchi L, Meadows V, et al
    Mast cells in liver disease progression: An update on current studies and implications.
    Hepatology. 2022;75:213-218.
    PubMed    


    December 2021
  168. LABENZ C, Labenz J, Galle PR
    Letter to the Editor: Evidence on the use of L-ornithine L-aspartate in overt hepatic encephalopathy - but does it really improve prognosis?
    Hepatology. 2021 Dec 27. doi: 10.1002/hep.32309.
    PubMed    


  169. RIDOLA L, Nardelli S, Gioia S, Faccioli J, et al
    Letter to the editor: Episodic-precipitant induced hepatic encephalopathy treatment: look at new and old precipitants!
    Hepatology. 2021 Dec 24. doi: 10.1002/hep.32306.
    PubMed    


  170. MASYUK AI, Masyuk TV, Trussoni CE, Pirius NE, et al
    Autophagy Promotes Hepatic Cystogenesis in Polycystic Liver Disease via Depletion of Cholangiocyte Ciliogenic Proteins.
    Hepatology. 2021 Dec 23. doi: 10.1002/hep.32298.
    PubMed     Abstract available


  171. LAEMMLE A, Haberle J, Willenbring H
    Reply to "The Role of Aquaporin 9 in Modeling of Ornithine Transcarbamylase Deficiency".
    Hepatology. 2021 Dec 21. doi: 10.1002/hep.32290.
    PubMed    


  172. KODAMA T, Takehara T
    Reply; Transcriptomics identify thrombospondin-2 as a biomarker for nonalcoholic steatohepatitis and advanced liver fibrosis.
    Hepatology. 2021 Dec 20. doi: 10.1002/hep.32292.
    PubMed    


  173. REMETIC J, Ghallab A, Hobloss Z, Brackhagen L, et al
    Loss of bile salt export pump aggravates lipopolysaccharide-induced liver injury in mice due to impaired hepatic endotoxin clearance.
    Hepatology. 2021 Dec 20. doi: 10.1002/hep.32289.
    PubMed     Abstract available


  174. RICH NE, Singal AG
    Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines?
    Hepatology. 2021 Dec 19. doi: 10.1002/hep.32284.
    PubMed     Abstract available


  175. FRIEDMAN SL, Pinzani M
    Hepatic Fibrosis 2022: Unmet Needs and a Blueprint for the Future.
    Hepatology. 2021 Dec 19. doi: 10.1002/hep.32285.
    PubMed     Abstract available


  176. CARABALLO GALVA LD, Jiang X, Hussein MS, Zhang H, et al
    Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against hepatocellular carcinoma.
    Hepatology. 2021 Dec 12. doi: 10.1002/hep.32279.
    PubMed     Abstract available


  177. LIBRERO JIMENEZ M, Lopez Garrido MA, Fernandez Cano MC
    Letter to the editor: Reactivation of HBV triggered by SARS-CoV-2 in a patient with cirrhosis.
    Hepatology. 2021 Dec 8. doi: 10.1002/hep.32271.
    PubMed    


  178. LAI JC, Shui AM, Duarte-Rojo A, Ganger DR, et al
    Frailty, Mortality, and Healthcare Utilization after Liver Transplantation: From the Multi-Center Functional Assessment in Liver Transplantation (FrAILT) Study.
    Hepatology. 2021 Dec 4. doi: 10.1002/hep.32268.
    PubMed     Abstract available


  179. XIN B, Yang M, Wu P, Du L, et al
    Enhancing the Therapeutic Efficacy of PD-L1 Antibody for Metastasized Liver Cancer by Overcoming Hepatic Immunotolerance.
    Hepatology. 2021 Dec 3. doi: 10.1002/hep.32266.
    PubMed     Abstract available


  180. SAPISOCHIN G, Ivanics T, Heimbach J
    Liver Transplantation for intrahepatic cholangiocarcinoma: ready for prime time?
    Hepatology. 2021 Dec 3. doi: 10.1002/hep.32258.
    PubMed     Abstract available


  181. KAWAI H, Osawa Y, Matsuda M, Tsunoda T, et al
    Sphingosine-1-phosphate promotes tumor development and liver fibrosis in mouse model of congestive hepatopathy.
    Hepatology. 2021 Dec 2. doi: 10.1002/hep.32256.
    PubMed     Abstract available



  182. 2021 Hepatology Referees (Volumes 73 and 74).
    Hepatology. 2021;74:3565-3569.
    PubMed    


  183. CODISPODO G, Brown RS Jr, Hans A, Roccaro G, et al
    Hepatology Highlights.
    Hepatology. 2021;74:2931-2934.
    PubMed    


  184. KUMAR K, Kulkarni A, Jagdish RK
    Letter to the Editor: Saroglitazar for Treatment of NAFLD and NASH.
    Hepatology. 2021;74:3559-3560.
    PubMed    


  185. AGARWAL A, Sharma S, Saraya A
    Letter to the Editor: Defining the Futility for Rescue Transjugular Intrahepatic Portosystemic Shunt Using the Model for End-Stage Liver Disease Score and Lactate in Variceal Bleed.
    Hepatology. 2021;74:3556-3557.
    PubMed    


  186. JINDAL A, Sarin SK, Mukund A
    Letter to the Editor: Salvage TIPS for Refractory Variceal Bleed-More Questions Than Answers!
    Hepatology. 2021;74:3557-3558.
    PubMed    


  187. VALENTI LVC, Cherubini A
    To Be or Not to Be: The Quest for Patatin-Like Phospholipase Domain Containing 3 p.I148M Function.
    Hepatology. 2021;74:2942-2944.
    PubMed    


  188. GOH GB, Chan WK, Wong VW
    Breastfeeding to Prevent NAFLD.
    Hepatology. 2021;74:2939-2941.
    PubMed    


  189. SONG J, Liu Y, Wan J, Zhao GN, et al
    SIMPLE Is an Endosomal Regulator That Protects Against NAFLD by Targeting the Lysosomal Degradation of EGFR.
    Hepatology. 2021;74:3091-3109.
    PubMed     Abstract available


  190. WAN J, Zhang Y, Yang D, Liang Y, et al
    Gastrodin Improves Nonalcoholic Fatty Liver Disease Through Activation of the Adenosine Monophosphate-Activated Protein Kinase Signaling Pathway.
    Hepatology. 2021;74:3074-3090.
    PubMed     Abstract available


  191. TILSON SG, Morell CM, Lenaerts AS, Park SB, et al
    Modeling PNPLA3-Associated NAFLD Using Human-Induced Pluripotent Stem Cells.
    Hepatology. 2021;74:2998-3017.
    PubMed     Abstract available


  192. SHAH NL, Miller JB, Kalman RS, Kumar S, et al
    AASLD Educating and Engaging in the Digital Age: Editorial from Communications and Technology Committee.
    Hepatology. 2021;74:2935-2938.
    PubMed    


  193. PARK Y, Sinn DH, Oh JH, Goh MJ, et al
    The Association Between Breastfeeding and Nonalcoholic Fatty Liver Disease in Parous Women: A Nation-wide Cohort Study.
    Hepatology. 2021;74:2988-2997.
    PubMed     Abstract available


  194. WU T, Luo G, Lian Q, Sui C, et al
    Discovery of a Carbamoyl Phosphate Synthetase 1-Deficient HCC Subtype With Therapeutic Potential Through Integrative Genomic and Experimental Analysis.
    Hepatology. 2021;74:3249-3268.
    PubMed     Abstract available


  195. KUMAR S, Wong R, Newberry C, Yeung M, et al
    Multidisciplinary Clinic Models: A Paradigm of Care for Management of NAFLD.
    Hepatology. 2021;74:3472-3478.
    PubMed    


  196. OTT P, Ala A, Askari FK, Czlonkowska A, et al
    Designing Clinical Trials in Wilson's Disease.
    Hepatology. 2021;74:3460-3471.
    PubMed     Abstract available


  197. GARCIA-MACIA M, Santos-Ledo A, Leslie J, Paish HL, et al
    A Mammalian Target of Rapamycin-Perilipin 3 (mTORC1-Plin3) Pathway is essential to Activate Lipophagy and Protects Against Hepatosteatosis.
    Hepatology. 2021;74:3441-3459.
    PubMed     Abstract available


  198. LANGE AP, Usmani AA, Wald C, Gordon FD, et al
    Sinusoidal Obstruction Syndrome in a Young Woman With Antiphospholipid Syndrome on Oral Contraceptives.
    Hepatology. 2021;74:3539-3541.
    PubMed    


  199. HAKIM A, Moll M, Brancale J, Liu J, et al
    Genetic Variation in the Mitochondrial Glycerol-3-Phosphate Acyltransferase Is Associated With Liver Injury.
    Hepatology. 2021;74:3394-3408.
    PubMed     Abstract available


  200. BAI W, Al-Karaghouli M, Stach J, Sung S, et al
    Test-Retest Reliability and Consistency of HVPG and Impact on Trial Design: A Study in 289 Patients from 20 Randomized Controlled Trials.
    Hepatology. 2021;74:3301-3315.
    PubMed     Abstract available


  201. RUSYN I, Arzuaga X, Cattley RC, Corton JC, et al
    Key Characteristics of Human Hepatotoxicants as a Basis for Identification and Characterization of the Causes of Liver Toxicity.
    Hepatology. 2021;74:3486-3496.
    PubMed     Abstract available


    November 2021
  202. JAIN A, Sharma BC, Mahajan B, Srivastava S, et al
    "L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial".
    Hepatology. 2021 Nov 25. doi: 10.1002/hep.32255.
    PubMed     Abstract available


  203. GHANY MG, King WC, Lisker-Melman M, Sf Lok A, et al
    Letter to the Editor: HBcrAg and Prediction of Hepatocellular Carcinoma Risk.
    Hepatology. 2021 Nov 20. doi: 10.1002/hep.32251.
    PubMed     Abstract available


  204. LAEMMLE A, Poms M, Hsu B, Borsuk M, et al
    Aquaporin 9 Induction in Human iPSC-derived Hepatocytes Facilitates Modeling of Ornithine Transcarbamylase Deficiency.
    Hepatology. 2021 Nov 16. doi: 10.1002/hep.32247.
    PubMed     Abstract available


  205. KRAMER JR, Natarajan Y, Dai J, Yu X, et al
    Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease.
    Hepatology. 2021 Nov 15. doi: 10.1002/hep.32244.
    PubMed     Abstract available


  206. KIM ER, Park JS, Kim JH, Oh JY, et al
    A GLP-1/GLP-2 receptor dual agonist to treat non-alcoholic steatohepatitis: targeting the gut-liver axis and microbiome.
    Hepatology. 2021 Nov 12. doi: 10.1002/hep.32235.
    PubMed     Abstract available


  207. TIAN L, Zhao L, Sze KM, Kam CS, et al
    Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma.
    Hepatology. 2021 Nov 12. doi: 10.1002/hep.32236.
    PubMed     Abstract available


  208. YANG J, Ye J, Ma T, Tang F, et al
    TRIM11 promotes hepatocellular carcinogenesis through ubiquitin-proteasome mediated degradation of PHLPP1.
    Hepatology. 2021 Nov 12. doi: 10.1002/hep.32234.
    PubMed     Abstract available


  209. LI H, Lan T, Liu H, Liu C, et al
    IL-6 induced cGGNBP2 encodes a novel protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma.
    Hepatology. 2021 Nov 10. doi: 10.1002/hep.32232.
    PubMed     Abstract available


  210. WU N, Carpino G, Ceci L, Baiocchi L, et al
    MT1 but not MT2 melatonin receptor knockout decreases biliary damage and liver fibrosis during cholestatic liver injury.
    Hepatology. 2021 Nov 7. doi: 10.1002/hep.32233.
    PubMed     Abstract available


  211. DING MJ, Fang HR, Zhang JK, Shi JH, et al
    E3 ubiquitin ligase RNF5 protects against hepatic ischemia reperfusion injury by mediating PGAM5 ubiquitination.
    Hepatology. 2021 Nov 4. doi: 10.1002/hep.32226.
    PubMed     Abstract available


  212. KAPLAN A, Brown RS Jr, Buckholz A, Hang TP, et al
    Hepatology Highlights.
    Hepatology. 2021;74:2329-2332.
    PubMed    


  213. BERNUAU J, Cazals-Hatem D, Vigrain V, Durand F, et al
    Letter to the Editor: Serum Aminotransferase Activity Beyond 100 Times the Upper Limit of Normal Value Does Not Suggest Acute Fatty Liver of Pregnancy Alone.
    Hepatology. 2021;74:2922.
    PubMed    


  214. JINDAL A
    Letter to the Editor: Infections in Severe Forms of Alcohol-Associated Liver Disease: Need a Closer Look!
    Hepatology. 2021;74:2926-2927.
    PubMed    


  215. BAZARBASHI AN, Li M, Ryou M
    Letter to the Editor: Endoscopic Ultrasound-Guided Coil Therapy for Secondary Prevention After Gastric Variceal Bleeding: A Promising Alternative.
    Hepatology. 2021;74:2914.
    PubMed    


  216. LOU L, Li X
    Letter to the Editor: Liver Stiffness by Transient Elastography to Detect Porto-sinusoidal Vascular Liver Disease.
    Hepatology. 2021;74:2910-2911.
    PubMed    


  217. CHINNADURAI KK, De A, Duseja A, Singh V, et al
    Letter to the Editor: Is Balloon-Occluded Retrograde Transvenous Obliteration Superior to Endoscopic Cyanoacrylate in Gastric Varices?
    Hepatology. 2021;74:2907-2908.
    PubMed    


  218. VOJJALA N, Mehtani R, Singh V
    Letter to the Editor: Acute Liver Injury Due to Therapeutic Doses of Acetaminophen-Confounders Must Be Ruled Out!
    Hepatology. 2021;74:2904.
    PubMed    


  219. ZHOU J, Bai L, Zhang XJ, Li H, et al
    Nonalcoholic Fatty Liver Disease and Cardiac Remodeling Risk: Pathophysiological Mechanisms and Clinical Implications.
    Hepatology. 2021;74:2839-2847.
    PubMed    


  220. INARRAIRAEGUI M, Sangro B
    Selective Internal Radiation Therapy Approval for Early HCC: What Comes Next?
    Hepatology. 2021;74:2333-2335.
    PubMed    


  221. HU Y, He W, Huang Y, Xiang H, et al
    Fatty Acid Synthase-Suppressor Screening Identifies Sorting Nexin 8 as a Therapeutic Target for NAFLD.
    Hepatology. 2021;74:2508-2525.
    PubMed     Abstract available


  222. DIAZ LA, Idalsoaga F, Fuentes-Lopez E, Marquez-Lomas A, et al
    Impact of Public Health Policies on Alcohol-Associated Liver Disease in Latin America: An Ecological Multinational Study.
    Hepatology. 2021;74:2478-2490.
    PubMed     Abstract available


  223. PAISANT A, Bellal S, Lebigot J, Canivet CM, et al
    Imaging Features of Hepatic Small Vessel Neoplasm: Case Series.
    Hepatology. 2021;74:2894-2896.
    PubMed    


  224. VAN DALEM J, Driessen JHM, Burden AM, Stehouwer CDA, et al
    Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study.
    Hepatology. 2021;74:2467-2477.
    PubMed     Abstract available


  225. SUN H, Meng Q, Shi C, Yang H, et al
    Hypoxia-Inducible Exosomes Facilitate Liver-Tropic Premetastatic Niche in Colorectal Cancer.
    Hepatology. 2021;74:2633-2651.
    PubMed     Abstract available


  226. BURYSKA S, Ahn JC, Allen AM, Simha V, et al
    Familial Hypobetalipoproteinemia: An Underrecognized Cause of Lean NASH.
    Hepatology. 2021;74:2897-2898.
    PubMed    


  227. BARCENA-VARELA M, Lujambio A
    Dissecting Early Relapse in Liver Cancer, One Cell at a Time.
    Hepatology. 2021;74:2891-2893.
    PubMed    


  228. DRISCOLL J, Wehrkamp C, Ota Y, Thomas JN, et al
    Biological Nanotherapeutics for Liver Disease.
    Hepatology. 2021;74:2863-2875.
    PubMed     Abstract available


  229. SIMON TG, Roelstraete B, Sharma R, Khalili H, et al
    Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study.
    Hepatology. 2021;74:2410-2423.
    PubMed     Abstract available


  230. JAGDISH RK, Maras JS, Sarin SK
    Albumin in Advanced Liver Diseases: The Good and Bad of a Drug!
    Hepatology. 2021;74:2848-2862.
    PubMed     Abstract available


    October 2021
  231. LAN T, Jiang S, Zhang J, Weng Q, et al
    Breviscapine Alleviates Nonalcoholic Steatohepatitis by Inhibiting TGF-beta-activated Kinase 1-dependent Signaling.
    Hepatology. 2021 Oct 30. doi: 10.1002/hep.32221.
    PubMed     Abstract available


  232. KONIGSHOFER P, Hofer BS, Brusilovskaya K, Simbrunner B, et al
    Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies.
    Hepatology. 2021 Oct 30. doi: 10.1002/hep.32220.
    PubMed     Abstract available


  233. MANCUSO A
    Portal vein thrombosis in cirrhosis: the issue of treatment.
    Hepatology. 2021 Oct 28. doi: 10.1002/hep.32216.
    PubMed     Abstract available


  234. LI M, Wong D, Vogel AS, Sack JS, et al
    Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis.
    Hepatology. 2021 Oct 28. doi: 10.1002/hep.32215.
    PubMed     Abstract available


  235. LUCE E, Steichen C, Allouche M, Messina A, et al
    In vitro recovery of FIX clotting activity as a marker of highly functional hepatocytes in a hemophilia B iPSC model.
    Hepatology. 2021 Oct 23. doi: 10.1002/hep.32211.
    PubMed     Abstract available


  236. SANYAL AJ, Anstee QM, Trauner M, Lawitz EJ, et al
    Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis.
    Hepatology. 2021 Oct 18. doi: 10.1002/hep.32204.
    PubMed     Abstract available


  237. ZHOU J, Guo L, Ma T, Qiu T, et al
    N-Acetylgalactosaminyltransferase-4 protects against hepatic ischaemia/reperfusion injury via blocking ASK1 N-terminal dimerization.
    Hepatology. 2021 Oct 18. doi: 10.1002/hep.32202.
    PubMed     Abstract available



  238. Correction of HEPATOLOGY 2020;71:259-274.
    Hepatology. 2021 Oct 12. doi: 10.1002/hep.32036.
    PubMed    


  239. GRAHAM JJ, Mukherjee S, Yuksel M, Sanabria Mateos R, et al
    Aberrant hepatic trafficking of gut-derived T-cells is not specific to primary sclerosing cholangitis.
    Hepatology. 2021 Oct 11. doi: 10.1002/hep.32193.
    PubMed     Abstract available


  240. SINGAL AG, Nabihah T, Mehta A, Marrero JA, et al
    GALAD Demonstrates High Sensitivity for HCC Surveillance in a Cohort of Patients with Cirrhosis.
    Hepatology. 2021 Oct 7. doi: 10.1002/hep.32185.
    PubMed     Abstract available


  241. LIU N, Steer CJ, Song G
    MicroRNA-206 Enhances Antitumor Immunity by Disrupting the Communication between Malignant Hepatocytes and Tregs in c-Myc Mice.
    Hepatology. 2021 Oct 4. doi: 10.1002/hep.32182.
    PubMed     Abstract available


  242. LAWITZ EJ, Shevell DE, Tirucherai GS, Du S, et al
    BMS-986263 in Patients with Advanced Hepatic Fibrosis: 36-Week Results from a Randomized, Placebo-Controlled Phase 2 Trial.
    Hepatology. 2021 Oct 4. doi: 10.1002/hep.32181.
    PubMed     Abstract available


  243. ALLAMNENI C, Vora RS, Bamidele AO, Schwartz RE, et al
    Hepatology Highlights.
    Hepatology. 2021;74:1727-1729.
    PubMed    


  244. MCCARRON S, Bathon B, Conlon DM, Abbey D, et al
    Functional Characterization of Organoids Derived From Irreversibly Damaged Liver of Patients With NASH.
    Hepatology. 2021;74:1825-1844.
    PubMed     Abstract available


  245. EDELSON JC, Rockey DC
    Letter to the Editor: Complications Associated With Anesthesia Services in Endoscopic Procedures Among Patients With Cirrhosis.
    Hepatology. 2021;74:2313-2314.
    PubMed    


  246. LLEO A, Hirschfield GM
    Letter to the Editor: Are We Confident That Primary Biliary Cholangitis Liver-Related Mortality Is Higher in Males?
    Hepatology. 2021;74:2307.
    PubMed    


  247. VILARINHO S, Ajmera V, Zheng M, Loomba R, et al
    Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD.
    Hepatology. 2021;74:2241-2250.
    PubMed    


  248. FRANCQUE S
    Saroglitazar for the Treatment of NASH: The Peroxisome Proliferator-Activated Receptor Story Goes On!
    Hepatology. 2021;74:1730-1733.
    PubMed    


  249. ZHOU J, Hu M, He M, Wang X, et al
    TNFAIP3 Interacting Protein 3 Is an Activator of Hippo-YAP Signaling Protecting Against Hepatic Ischemia/Reperfusion Injury.
    Hepatology. 2021;74:2133-2153.
    PubMed     Abstract available


  250. MALESPIN M, May EJ, Nephew LD, Paul S, et al
    AASLD Deepens Commitment to Diversity, Equity, and Inclusion.
    Hepatology. 2021;74:2216-2225.
    PubMed    


  251. WALTER A, Rudler M, Olivas P, Moga L, et al
    Combination of Model for End-Stage Liver Disease and Lactate Predicts Death in Patients Treated With Salvage Transjugular Intrahepatic Portosystemic Shunt for Refractory Variceal Bleeding.
    Hepatology. 2021;74:2085-2101.
    PubMed     Abstract available


  252. GEURTSEN ML, Wahab RJ, Felix JF, Gaillard R, et al
    Maternal Early-Pregnancy Glucose Concentrations and Liver Fat Among School-Age Children.
    Hepatology. 2021;74:1902-1913.
    PubMed     Abstract available


  253. NI M, Zhang J, Sosa R, Zhang H, et al
    T-Cell Immunoglobulin and Mucin Domain-Containing Protein-4 Is Critical for Kupffer Cell Homeostatic Function in the Activation and Resolution of Liver Ischemia Reperfusion Injury.
    Hepatology. 2021;74:2118-2132.
    PubMed     Abstract available


  254. COLUCCI S, Altamura S, Marques O, Dropmann A, et al
    Liver Sinusoidal Endothelial Cells Suppress Bone Morphogenetic Protein 2 Production in Response to TGFbeta Pathway Activation.
    Hepatology. 2021;74:2186-2200.
    PubMed     Abstract available


  255. IM YR, Hunter H, de Gracia Hahn D, Duret A, et al
    A Systematic Review of Animal Models of NAFLD Finds High-Fat, High-Fructose Diets Most Closely Resemble Human NAFLD.
    Hepatology. 2021;74:1884-1901.
    PubMed     Abstract available


  256. BARROW F, Khan S, Wang H, Revelo XS, et al
    The Emerging Role of B Cells in the Pathogenesis of NAFLD.
    Hepatology. 2021;74:2277-2286.
    PubMed     Abstract available


  257. CHOI WM, Ryu T, Lee JH, Shim YR, et al
    Metabotropic Glutamate Receptor 5 in Natural Killer Cells Attenuates Liver Fibrosis by Exerting Cytotoxicity to Activated Stellate Cells.
    Hepatology. 2021;74:2170-2185.
    PubMed     Abstract available


  258. CHEN L, Wu N, Kennedy L, Francis H, et al
    Inhibition of Secretin/Secretin Receptor Axis Ameliorates NAFLD Phenotypes.
    Hepatology. 2021;74:1845-1863.
    PubMed     Abstract available


  259. DINANI AM, Kowdley KV, Noureddin M
    Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH: The State of the Art.
    Hepatology. 2021;74:2233-2240.
    PubMed     Abstract available


  260. YU H, He J, Liu W, Feng S, et al
    The Transcriptional Coactivator, ALL1-Fused Gene From Chromosome 9, Simultaneously Sustains Hypoxia Tolerance and Metabolic Advantages in Liver Cancer.
    Hepatology. 2021;74:1952-1970.
    PubMed     Abstract available


  261. GAWRIEH S, Noureddin M, Loo N, Mohseni R, et al
    Saroglitazar, a PPAR-alpha/gamma Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
    Hepatology. 2021;74:1809-1824.
    PubMed     Abstract available


  262. LUO X, Xiang T, Wu J, Wang X, et al
    Endoscopic Cyanoacrylate Injection Versus Balloon-Occluded Retrograde Transvenous Obliteration for Prevention of Gastric Variceal Bleeding: A Randomized Controlled Trial.
    Hepatology. 2021;74:2074-2084.
    PubMed     Abstract available


    September 2021
  263. FANG Y, Zhan Y, Xie Y, Du S, et al
    Integration of Glucose and Cardiolipin Anabolism Confers Radiation Resistance of Hepatocellular Carcinoma.
    Hepatology. 2021 Sep 28. doi: 10.1002/hep.32177.
    PubMed     Abstract available


  264. LI H, Liu G, Wan X, Zhou L, et al
    ZBTB20 regulates plasma triglyceride metabolism by repressing lipoprotein lipase gene transcription in hepatocytes.
    Hepatology. 2021 Sep 28. doi: 10.1002/hep.32176.
    PubMed     Abstract available


  265. GARCIA-TSAO G
    Can we rely on changes in HVPG in patients with cirrhosis?
    Hepatology. 2021 Sep 27. doi: 10.1002/hep.32159.
    PubMed     Abstract available


  266. ZHAO C, Lancman JJ, Yang Y, Gates KP, et al
    Intrahepatic cholangiocyte regeneration from an Fgf-dependent extrahepatic progenitor niche in a zebrafish model of Alagille Syndrome.
    Hepatology. 2021 Sep 27. doi: 10.1002/hep.32173.
    PubMed     Abstract available


  267. DRIEVER EG, von Meijenfeldt FA, Adelmeijer J, de Haas RJ, et al
    Non-malignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus.
    Hepatology. 2021 Sep 24. doi: 10.1002/hep.32169.
    PubMed     Abstract available


  268. ZHAO Y, Gao L, Jiang C, Chen J, et al
    The Transcription Factor ZHX2 Alleviates Nonalcoholic Steatohepatitis by Transcriptional Activation of PTEN.
    Hepatology. 2021 Sep 21. doi: 10.1002/hep.32165.
    PubMed     Abstract available


  269. ZHOU SL, Luo CB, Song CL, Zhou ZJ, et al
    Genomic evolution and the impact of SLIT2 mutation in relapsed intrahepatic cholangiocarcinoma.
    Hepatology. 2021 Sep 20. doi: 10.1002/hep.32164.
    PubMed     Abstract available


  270. ZHAI LL, Zhen SH, Tang ZG
    Letter to the Editor: Serum bioavailable 25-hydroxyvitamin D levels correlate with hepatocellular carcinoma survival.
    Hepatology. 2021 Sep 18. doi: 10.1002/hep.32158.
    PubMed     Abstract available


  271. FANG AP, Zhang YJ, Chen MS, Zhu HL, et al
    Response to "Serum bioavailable 25-hydroxyvitamin D levels correlate with hepatocellular carcinoma survival".
    Hepatology. 2021 Sep 18. doi: 10.1002/hep.32160.
    PubMed     Abstract available


  272. WANG S, Whitlock R, Xu C, Taneja S, et al
    Frailty is associated with increased risk of cirrhosis disease progression and death.
    Hepatology. 2021 Sep 15. doi: 10.1002/hep.32157.
    PubMed     Abstract available


  273. HUANG R, Liu J, Wang J, Li J, et al
    Letter to the Editor: Is hepatitis B virus genotype strongly associated with hepatocellular carcinoma risk in patients with chronic hepatitis B?
    Hepatology. 2021 Sep 14. doi: 10.1002/hep.32155.
    PubMed     Abstract available


  274. DUAN J, Wang Z, Duan R, Yang C, et al
    Therapeutic Targeting of Hepatic ACSL4 Ameliorates Non-alcoholic Steatohepatitis in Mice.
    Hepatology. 2021 Sep 12. doi: 10.1002/hep.32148.
    PubMed     Abstract available


  275. CARAPETO F, Bozorgui B, Shroff RT, Chagani S, et al
    The Immunogenomic Landscape of Resected Intrahepatic Cholangiocarcinoma.
    Hepatology. 2021 Sep 12. doi: 10.1002/hep.32150.
    PubMed     Abstract available


  276. BLOOM PP, Fontana RJ
    With Alcohol as the fuel, COVID is the match: Liver Transplantation for Alcoholic liver disease is increasing in the United States.
    Hepatology. 2021 Sep 8. doi: 10.1002/hep.32141.
    PubMed     Abstract available


  277. SHAH BJ, Onken JE, Edgar L, Jou JH, et al
    Development of Gastroenterology and Transplant Hepatology Milestones 2.0: A Guide For Programs, Faculty, and Fellows.
    Hepatology. 2021 Sep 7. doi: 10.1002/hep.32097.
    PubMed    


  278. COLL M, Arino S, Martinez-Sanchez C, Garcia-Pras E, et al
    Ductular Reaction Promotes Intrahepatic Angiogenesis Via Slit2-Robo1 Signaling.
    Hepatology. 2021 Sep 7. doi: 10.1002/hep.32140.
    PubMed     Abstract available


  279. ZHANG X, Yang H, Zeng S, Tian S, et al
    Melanoma-Differentiation-Associated gene 5 protects against nonalcoholic steatohepatitis in mice.
    Hepatology. 2021 Sep 5. doi: 10.1002/hep.32139.
    PubMed     Abstract available


  280. AN J, Kim D, Oh B, Oh YJ, et al
    Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas.
    Hepatology. 2021 Sep 3. doi: 10.1002/hep.32135.
    PubMed     Abstract available


  281. GORES GJ, Malhi H
    Presenting the New Incoming Editorial Team for HEPATOLOGY: Team Members and Perspectives.
    Hepatology. 2021 Sep 2. doi: 10.1002/hep.32137.
    PubMed     Abstract available


  282. KHAN IW, Ali MA, Lau DTY, Hang TP, et al
    Hepatology Highlights.
    Hepatology. 2021;74:1137-1140.
    PubMed    


  283. RAEVENS S, Boret M, De Pauw M, Fallon MB, et al
    Pulmonary Abnormalities in Liver Disease: Relevance to Transplantation and Outcome.
    Hepatology. 2021;74:1674-1686.
    PubMed     Abstract available


  284. SHARMA S, Gunjan D, Saraya A
    Letter to the Editor: Balloon-Occluded Retrograde Transvenous Obliteration for Prevention of Gastric Variceal Rebleeding: A Paradigm Shift?
    Hepatology. 2021;74:1721-1722.
    PubMed    


  285. ZHANG XP, Zhao GD, Liu Q, Liu R, et al
    Letter to the Editor: Recognizing Significant Role of Neoadjuvant Radiotherapy for HCC With Vascular Invasion.
    Hepatology. 2021;74:1719.
    PubMed    


  286. SEKAR D, K AP
    Letter to the Editor: H19 Promotes HCC Bone Metastasis by Reducing Osteoprotegerin Expression in a PPP1CA/p38MAPK-Dependent Manner and Sponging miR-200b-3p.
    Hepatology. 2021;74:1713.
    PubMed    


  287. CRAXI L
    Letter to the Editor: Comment on "The Application of Artificial Intelligence for the Diagnosis and Treatment of Liver Diseases".
    Hepatology. 2021;74:1710.
    PubMed    


  288. ALLEN AM, Neuschwander-Tetri BA
    The Importance of Glycemic Equipoise in NASH.
    Hepatology. 2021;74:1145-1147.
    PubMed    


  289. JIANG X, Qian H, Ding WX
    New Glance at the Role of TM6SF2 in Lipid Metabolism and Liver Cancer.
    Hepatology. 2021;74:1141-1144.
    PubMed    


  290. WANG SS, Tang XT, Lin M, Yuan J, et al
    Perivenous Stellate Cells Are the Main Source of Myofibroblasts and Cancer-Associated Fibroblasts Formed After Chronic Liver Injuries.
    Hepatology. 2021;74:1578-1594.
    PubMed     Abstract available


  291. NIU Y, Lin Z, Wan A, Sun L, et al
    Loss-of-Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia.
    Hepatology. 2021;74:1461-1479.
    PubMed     Abstract available


  292. STARLINGER P, Ahn JC, Mullan A, Gyoeri GP, et al
    The Addition of C-Reactive Protein and von Willebrand Factor to Model for End-Stage Liver Disease-Sodium Improves Prediction of Waitlist Mortality.
    Hepatology. 2021;74:1533-1545.
    PubMed     Abstract available


  293. LAGO-HERNANDEZ C, Nguyen NH, Khera R, Loomba R, et al
    Financial Hardship From Medical Bills Among Adults With Chronic Liver Diseases: National Estimates From the United States.
    Hepatology. 2021;74:1509-1522.
    PubMed     Abstract available


  294. LIU Y, Song J, Yang J, Zheng J, et al
    Tumor Necrosis Factor alpha-Induced Protein 8-Like 2 Alleviates Nonalcoholic Fatty Liver Disease Through Suppressing Transforming Growth Factor Beta-Activated Kinase 1 Activation.
    Hepatology. 2021;74:1300-1318.
    PubMed     Abstract available


  295. BEALS JW, Smith GI, Shankaran M, Fuchs A, et al
    Increased Adipose Tissue Fibrogenesis, Not Impaired Expandability, Is Associated With Nonalcoholic Fatty Liver Disease.
    Hepatology. 2021;74:1287-1299.
    PubMed     Abstract available


  296. ANDREWS TS, MacParland SA
    A Spotlight on the Drivers of Inflammation in Acute Liver Failure.
    Hepatology. 2021;74:1687-1689.
    PubMed    


  297. STRATAKIS N, Golden-Mason L, Margetaki K, Zhao Y, et al
    In Utero Exposure to Mercury Is Associated With Increased Susceptibility to Liver Injury and Inflammation in Childhood.
    Hepatology. 2021;74:1546-1559.
    PubMed     Abstract available


  298. KUSUMANCHI P, Liang T, Zhang T, Ross RA, et al
    Stress-Responsive Gene FK506-Binding Protein 51 Mediates Alcohol-Induced Liver Injury Through the Hippo Pathway and Chemokine (C-X-C Motif) Ligand 1 Signaling.
    Hepatology. 2021;74:1234-1250.
    PubMed     Abstract available


  299. WANG Y, Hylemon PB, Zhou H
    Long Noncoding RNA H19: A Key Player in Liver Diseases.
    Hepatology. 2021;74:1652-1659.
    PubMed    


    August 2021
  300. INNES H, Crooks CJ, Aspinall E, Card TR, et al
    Characterising the risk interplay between alcohol intake and body mass index on cirrhosis morbidity.
    Hepatology. 2021 Aug 28. doi: 10.1002/hep.32123.
    PubMed     Abstract available


  301. VARGHESE J, Malleswaran S, Mouleeswaran K
    Letter to the Editor: Toxin-induced Graft Injury following Liver Transplantation for Yellow Phosphorus Poisoning.
    Hepatology. 2021 Aug 28. doi: 10.1002/hep.32124.
    PubMed     Abstract available


  302. PLUMMER MD, Regenstein F
    Light chain deposition disease: an unusual cause of portal hypertension.
    Hepatology. 2021 Aug 27. doi: 10.1002/hep.32118.
    PubMed     Abstract available


  303. FU J, Hu F, Ma T, Zhao WJ, et al
    A conventional immune regulator MAVS blocks hepatic steatosis via maintaining mitochondrial homeostasis.
    Hepatology. 2021 Aug 26. doi: 10.1002/hep.32126.
    PubMed     Abstract available


  304. IMAI N, Nicholls HT, Alves-Bezerra M, Li Y, et al
    Upregulation of Thioesterase Superfamily Member 2 in Skeletal Muscle Promotes Hepatic Steatosis and Insulin Resistance.
    Hepatology. 2021 Aug 25. doi: 10.1002/hep.32122.
    PubMed     Abstract available


  305. LINDOR KD, Bowlus CL, Boyer J, Levy C, et al
    Primary Biliary Cholangitis: 2021 Practice Guidance Update from the American Association for the Study of Liver Diseases.
    Hepatology. 2021 Aug 24. doi: 10.1002/hep.32117.
    PubMed     Abstract available


  306. FAN S, Gao Y, Qu A, Jiang Y, et al
    YAP-TEAD mediates peroxisome proliferator-activated receptor alpha-induced hepatomegaly and liver regeneration in mice.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32105.
    PubMed     Abstract available


  307. FUCHS CD, Radun R, Dixon ED, Mlitz V, et al
    Hepatocyte-specific deletion of adipose triglyceride lipase (ATGL/PNPLA2) ameliorates dietary induced steatohepatitis in mice.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32112.
    PubMed     Abstract available


  308. EL KASMI KC, Ghosh S, Anderson AL, Devereaux MW, et al
    Pharmacologic Activation of Hepatic Farnesoid X Receptor Prevents Parenteral Nutrition Associated Cholestasis in Mice.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32101.
    PubMed     Abstract available


  309. LIN Y, Cai Q, Chen Y, Shi T, et al
    CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma via 5-lipoxygenase.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32099.
    PubMed     Abstract available


  310. WADHWANI SI, Ge J, Gottlieb L, Lyles C, et al
    Racial/Ethnic Disparities in Wait List Outcomes Are Only Partly Explained by Socioeconomic Deprivation Among Children Awaiting Liver Transplantation.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32106.
    PubMed     Abstract available


  311. ALLAIRE M, Garcia-Pagan JC, Walter A, Bureau C, et al
    Salvage TIPS in cirrhotic patients with variceal bleeding: MELD, lactates and << a la carte >> decision.
    Hepatology. 2021 Aug 5. doi: 10.1002/hep.32091.
    PubMed     Abstract available


  312. BOSCH J, Chung C, Carrasco-Zevallos OM, Harrison SA, et al
    A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis.
    Hepatology. 2021 Aug 1. doi: 10.1002/hep.32087.
    PubMed     Abstract available


  313. WAHID N, Jesudian A, Buckholz A, Brown RS Jr, et al
    Hepatology Highlights.
    Hepatology. 2021;74:539-542.
    PubMed    


  314. FIX OK, Blumberg EA, Chang KM, Chu J, et al
    American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease.
    Hepatology. 2021;74:1049-1064.
    PubMed     Abstract available


  315. SAVIANO A, Wrensch F, Ghany MG, Baumert TF, et al
    Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care.
    Hepatology. 2021;74:1088-1100.
    PubMed     Abstract available


  316. TROVATO FM, Zia R, Napoli S, Wolfer K, et al
    Dysregulation of the Lysophosphatidylcholine/Autotaxin/Lysophosphatidic Acid Axis in Acute-on-Chronic Liver Failure Is Associated With Mortality and Systemic Inflammation by Lysophosphatidic Acid-Dependent Monocyte Activation.
    Hepatology. 2021;74:907-925.
    PubMed     Abstract available


  317. CARTER J, Wang S, Friedman SL
    Ten Thousand Points of Light: Heterogeneity Among the Stars of NASH Fibrosis.
    Hepatology. 2021;74:543-546.
    PubMed    


  318. FONTANA RJ, Stravitz RT, Durkalski V, Hanje J, et al
    Prognostic Value of the (13) C-Methacetin Breath Test in Adults with Acute Liver Failure and Non-acetaminophen Acute Liver Injury.
    Hepatology. 2021;74:961-972.
    PubMed     Abstract available


  319. REN H, Hu F, Wang D, Kang X, et al
    Sirtuin 2 Prevents Liver Steatosis and Metabolic Disorders by Deacetylation of Hepatocyte Nuclear Factor 4alpha.
    Hepatology. 2021;74:723-740.
    PubMed     Abstract available


  320. STRAVITZ RT, Fontana RJ, Meinzer C, Durkalski-Mauldin V, et al
    Coagulopathy, Bleeding Events, and Outcome According to Rotational Thromboelastometry in Patients With Acute Liver Injury/Failure.
    Hepatology. 2021;74:937-949.
    PubMed     Abstract available


  321. LEE D, Zhang MS, Tsang FH, Bao MH, et al
    Adaptive and Constitutive Activations of Malic Enzymes Confer Liver Cancer Multilayered Protection Against Reactive Oxygen Species.
    Hepatology. 2021;74:776-796.
    PubMed     Abstract available


  322. VEERAMACHANENI H, Subramanian RM
    Combined High-Dose Continuous Renal Replacement Therapy and Plasma Exchange in the Management of Severe Multiorgan System Dysfunction Associated With Acute Liver Failure.
    Hepatology. 2021;74:1124-1126.
    PubMed    


  323. TRIANTOS C, Aggeletopoulou I, Thomopoulos K, Mouzaki A, et al
    Vitamin D-Liver Disease Association: Biological Basis and Mechanisms of Action.
    Hepatology. 2021;74:1065-1073.
    PubMed    


    July 2021
  324. WIN S, Min RWM, Zhang J, Kanel G, et al
    Hepatic mitochondrial SAB deletion or knockdown alleviates diet induced metabolic syndrome, steatohepatitis and hepatic fibrosis.
    Hepatology. 2021 Jul 31. doi: 10.1002/hep.32083.
    PubMed     Abstract available


  325. ZHANG Z, Ji Z, He J, Lu Y, et al
    GNAI2 exacerbates non-alcoholic steatohepatitis progression via regulating PRDX1-related inflammation and lipophagy.
    Hepatology. 2021 Jul 29. doi: 10.1002/hep.32078.
    PubMed     Abstract available


  326. SUDA T, Yoshikawa S, Kanefuji T, Abe S, et al
    Suppression of Noncoding RNAs as Shared Early Genetic Events in Multistep Hepatocarcinogenesis.
    Hepatology. 2021 Jul 29. doi: 10.1002/hep.32077.
    PubMed     Abstract available


  327. MA L, Xu A, Kang L, Cong R, et al
    LSD1-Demethylated LINC01134 Confers Oxaliplatin Resistance via SP1-induced p62 Transcription in Hepatocellular Carcinoma.
    Hepatology. 2021 Jul 29. doi: 10.1002/hep.32079.
    PubMed     Abstract available


  328. LIU G, Wang N, Zhang C, Li M, et al
    ALDOB depletion promotes hepatocellular carcinogenesis through activating insulin receptor signaling and lipogenesis.
    Hepatology. 2021 Jul 22. doi: 10.1002/hep.32064.
    PubMed     Abstract available


  329. MCMAHON BJ, Nolen S, Snowball M, Homan C, et al
    Hepatitis B Virus (HBV) Genotype: A Significant Risk Factor in Determining which Patients with Chronic HBV Infection should Undergo Surveillance for Hepatocellular Carcinoma: The Hepatitis B Alaska (HEP-B-AK) Study.
    Hepatology. 2021 Jul 22. doi: 10.1002/hep.32065.
    PubMed     Abstract available


  330. HU M, Zhang D, Xu H, Zhang Y, et al
    Salidroside activates the AMP-activated protein kinase pathway to suppress non-alcoholic steatohepatitis.
    Hepatology. 2021 Jul 22. doi: 10.1002/hep.32066.
    PubMed     Abstract available


  331. HE Q, Liu M, Huang W, Chen X, et al
    IL-1beta-induced Elevation of SLC7A11 Promotes Hepatocellular Carcinoma Metastasis through Upregulating PD-L1 and CSF1.
    Hepatology. 2021 Jul 20. doi: 10.1002/hep.32062.
    PubMed     Abstract available


  332. YANG Q, Chen X, Zhang Y, Hu S, et al
    The E3 ubiquitin ligase RNF5 ameliorates nonalcoholic steatohepatitis via ubiquitin-mediated degradation of HRD1.
    Hepatology. 2021 Jul 17. doi: 10.1002/hep.32061.
    PubMed     Abstract available


  333. PIANO S, Cardenas A
    Metabolomics to predict acute kidney injury in cirrhosis.
    Hepatology. 2021 Jul 16. doi: 10.1002/hep.32060.
    PubMed     Abstract available


  334. MILLER BM, Oderberg IM, Goessling W
    The Hepatic Nervous System in Development, Regeneration, and Disease.
    Hepatology. 2021 Jul 13. doi: 10.1002/hep.32055.
    PubMed     Abstract available


  335. ZHENG J, Daniel CR, Hatia RI, Stuff J, et al
    Dietary N-Nitroso Compounds and Risk of Hepatocellular Carcinoma: A US-Based Study.
    Hepatology. 2021 Jul 7. doi: 10.1002/hep.32046.
    PubMed     Abstract available


  336. LAI JC, Tandon P, Bernal W, Tapper EB, et al
    Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.
    Hepatology. 2021 Jul 7. doi: 10.1002/hep.32049.
    PubMed     Abstract available


  337. KIM OK, Nam DE, Hahn YS
    The Panx1/P2X4 pathway controls the secretion of miRNA-containing exosomes by HCV-infected hepatocytes.
    Hepatology. 2021 Jul 4. doi: 10.1002/hep.32042.
    PubMed     Abstract available


  338. CAPORALI C, Turco L, Prampolini F, Quaretti P, et al
    Proximal splenic artery embolization to treat refractory ascites in a cirrhotic patient.
    Hepatology. 2021 Jul 4. doi: 10.1002/hep.32037.
    PubMed     Abstract available


  339. BUCKHOLZ A, Lucero C, Yang LM, Lau DTY, et al
    Hepatology Highlights.
    Hepatology. 2021;74:1-4.
    PubMed    


  340. WILSON A, Beaton M, Brahmania M
    Letter to the Editor: Nonalcoholic Fatty Liver Disease-One Size May Not Fit All.
    Hepatology. 2021;74:528.
    PubMed    


  341. DIENSTAG JL
    Introducing Raymond T. Chung, M.D., Our 2021 AASLD President.
    Hepatology. 2021;74:12-18.
    PubMed    


  342. SZABO G
    Exosomes and MicroRNA-223 at the Intersection of Inflammation and Fibrosis in NAFLD.
    Hepatology. 2021;74:5-8.
    PubMed    


  343. PARTHASARATHY G, Malhi H
    Macrophage Heterogeneity in NASH: More Than Just Nomenclature.
    Hepatology. 2021;74:515-518.
    PubMed    


  344. NOUREDDIN M
    Artificial Intelligence in NASH Histology: Human Teaches a Machine for the Machine to Help Humans.
    Hepatology. 2021;74:9-11.
    PubMed    


  345. HUANG Z, Chu L, Liang J, Tan X, et al
    H19 Promotes HCC Bone Metastasis Through Reducing Osteoprotegerin Expression in a Protein Phosphatase 1 Catalytic Subunit Alpha/p38 Mitogen-Activated Protein Kinase-Dependent Manner and Sponging microRNA 200b-3p.
    Hepatology. 2021;74:214-232.
    PubMed     Abstract available


  346. TAYLOR-WEINER A, Pokkalla H, Han L, Jia C, et al
    A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH.
    Hepatology. 2021;74:133-147.
    PubMed     Abstract available


  347. COPPLE IM, Park BK, Goldring CE
    Gene Signatures Reduce the Stress of Preclinical Drug Hepatotoxicity Screening.
    Hepatology. 2021;74:513-515.
    PubMed    


  348. HAGSTROM H, Adams LA, Allen AM, Byrne CD, et al
    Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement.
    Hepatology. 2021;74:474-482.
    PubMed     Abstract available


  349. HE Y, Shi M, Wu X, Ma J, et al
    Mutational Signature Analysis Reveals Widespread Contribution of Pyrrolizidine Alkaloid Exposure to Human Liver Cancer.
    Hepatology. 2021;74:264-280.
    PubMed     Abstract available


  350. KENNEDY L, Meadows V, Sybenga A, Demieville J, et al
    Mast Cells Promote Nonalcoholic Fatty Liver Disease Phenotypes and Microvesicular Steatosis in Mice Fed a Western Diet.
    Hepatology. 2021;74:164-182.
    PubMed     Abstract available


  351. WANG H, Song X, Liao H, Wang P, et al
    Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans.
    Hepatology. 2021;74:248-263.
    PubMed     Abstract available


  352. JIANG T, Sanchez-Rivera FJ, Soto-Feliciano YM, Yang Q, et al
    Targeting the De Novo Purine Synthesis Pathway Through Adenylosuccinate Lyase Depletion Impairs Liver Cancer Growth by Perturbing Mitochondrial Function.
    Hepatology. 2021;74:233-247.
    PubMed     Abstract available


  353. GOUDSMIT BFJ, Putter H, Tushuizen ME, Vogelaar S, et al
    Refitting the Model for End-Stage Liver Disease for the Eurotransplant Region.
    Hepatology. 2021;74:351-363.
    PubMed     Abstract available


  354. BERNARDO-SEISDEDOS G, Bilbao J, Fernandez-Ramos D, Lopitz-Otsoa F, et al
    Metabolic Landscape of the Mouse Liver by Quantitative (31) P Nuclear Magnetic Resonance Analysis of the Phosphorome.
    Hepatology. 2021;74:148-163.
    PubMed     Abstract available


  355. HOU X, Yin S, Ren R, Liu S, et al
    Myeloid-Cell-Specific IL-6 Signaling Promotes MicroRNA-223-Enriched Exosome Production to Attenuate NAFLD-Associated Fibrosis.
    Hepatology. 2021;74:116-132.
    PubMed     Abstract available


  356. WOOD NL, Kernodle AB, Hartley AJ, Segev DL, et al
    Heterogeneous Circles for Liver Allocation.
    Hepatology. 2021;74:312-321.
    PubMed     Abstract available


  357. POSE E, Coll M, Martinez-Sanchez C, Zeng Z, et al
    Programmed Death Ligand 1 Is Overexpressed in Liver Macrophages in Chronic Liver Diseases, and Its Blockade Improves the Antibacterial Activity Against Infections.
    Hepatology. 2021;74:296-311.
    PubMed     Abstract available


    June 2021
  358. FLEMMING JA, Djerboua M, Groome PA, Booth CM, et al
    NAFLD and alcohol-related liver disease will be responsible for almost all new diagnoses of cirrhosis in Canada by 2040.
    Hepatology. 2021 Jun 26. doi: 10.1002/hep.32032.
    PubMed     Abstract available


  359. GARATE-RASCON M, Recalde M, Jimenez M, Elizalde M, et al
    SLU7 prevents oxidative stress-mediated HNF4alpha degradation preserving hepatic differentiation and protecting from liver damage.
    Hepatology. 2021 Jun 25. doi: 10.1002/hep.32029.
    PubMed     Abstract available


  360. HIRAO H, Ito T, Kadono K, Kojima H, et al
    Donor Hepatic Occult Collagen Deposition Predisposes to Peri-transplant Stress and Impacts Human Liver Transplantation.
    Hepatology. 2021 Jun 25. doi: 10.1002/hep.32030.
    PubMed     Abstract available


  361. KRIEGERMEIER A, Hyon A, Sommars M, Hubchak S, et al
    Hepatic X-box binding protein 1 and unfolded protein response is impaired in weanling mice with resultant hepatic injury.
    Hepatology. 2021 Jun 25. doi: 10.1002/hep.32031.
    PubMed     Abstract available


  362. CHOLANKERIL G, Kanwal F
    Nonalcoholic fatty liver disease and Hepatocellular Carcinoma: Time to Bridge the Gap.
    Hepatology. 2021 Jun 23. doi: 10.1002/hep.32025.
    PubMed     Abstract available


  363. TORRENS L, Montironi C, Puigvehi M, Mesropian A, et al
    Immunomodulatory effects of lenvatinib plus anti-PD1 in mice and rationale for patient enrichment in hepatocellular carcinoma.
    Hepatology. 2021 Jun 22. doi: 10.1002/hep.32023.
    PubMed     Abstract available


  364. LIU H, Lee SS
    Diagnostic criteria of cirrhotic cardiomyopathy: out with the old, in with the new?
    Hepatology. 2021 Jun 21. doi: 10.1002/hep.32021.
    PubMed     Abstract available


  365. JEPSEN P, Tapper EB, Deleuran T, Kazankov K, et al
    Risk and outcome of venous and arterial thrombosis in patients with cirrhosis: a Danish nationwide cohort study.
    Hepatology. 2021 Jun 16. doi: 10.1002/hep.32019.
    PubMed     Abstract available


  366. SHI YF, Xie WZ
    Letter to the Editor: Risk Stratification in Patients With Child-Pugh B Cirrhosis and Acute Variceal Bleeding.
    Hepatology. 2021 Jun 15. doi: 10.1002/hep.32013.
    PubMed     Abstract available


  367. MAZUMDER NR, Simpson D, Atiemo K, Jackson K, et al
    Black Patients With Cirrhosis Have Higher Mortality and Lower Transplant Rates: Results From a Metropolitan Cohort Study.
    Hepatology. 2021 Jun 15. doi: 10.1002/hep.31742.
    PubMed     Abstract available


  368. BARRON-MILLAR B, Ogle L, Mells G, Flack S, et al
    The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis.
    Hepatology. 2021 Jun 15. doi: 10.1002/hep.32011.
    PubMed     Abstract available


  369. LEE YT, Wang JJ, Luu M, Noureddin M, et al
    Comparison of Clinical Features and Outcomes between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.
    Hepatology. 2021 Jun 11. doi: 10.1002/hep.32007.
    PubMed     Abstract available


  370. JINDAL A, Sharma S
    Biomarkers for predicting renal outcomes in decompensated cirrhosis - Need a closer look!
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.32005.
    PubMed     Abstract available


  371. SOLIPURAM V, Baretti M, Kim AY, Chen LX, et al
    Surgical Debulking for Refractory Hyperammonemic Encephalopathy in Fibrolamellar Hepatocellular Carcinoma.
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.31998.
    PubMed     Abstract available


  372. SHAH V, Iwakiri Y, Boyer JL
    Obituary for Roberto J. Groszmann - the Father of Portal Hypertension.
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.31996.
    PubMed     Abstract available


  373. KOZUMI K, Kodama T, Murai H, Sakane S, et al
    Transcriptomics Identify Thrombospondin-2 as a Biomarker for Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis.
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.31995.
    PubMed     Abstract available


  374. CHO K, Ro SW, Lee HW, Moon H, et al
    YAP/TAZ suppress drug penetration into hepatocellular carcinoma via stromal activation.
    Hepatology. 2021 Jun 8. doi: 10.1002/hep.32000.
    PubMed     Abstract available


  375. CHEN B, Wu JX, Cheng SH, Wang LM, et al
    Phase II study of adjuvant radiotherapy following narrow-margin hepatectomy in patients with hepatocellular carcinoma.
    Hepatology. 2021 Jun 7. doi: 10.1002/hep.31993.
    PubMed     Abstract available


  376. JINDAL A, Jagdish RK
    Response to terlipressin plus albumin in Hepatorenal syndrome - Need a closer look!
    Hepatology. 2021 Jun 6. doi: 10.1002/hep.31990.
    PubMed     Abstract available


  377. WONG TC, Lee VH, Law AL, Pang HH, et al
    Prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant.
    Hepatology. 2021 Jun 6. doi: 10.1002/hep.31992.
    PubMed     Abstract available


  378. YANG W, He H, Wang T, Su N, et al
    Single-cell transcriptomic analysis reveals a hepatic stellate cell-activation roadmap and myofibroblast origin during liver fibrosis.
    Hepatology. 2021 Jun 5. doi: 10.1002/hep.31987.
    PubMed     Abstract available


  379. MUHAMMAD KHAN M, Alejandra Luna-Cuadros M, Lau DTY, Sehrawat TS, et al
    Hepatology Highlights.
    Hepatology. 2021;73:2085-2088.
    PubMed    


  380. ROSENBLATT R, Lee H, Liapakis A, Lunsford KE, et al
    Equitable access to liver transplant: Bridging the gaps in the social determinants of health.
    Hepatology. 2021 Jun 1. doi: 10.1002/hep.31986.
    PubMed     Abstract available


  381. KULKARNI AV, Kumar P, Sharma M, Menon B, et al
    Letter to the Editor: Living Donor Liver Transplantation or Deceased Donor Liver Transplantation in High Model for End-Stage Liver Disease Score-Which Is Better?
    Hepatology. 2021;73:2619-2620.
    PubMed    


  382. VUPPALANCHI R, Loomba R
    Noninvasive Tests to Phenotype Nonalcoholic Fatty Liver Disease: Sequence and Consequences of Arranging the Tools in the Tool Box.
    Hepatology. 2021;73:2095-2098.
    PubMed    


  383. CASSINOTTO C, Boursier J, Paisant A, Guiu B, et al
    Transient Versus Two-Dimensional Shear-Wave Elastography in a Multistep Strategy to Detect Advanced Fibrosis in NAFLD.
    Hepatology. 2021;73:2196-2205.
    PubMed     Abstract available


  384. LIN Q, Huang Z, Cai G, Fan X, et al
    Activating Adenosine Monophosphate-Activated Protein Kinase Mediates Fibroblast Growth Factor 1 Protection From Nonalcoholic Fatty Liver Disease in Mice.
    Hepatology. 2021;73:2206-2222.
    PubMed     Abstract available


  385. KENNEDY L, Francis H, Alpini G
    Fructose Promotion of Intestinal and Liver Injury: A Sugar by Any Other Name That Isn't So Sweet.
    Hepatology. 2021;73:2092-2094.
    PubMed    


  386. CHO YE, Kim DK, Seo W, Gao B, et al
    Fructose Promotes Leaky Gut, Endotoxemia, and Liver Fibrosis Through Ethanol-Inducible Cytochrome P450-2E1-Mediated Oxidative and Nitrative Stress.
    Hepatology. 2021;73:2180-2195.
    PubMed     Abstract available


  387. MARTINS PN, Clavien PA, Jalan R, Ghinolfi D, et al
    A Call for Randomization in Clinical Trials of Liver Machine Perfusion Preservation.
    Hepatology. 2021;73:2586-2591.
    PubMed    


  388. MOON JH, Stormon MO
    Sucrose Toxicity in Infants.
    Hepatology. 2021;73:2607-2609.
    PubMed    


  389. AHN JC, Connell A, Simonetto DA, Hughes C, et al
    Application of Artificial Intelligence for the Diagnosis and Treatment of Liver Diseases.
    Hepatology. 2021;73:2546-2563.
    PubMed     Abstract available


  390. HOOFNAGLE JH, Bonkovsky HL, Phillips EJ, Li YJ, et al
    HLA-B*35:01 and Green Tea-Induced Liver Injury.
    Hepatology. 2021;73:2484-2493.
    PubMed     Abstract available


  391. KYRITSI K, Kennedy L, Meadows V, Hargrove L, et al
    Mast Cells Induce Ductular Reaction Mimicking Liver Injury in Mice Through Mast Cell-Derived Transforming Growth Factor Beta 1 Signaling.
    Hepatology. 2021;73:2397-2410.
    PubMed     Abstract available


    May 2021
  392. VIVEIROS A, Schaefer B, Panzer M, Henninger B, et al
    MRI-based Iron Phenotyping and Patient Selection for Next-Generation Sequencing of non-HFE Hemochromatosis Genes.
    Hepatology. 2021 May 28. doi: 10.1002/hep.31982.
    PubMed     Abstract available


  393. LEPORE A, Choy PM, Lee NC, Carella MA, et al
    Phosphorylation and stabilization of PIN1 by JNK promote intrahepatic cholangiocarcinoma growth.
    Hepatology. 2021 May 28. doi: 10.1002/hep.31983.
    PubMed     Abstract available


  394. JOHNSTON ME 2ND, Rivas MP, Nicolle D, Gorse A, et al
    Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient Derived Xenograft Models.
    Hepatology. 2021 May 26. doi: 10.1002/hep.31919.
    PubMed     Abstract available


  395. YI C, Chen L, Ling Z, Liu L, et al
    Lenvatinib Targets FGFR4 to Enhance Antitumor Immune Response of Anti-PD-1 in Hepatocellular Carcinoma.
    Hepatology. 2021 May 26. doi: 10.1002/hep.31921.
    PubMed     Abstract available


  396. SUN LY, Hu JY, Liang L, Tong XM, et al
    Letter to the Editor: Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?
    Hepatology. 2021 May 22. doi: 10.1002/hep.31916.
    PubMed     Abstract available


  397. JOHN BV, Deng Y, Martin P, Levy C, et al
    Response to "Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?"
    Hepatology. 2021 May 22. doi: 10.1002/hep.31917.
    PubMed     Abstract available


  398. MEHTA G, Jalan R
    The 'Alter Ego' of Albumin in Cirrhosis.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31908.
    PubMed     Abstract available


  399. BAJAJ JS, Garcia-Tsao G, Reddy KR, O'Leary JG, et al
    Admission urinary and serum metabolites predict renal outcomes in hospitalized patients with cirrhosis.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31907.
    PubMed     Abstract available


  400. JANSSON H, Sparrelid E
    Letter to the Editor: The role of surgery in multiple intrahepatic cholangiocarcinoma should not be dismissed without further analysis.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31905.
    PubMed     Abstract available


  401. MARTINEZ M, Perito ER, Valentino P, Mack CL, et al
    Recurrence of primary sclerosing cholangitis after liver transplant in children: an international observational study.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31911.
    PubMed     Abstract available


  402. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
    Reply to (20-1119.R1) Surgery for advanced intrahepatic cholangiocarcinoma warrants further investigation.
    Hepatology. 2021 May 17. doi: 10.1002/hep.31904.
    PubMed     Abstract available


  403. PEISELER M, Tacke F
    An unexpected line of defense: hepatoprotective eosinophils in ischemia-reperfusion injury.
    Hepatology. 2021 May 11. doi: 10.1002/hep.31895.
    PubMed     Abstract available


  404. VALSAN A, Verma N, Singh V
    Non-invasive differentiation of porto-sinusoidal vascular disease and cirrhosis: The Devil is in the details!
    Hepatology. 2021 May 11. doi: 10.1002/hep.31896.
    PubMed     Abstract available


  405. ELKRIEF L, Lazareth M, Rautou PE
    Reply to: "Non-invasive differentiation of porto-sinusoidal vascular disease and cirrhosis: The Devil is in the details!"
    Hepatology. 2021 May 11. doi: 10.1002/hep.31894.
    PubMed     Abstract available


  406. DICHTEL LE
    The GLP-1 Receptor Agonist Semaglutide for the Treatment of Nonalcoholic Steatohepatitis.
    Hepatology. 2021 May 6. doi: 10.1002/hep.31886.
    PubMed     Abstract available


  407. BIGGINS SW, Angeli P, Garcia-Tsao G, Gines P, et al
    Diagnosis, evaluation, and management of ascites and hepatorenal syndrome.
    Hepatology. 2021 May 3. doi: 10.1002/hep.31884.
    PubMed     Abstract available


  408. LIU Y, Dou X, Zhou WY, Ding M, et al
    Hepatic SENP2 Controls Systemic Metabolism via SUMOylation-dependent Regulation of Liver-Adipose Tissue Crosstalk.
    Hepatology. 2021 May 2. doi: 10.1002/hep.31881.
    PubMed     Abstract available


  409. BUCKHOLZ A, Jesudian A, Sehrawat TS, Sehrawat O, et al
    Hepatology Highlights.
    Hepatology. 2021;73:1627-1630.
    PubMed    



  410. Seeking Editor for Hepatology Communications.
    Hepatology. 2021;73:i.
    PubMed    


  411. LEI MML, Lee TKW
    Cancer-Associated Fibroblasts: Orchestrating the Crosstalk Between Liver Cancer Cells and Neutrophils Through the Cardiotrophin-Like Cytokine Factor 1-Mediated Chemokine (C-X-C motif) Ligand 6/TGF-beta Axis.
    Hepatology. 2021;73:1631-1633.
    PubMed    


  412. LEE WM, Kaplowitz N
    Alcohol, Fasting, and Therapeutic Dosing of Acetaminophen: A Perfect Storm.
    Hepatology. 2021;73:1634-1636.
    PubMed    


  413. LOUVET A, Ntandja Wandji LC, Lemaitre E, Khaldi M, et al
    Acute Liver Injury With Therapeutic Doses of Acetaminophen: A Prospective Study.
    Hepatology. 2021;73:1945-1955.
    PubMed     Abstract available


  414. ASRANI SK, Mellinger J, Arab JP, Shah VH, et al
    Reducing the Global Burden of Alcohol-Associated Liver Disease: A Blueprint for Action.
    Hepatology. 2021;73:2039-2050.
    PubMed     Abstract available


  415. SUNDARAM V, Jalan R, Shah P, Singal AK, et al
    Acute on Chronic Liver Failure From Nonalcoholic Fatty Liver Disease: A Growing and Aging Cohort With Rising Mortality.
    Hepatology. 2021;73:1932-1944.
    PubMed     Abstract available


  416. HAFNER S, Seufferlein T, Kleger A, Muller M, et al
    Aseptic Liver Abscesses as an Exceptional Finding in Cogan's Syndrome.
    Hepatology. 2021;73:2067-2070.
    PubMed    


  417. LI Z, Lu X, Liu Y, Zhao J, et al
    Gain of LINC00624 Enhances Liver Cancer Progression by Disrupting the Histone Deacetylase 6/Tripartite Motif Containing 28/Zinc Finger Protein 354C Corepressor Complex.
    Hepatology. 2021;73:1764-1782.
    PubMed     Abstract available


  418. DAVULURI G, Welch N, Sekar J, Gangadhariah M, et al
    Activated Protein Phosphatase 2A Disrupts Nutrient Sensing Balance Between Mechanistic Target of Rapamycin Complex 1 and Adenosine Monophosphate-Activated Protein Kinase, Causing Sarcopenia in Alcohol-Associated Liver Disease.
    Hepatology. 2021;73:1892-1908.
    PubMed     Abstract available


  419. MA Y, Brown PM, Lin DD, Ma J, et al
    17-Beta Hydroxysteroid Dehydrogenase 13 Deficiency Does Not Protect Mice From Obesogenic Diet Injury.
    Hepatology. 2021;73:1701-1716.
    PubMed     Abstract available


  420. DRIEVER EG, Stravitz RT, Zhang J, Adelmeijer J, et al
    VWF/ADAMTS13 Imbalance, But Not Global Coagulation or Fibrinolysis, Is Associated With Outcome and Bleeding in Acute Liver Failure.
    Hepatology. 2021;73:1882-1891.
    PubMed     Abstract available


    April 2021
  421. SHENG J, Kohno S, Okada N, Okahashi N, et al
    Treatment of RB1-intact hepatocellular carcinoma with CDK4/6 inhibitor combination therapy.
    Hepatology. 2021 Apr 30. doi: 10.1002/hep.31872.
    PubMed     Abstract available


  422. BUCKARMA E, Smoot R
    Hepatocytes Induce Change in Their Neighbors by YAP-ing at Them.
    Hepatology. 2021 Apr 30. doi: 10.1002/hep.31874.
    PubMed     Abstract available


  423. ISHIKAWA T, Sasaki R, Matsuda T, Saeki I, et al
    Successful Management with Dual Therapy of Lenvatinib and Macitentan for Hepatocellular Carcinoma with Portopulmonary Hypertension.
    Hepatology. 2021 Apr 26. doi: 10.1002/hep.31865.
    PubMed     Abstract available


  424. LUO Y, Gao Y, Liu W, Yang Y, et al
    MYC-Protein Arginine Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma.
    Hepatology. 2021 Apr 25. doi: 10.1002/hep.31864.
    PubMed     Abstract available


  425. YANG X, Sun D, Xiang H, Wang S, et al
    Hepatocyte SH3RF2 Deficiency is a Key Aggravator for Nonalcoholic Fatty Liver Disease.
    Hepatology. 2021 Apr 24. doi: 10.1002/hep.31863.
    PubMed     Abstract available


  426. LIU D, Pang J, Shao W, Gu J, et al
    Hepatic fibroblast growth factor 21 is involved in mediating functions of liraglutide in mice with dietary challenge.
    Hepatology. 2021 Apr 13. doi: 10.1002/hep.31856.
    PubMed     Abstract available


  427. XU X, Ye L, Zhang Q, Shen H, et al
    Group-2 Innate Lymphoid Cells Promote Hepatocellular Carcinoma Progression via CXCL2-Neutrophil Induced Immunosuppression.
    Hepatology. 2021 Apr 8. doi: 10.1002/hep.31855.
    PubMed     Abstract available


  428. SUN D, Yang X, Wu B, Zhang XJ, et al
    Therapeutic Potential of G Protein-Coupled Receptors against Nonalcoholic Steatohepatitis.
    Hepatology. 2021 Apr 7. doi: 10.1002/hep.31852.
    PubMed     Abstract available


  429. WING-SUM CHEU J, Chak-Lui Wong C
    Mechanistic Rationales guiding Combination Hepatocellular Carcinoma Therapies involving Immune Checkpoint Inhibitors.
    Hepatology. 2021 Apr 3. doi: 10.1002/hep.31840.
    PubMed     Abstract available


  430. KOVALIC AJ, Huang G, Thuluvath PJ, Satapathy SK, et al
    Elevated Liver Biochemistries in Hospitalized Chinese Patients With Severe COVID-19: Systematic Review and Meta-analysis.
    Hepatology. 2021;73:1521-1530.
    PubMed     Abstract available


  431. FU Y, Zhu R, Bai T, Han P, et al
    Clinical Features of Patients Infected With Coronavirus Disease 2019 With Elevated Liver Biochemistries: A Multicenter, Retrospective Study.
    Hepatology. 2021;73:1509-1520.
    PubMed     Abstract available


  432. KAUR SP, Trivedi H, Lau DTY, Bamidele AO, et al
    Hepatology Highlights.
    Hepatology. 2021;73:1245-1247.
    PubMed    



  433. Seeking Editor for Hepatology Communications.
    Hepatology. 2021;73:i.
    PubMed    


  434. DE ZEGHER F, Ibanez L
    Letter to the Editor: Tackling NAFLD in Adolescent Polycystic Ovary Syndrome: Reducing Liver Fat to Mimic Weight Loss.
    Hepatology. 2021;73:1623-1624.
    PubMed    


  435. GOLRIZ M, Ramouz A, Mehrabi A
    Letter to the Editor: Surgical Method for Establishing Posthepatectomy Liver Failure.
    Hepatology. 2021;73:1621.
    PubMed    


  436. DHAR D, Loomba R
    Emerging Metabolic and Transcriptomic Signature of PNPLA3-Associated NASH.
    Hepatology. 2021;73:1248-1250.
    PubMed    


  437. XU H, Tian Y, Tang D, Zou S, et al
    An Endoplasmic Reticulum Stress-MicroRNA-26a Feedback Circuit in NAFLD.
    Hepatology. 2021;73:1327-1345.
    PubMed     Abstract available


  438. SONG Z, Chen W, Athavale D, Ge X, et al
    Osteopontin Takes Center Stage in Chronic Liver Disease.
    Hepatology. 2021;73:1594-1608.
    PubMed     Abstract available


  439. ALKHOURI N, Reddy GK, Lawitz E
    Oligonucleotide-Based Therapeutics: An Emerging Strategy for the Treatment of Chronic Liver Diseases.
    Hepatology. 2021;73:1581-1593.
    PubMed    


  440. ARJUNAN V, Hansen A, Deutzmann A, Sze DY, et al
    Spontaneous Regression of Hepatocellular Carcinoma: When the Immune System Stands Up to Cancer.
    Hepatology. 2021;73:1611-1614.
    PubMed    


  441. OSTROUMOV D, Duong S, Wingerath J, Woller N, et al
    Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.
    Hepatology. 2021;73:1399-1418.
    PubMed     Abstract available


  442. CHEN L, Guo P, Li W, Fang F, et al
    Perturbation of Specific Signaling Pathways Is Involved in Initiation of Mouse Liver Fibrosis.
    Hepatology. 2021;73:1551-1569.
    PubMed     Abstract available


    March 2021
  443. NINA KIM H, Newcomb CW, Carbonari DM, Roy JA, et al
    Risk of Hepatocellular Carcinoma with Hepatitis B Viremia among HIV/Hepatitis B Virus-Coinfected Persons in North America.
    Hepatology. 2021 Mar 29. doi: 10.1002/hep.31839.
    PubMed     Abstract available


  444. ROSENBLATT R, Wahid N, Halazun KJ, Kaplan A, et al
    Black Patients Have Unequal Access to Listing for Liver Transplantation in the United States.
    Hepatology. 2021 Mar 29. doi: 10.1002/hep.31837.
    PubMed     Abstract available


  445. DI-LUOFFO M, Pirenne S, Saandi T, Loriot A, et al
    A novel mouse model of cholangiocarcinoma uncovers a role for Tensin-4 in tumor progression.
    Hepatology. 2021 Mar 26. doi: 10.1002/hep.31834.
    PubMed     Abstract available


  446. BOERNER T, Drill E, Pak LM, Nguyen B, et al
    Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
    Hepatology. 2021 Mar 25. doi: 10.1002/hep.31829.
    PubMed     Abstract available


  447. DOURTHE C, Julien C, Di Tommaso S, Dupuy JW, et al
    Proteomic profiling of hepatocellular adenomas paves the way to new diagnostic and prognostic approaches.
    Hepatology. 2021 Mar 23. doi: 10.1002/hep.31826.
    PubMed     Abstract available


  448. BLOOM PP, Matherly S, Kumar S, Koh C, et al
    Professional Use of Social Media by Hepatology Providers.
    Hepatology. 2021 Mar 20. doi: 10.1002/hep.31824.
    PubMed     Abstract available


  449. SALEM R, Johnson GE, Kim E, Riaz A, et al
    Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable Hepatocellular Carcinoma: The LEGACY Study.
    Hepatology. 2021 Mar 19. doi: 10.1002/hep.31819.
    PubMed     Abstract available


  450. YASUDO H, Ando T, Maehara A, Ando T, et al
    A possible association between a novel NLRP1 mutation and an autoinflammatory disease involving liver cirrhosis.
    Hepatology. 2021 Mar 19. doi: 10.1002/hep.31818.
    PubMed     Abstract available


  451. ZHAO Y, Wang J, Liu WN, Fong SY, et al
    Analysis and validation of human targets and treatments using a hepatocellular carcinoma-immune humanized mouse model.
    Hepatology. 2021 Mar 18. doi: 10.1002/hep.31812.
    PubMed     Abstract available


  452. LEE YT, Wang JJ, Luu M, Tseng HR, et al
    State-Level Hepatocellular Carcinoma Incidence and Association with Obesity and Physical Activity in the United States.
    Hepatology. 2021 Mar 17. doi: 10.1002/hep.31811.
    PubMed     Abstract available


  453. WADA Y, Shimada M, Yamamura K, Toshima T, et al
    A transcriptomic signature for risk-stratification and recurrence prediction in intrahepatic cholangiocarcinoma.
    Hepatology. 2021 Mar 16. doi: 10.1002/hep.31803.
    PubMed     Abstract available


  454. SANO A, Kakazu E, Hamada S, Inoue J, et al
    Steatotic hepatocytes release mature VLDL via methionine and tyrosine metabolism in a Keap1-Nrf2 dependent manner.
    Hepatology. 2021 Mar 16. doi: 10.1002/hep.31808.
    PubMed     Abstract available


  455. ALEXOPOULOS AS, Crowley MJ, Wang Y, Moylan CA, et al
    Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease.
    Hepatology. 2021 Mar 16. doi: 10.1002/hep.31806.
    PubMed     Abstract available


  456. CRISTOFERI L, Calvaruso V, Overi D, Vigano M, et al
    Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naive patients with Primary Biliary Cholangitis: a dual cut-off approach.
    Hepatology. 2021 Mar 16. doi: 10.1002/hep.31810.
    PubMed     Abstract available


  457. MEUNIER L, Hirsch TZ, Caruso S, Imbeaud S, et al
    DNA Methylation Signatures Reveal the Diversity of Processes Remodeling Hepatocellular Carcinoma Methylomes.
    Hepatology. 2021 Mar 13. doi: 10.1002/hep.31796.
    PubMed     Abstract available


  458. WU H, Xu X, Zheng A, Wang W, et al
    TIPE1 Inhibits Hepatic Steatosis, Inflammation, and Fibrosis by Suppressing Polyubiquitination of ASK1.
    Hepatology. 2021 Mar 13. doi: 10.1002/hep.31801.
    PubMed     Abstract available


  459. BALDASSARRE M, Naldi M, Zaccherini G, Bartoletti M, et al
    Determination of effective albumin in patients with decompensated cirrhosis: clinical and prognostic implications.
    Hepatology. 2021 Mar 12. doi: 10.1002/hep.31798.
    PubMed     Abstract available


  460. SATHIYAPALAN A, Legault K, van der Pol CB, Meyers BM, et al
    Paraneoplastic Polyarthritis in Hepatocellular Carcinoma Treated with Lenvatinib.
    Hepatology. 2021 Mar 11. doi: 10.1002/hep.31794.
    PubMed     Abstract available


  461. KENDRE G, Marhenke S, Lorz G, Becker D, et al
    The co-mutational spectrum determines the therapeutic response in murine FGFR2 fusion - driven cholangiocarcinoma.
    Hepatology. 2021 Mar 11. doi: 10.1002/hep.31799.
    PubMed     Abstract available


  462. SONG M, He J, Pan QZ, Yang J, et al
    Cancer-associated fibroblast-mediated cellular crosstalk supports hepatocellular carcinoma progression.
    Hepatology. 2021 Mar 8. doi: 10.1002/hep.31792.
    PubMed     Abstract available


  463. PONZIANI FR, Gasbarrini A, Pompili M
    Letter to the Editor. Restructuring the Gut Microbiota of Cirrhotic Patients after HCV Eradication: a Matter of Time?
    Hepatology. 2021 Mar 5. doi: 10.1002/hep.31784.
    PubMed     Abstract available


  464. VAN WESSEL DBE, Thompson RJ, Gonzales E, Jankowska I, et al
    Impact of Genotype, Serum Bile Acids, and Surgical Biliary Diversion on Native Liver Survival in FIC1 Deficiency.
    Hepatology. 2021 Mar 5. doi: 10.1002/hep.31787.
    PubMed     Abstract available


  465. VANDERWERKEN D, Wood NL, Segev D, Gentry S, et al
    The Precise Relationship Between MELD and Survival Without a Liver Transplant.
    Hepatology. 2021 Mar 2. doi: 10.1002/hep.31781.
    PubMed     Abstract available


  466. ZHOU Y, Chen Y, Zhang X, Xu Q, et al
    Brg1 Inhibition Prevents Liver Fibrosis and Cholangiocarcinoma by Attenuating Progenitor Expansion.
    Hepatology. 2021 Mar 2. doi: 10.1002/hep.31780.
    PubMed     Abstract available



  467. Seeking Editor for Hepatology Communications.
    Hepatology. 2021;73:i.
    PubMed    


  468. HANIF H, Ali MJ, Chen HW, Lau DTY, et al
    Hepatology Highlights.
    Hepatology. 2021;73:877-880.
    PubMed    


  469. BLOOM PP, Meyerowitz EA, Reinus Z, Daidone M, et al
    Liver Biochemistries in Hospitalized Patients With COVID-19.
    Hepatology. 2021;73:890-900.
    PubMed     Abstract available


  470. MCHENRY SA, Davidson NO
    Ceramide Salvage, Gut Mucosal Immunoglobulin A Signaling, and Diet-Induced NASH.
    Hepatology. 2021;73:884-886.
    PubMed    


  471. MELLINGER J, Winder GS, Fernandez AC
    Measuring the Alcohol in Alcohol-Associated Liver Disease: Choices and Challenges for Clinical Research.
    Hepatology. 2021;73:1207-1212.
    PubMed    


  472. WEGERMANN K, Suzuki A, Mavis AM, Abdelmalek MF, et al
    Tackling Nonalcoholic Fatty Liver Disease: Three Targeted Populations.
    Hepatology. 2021;73:1199-1206.
    PubMed    


  473. PAPAROUPA M, Schrader J, Jung C, Boenisch O, et al
    Bilateral Hematothorax Without Hematemesis-An Unusual Presentation of Variceal Bleeding.
    Hepatology. 2021;73:1233-1235.
    PubMed    


  474. GODBEE M, Jakate S, Eswaran S
    A Case of Electronic Nicotine Delivery Systems (ENDS) Liver Injury.
    Hepatology. 2021;73:1230-1232.
    PubMed    


  475. YOUNOSSI ZM, Rinella ME, Sanyal AJ, Harrison SA, et al
    From NAFLD to MAFLD: Implications of a Premature Change in Terminology.
    Hepatology. 2021;73:1194-1198.
    PubMed     Abstract available


  476. PROTCHENKO O, Baratz E, Jadhav S, Li F, et al
    Iron Chaperone Poly rC Binding Protein 1 Protects Mouse Liver From Lipid Peroxidation and Steatosis.
    Hepatology. 2021;73:1176-1193.
    PubMed     Abstract available


    February 2021
  477. NEWBERRY EP, Hall Z, Xie Y, Molitor EA, et al
    Liver specific deletion of mouse Tm6sf2 promotes steatosis, fibrosis and hepatocellular cancer.
    Hepatology. 2021 Feb 27. doi: 10.1002/hep.31771.
    PubMed     Abstract available


  478. CHIU M, Garabon J, Chen L, Karp N, et al
    Mevalonic Aciduria Associated with Intrahepatic Bile Duct Paucity.
    Hepatology. 2021 Feb 27. doi: 10.1002/hep.31778.
    PubMed     Abstract available


  479. HERCUN J, Parikh E, Kleiner DE, Fuss I, et al
    Recurrent nodular regenerative hyperplasia post-liver transplantation in common variable immunodeficiency.
    Hepatology. 2021 Feb 27. doi: 10.1002/hep.31775.
    PubMed     Abstract available


  480. SHIOTA J, Samuelson LC, Razumilava N
    Hepatobiliary organoids and their applications for studies of liver health and disease: are we there yet?
    Hepatology. 2021 Feb 26. doi: 10.1002/hep.31772.
    PubMed     Abstract available


  481. SU T, Huang M, Liao J, Lin S, et al
    Insufficient Radiofrequency Ablation Promotes Hepatocellular Carcinoma Metastasis through m(6) A mRNA Methylation Dependent Mechanism.
    Hepatology. 2021 Feb 26. doi: 10.1002/hep.31766.
    PubMed     Abstract available


  482. JOHN BV, Aitcheson G, Schwartz KB, Shabbir Khakoo N, et al
    Male Gender is Associated with Higher Rates of Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis.
    Hepatology. 2021 Feb 26. doi: 10.1002/hep.31776.
    PubMed     Abstract available


  483. HUANG DQ, Yeo YH, Nguyen MH
    Letter to the Editor: HCC surveillance in cirrhosis patients: Is the real-world situation even worse than reported?
    Hepatology. 2021 Feb 22. doi: 10.1002/hep.31760.
    PubMed     Abstract available


  484. RICH NE, Parikh ND, Singal AG
    HCC Surveillance in Cirrhosis Patients: Room for Improvement.
    Hepatology. 2021 Feb 22. doi: 10.1002/hep.31762.
    PubMed     Abstract available


  485. YAMASHITA T, Koshikawa N, Shimakami T, Terashima T, et al
    Serum laminin gamma2 monomer as a novel diagnostic and predictive biomarker for hepatocellular carcinoma.
    Hepatology. 2021 Feb 20. doi: 10.1002/hep.31758.
    PubMed     Abstract available


  486. BARROW F, Khan S, Fredrickson G, Wang H, et al
    Microbiota-Driven Activation of Intrahepatic B Cells Aggravates Nonalcoholic Steatohepatitis through Innate and Adaptive Signaling.
    Hepatology. 2021 Feb 20. doi: 10.1002/hep.31755.
    PubMed     Abstract available


  487. QU C, He L, Yao N, Li J, et al
    Myofibroblast-specific Msi2 knockout inhibits hepatocellular carcinoma progression in a mouse model.
    Hepatology. 2021 Feb 20. doi: 10.1002/hep.31754.
    PubMed     Abstract available


  488. LAN T, Yu Y, Zhang J, Li H, et al
    Cordycepin Ameliorates Nonalcoholic Steatohepatitis via Activation of AMP-Activated Protein Kinase Signaling Pathway.
    Hepatology. 2021 Feb 12. doi: 10.1002/hep.31749.
    PubMed     Abstract available


  489. DAT NQ, Thuy LTT, Hieu VN, Hai H, et al
    6His-tagged Recombinant Human Cytoglobin Deactivates Hepatic Stellate Cells and Inhibits Liver Fibrosis by Scavenging Reactive Oxygen Species.
    Hepatology. 2021 Feb 11. doi: 10.1002/hep.31752.
    PubMed     Abstract available


  490. YOU Z, Li Y, Wang Q, Zhao Z, et al
    The Clinical Significance of Hepatic CD69(+) CD103(+) CD8(+) Resident Memory T Cells in Autoimmune Hepatitis.
    Hepatology. 2021 Feb 8. doi: 10.1002/hep.31739.
    PubMed     Abstract available


  491. MOHANTY SK, Donnelly B, Temple H, Ortiz-Perez A, et al
    HMGB1 release by cholangiocytes governs biliary atresia pathogenesis and correlates with increases in afflicted infants.
    Hepatology. 2021 Feb 8. doi: 10.1002/hep.31745.
    PubMed     Abstract available


  492. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
    Reply to "Does multiple intrahepatic cholangiocarcinoma worsen prognosis as "M1" stage?"; multiple primaries vs liver metastases.
    Hepatology. 2021 Feb 7. doi: 10.1002/hep.31740.
    PubMed     Abstract available


  493. ROSENTHAL SB, Liu X, Ganguly S, Dhar D, et al
    Heterogeneity of hepatic stellate cells in a mouse model of non-alcoholic steatohepatitis (NASH).
    Hepatology. 2021 Feb 7. doi: 10.1002/hep.31743.
    PubMed     Abstract available


  494. ZHANG XF, Lv Y, Pawlik TM
    Letter to the editor: Does multiple intrahepatic cholangiocarcinoma worsen prognosis as "M1" stage?
    Hepatology. 2021 Feb 6. doi: 10.1002/hep.31741.
    PubMed     Abstract available


  495. KE W, Cai De L, Jian Nan S, Chun Nian W, et al
    Primary Hepatic Squamous Cell Carcinoma With MSI-H Shows Good Response to PD-1 Inhibitor as Adjuvant Therapy.
    Hepatology. 2021 Feb 5. doi: 10.1002/hep.31737.
    PubMed     Abstract available


  496. NASSER-GHODSI N, Mara K, Watt KD
    De novo Colorectal and Pancreatic Cancer in Liver Transplant Recipients: Identifying the Higher Risk Populations.
    Hepatology. 2021 Feb 5. doi: 10.1002/hep.31731.
    PubMed     Abstract available


  497. TAO J, Krutsenko Y, Moghe A, Singh S, et al
    Nrf2 and beta-catenin coactivation in hepatocellular cancer: Biological and therapeutic implications.
    Hepatology. 2021 Feb 2. doi: 10.1002/hep.31730.
    PubMed     Abstract available


  498. SANSOE G, Aragno M, Wong F
    Covid-19 and liver cirrhosis: focus on the non-classical renin-angiotensin system and implications for therapy.
    Hepatology. 2021 Feb 1. doi: 10.1002/hep.31728.
    PubMed     Abstract available



  499. Seeking Editor for Hepatology Communications.
    Hepatology. 2021;73:1.
    PubMed    


  500. BUCKHOLZ A, Brown RS Jr, Parthasarathy G, Schwartz RE, et al
    Hepatology Highlights.
    Hepatology. 2021;73:475-478.
    PubMed    


  501. KARDASHIAN A, Wilder J, Terrault NA, Price JC, et al
    Addressing Social Determinants of Liver Disease During the COVID-19 Pandemic and Beyond: A Call to Action.
    Hepatology. 2021;73:811-820.
    PubMed     Abstract available


  502. DI GUGLIELMO MD, Perito ER
    To Juice or Not to Juice: Fatty Liver Repercussions for Infants.
    Hepatology. 2021;73:483-485.
    PubMed    


  503. PIROLA CJ, Sookoian S
    NAFLD and Cardiometabolic Risk Factors: The Liver Fibrosis Trajectory Through the Lens of Biological Interactions.
    Hepatology. 2021;73:479-482.
    PubMed    


  504. GEURTSEN ML, Santos S, Gaillard R, Felix JF, et al
    Associations Between Intake of Sugar-Containing Beverages in Infancy With Liver Fat Accumulation at School Age.
    Hepatology. 2021;73:560-570.
    PubMed     Abstract available


  505. TILG H, Adolph TE, Moschen AR
    Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade.
    Hepatology. 2021;73:833-842.
    PubMed    


  506. AL-NAAMANI N, Krowka MJ, Forde KA, Krok KL, et al
    Estrogen Signaling and Portopulmonary Hypertension: The Pulmonary Vascular Complications of Liver Disease Study (PVCLD2).
    Hepatology. 2021;73:726-737.
    PubMed     Abstract available


  507. JUNG YS, Stratton SA, Lee SH, Kim MJ, et al
    TMEM9-v-ATPase Activates Wnt/beta-Catenin Signaling Via APC Lysosomal Degradation for Liver Regeneration and Tumorigenesis.
    Hepatology. 2021;73:776-794.
    PubMed     Abstract available


  508. HU W, Zheng S, Guo H, Dai B, et al
    PLAGL2-EGFR-HIF-1/2alpha Signaling Loop Promotes HCC Progression and Erlotinib Insensitivity.
    Hepatology. 2021;73:674-691.
    PubMed     Abstract available


  509. ZUO Q, He J, Zhang S, Wang H, et al
    PPARgamma Coactivator-1alpha Suppresses Metastasis of Hepatocellular Carcinoma by Inhibiting Warburg Effect by PPARgamma-Dependent WNT/beta-Catenin/Pyruvate Dehydrogenase Kinase Isozyme 1 Axis.
    Hepatology. 2021;73:644-660.
    PubMed     Abstract available


    January 2021
  510. ITOH A, Adams D, Huang W, Wu Y, et al
    Enoxacin upregulates microRNA biogenesis and downregulates cytotoxic CD8 T cell function in autoimmune cholangitis.
    Hepatology. 2021 Jan 19. doi: 10.1002/hep.31724.
    PubMed     Abstract available


  511. KALASEKAR SM, Garrido-Laguna I, Evason KJ
    Immune Checkpoint Inhibitors in Novel Combinations for Hepatocellular Carcinoma.
    Hepatology. 2021 Jan 12. doi: 10.1002/hep.31706.
    PubMed     Abstract available


  512. CARACENI P, Vargas V, Sola E, Alessandria C, et al
    The use of Rifaximin in Patients with Cirrhosis.
    Hepatology. 2021 Jan 9. doi: 10.1002/hep.31708.
    PubMed     Abstract available


  513. LUCE E, Messina A, Duclos-Vallee JC, Dubart-Kupperschmitt A, et al
    Advanced techniques and awaited clinical applications for human pluripotent stem cell differentiation into hepatocytes.
    Hepatology. 2021 Jan 8. doi: 10.1002/hep.31705.
    PubMed     Abstract available


  514. WELLHONER F, Doscher N, Woelfl F, Vital M, et al
    Eradication of chronic HCV infection: improvement of dysbiosis only in patients without liver cirrhosis.
    Hepatology. 2021 Jan 7. doi: 10.1002/hep.31700.
    PubMed     Abstract available


  515. SATIYA J, Kaur SP, Lau DTY, Hejazifar N, et al
    Hepatology Highlights.
    Hepatology. 2021;73:1-3.
    PubMed    


  516. JAESCHKE H, Ramachandran A
    Letter to the Editor: Does c-Jun N-Terminal Kinase Regulate Acetaminophen Hepatotoxicity by Modulating Nuclear Factor Erythroid 2-Related Factor 2-Dependent Genes or Mitochondrial Oxidant Stress?
    Hepatology. 2021;73:467-468.
    PubMed    


  517. TANG X, Wang XJ
    REPLY.
    Hepatology. 2021;73:468-469.
    PubMed    


  518. CHOI J, Lim YS
    REPLY.
    Hepatology. 2021;73:467.
    PubMed    


  519. CASEY L, Aday A, Rule J, Lee WM, et al
    Letter to the Editor: Response to Letter Concerning Our Pregnancy Manuscript.
    Hepatology. 2021;73:465.
    PubMed    


  520. NORTHUP PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, et al
    Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases.
    Hepatology. 2021;73:366-413.
    PubMed    


  521. SARKAR M, Brady CW, Fleckenstein J, Forde KA, et al
    Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases.
    Hepatology. 2021;73:318-365.
    PubMed    


  522. DE JONGHE S, Weinstock D, Aligo J, Washington K, et al
    Biopsy Pathology and Immunohistochemistry of a Case of Immune-Mediated Drug-Induced Liver Injury With Atabecestat.
    Hepatology. 2021;73:452-455.
    PubMed    


  523. LEONIS MA, Miethke AG, Fei L, Maynor S, et al
    Four Biomarkers Linked to Activation of Cluster of Differentiation 8-Positive Lymphocytes Predict Clinical Outcomes in Pediatric Acute Liver Failure.
    Hepatology. 2021;73:233-246.
    PubMed     Abstract available


  524. LI YJ, Phillips EJ, Dellinger A, Nicoletti P, et al
    Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprim-Sulfamethoxazole Induced Liver Injury.
    Hepatology. 2021;73:268-281.
    PubMed     Abstract available


  525. MORENO E, Toussaint MJM, van Essen SC, Bongiovanni L, et al
    E2F7 Is a Potent Inhibitor of Liver Tumor Growth in Adult Mice.
    Hepatology. 2021;73:303-317.
    PubMed     Abstract available


  526. GU L, Zhu Y, Lin X, Lu B, et al
    The IKKbeta-USP30-ACLY Axis Controls Lipogenesis and Tumorigenesis.
    Hepatology. 2021;73:160-174.
    PubMed     Abstract available


  527. ZHOU B, Liu C, Xu L, Yuan Y, et al
    N(6) -Methyladenosine Reader Protein YT521-B Homology Domain-Containing 2 Suppresses Liver Steatosis by Regulation of mRNA Stability of Lipogenic Genes.
    Hepatology. 2021;73:91-103.
    PubMed     Abstract available


  528. CABALLERO-CAMINO FJ, Rivilla I, Herraez E, Briz O, et al
    Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease.
    Hepatology. 2021;73:186-203.
    PubMed     Abstract available


  529. FENG GS, Hanley KL, Liang Y, Lin X, et al
    Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies.
    Hepatology. 2021;73 Suppl 1:104-114.
    PubMed     Abstract available


  530. RIZVI S, Wang J, El-Khoueiry AB
    Liver Cancer Immunity.
    Hepatology. 2021;73 Suppl 1:86-103.
    PubMed    


  531. CARUSO S, O'Brien DR, Cleary SP, Roberts LR, et al
    Genetics of Hepatocellular Carcinoma: Approaches to Explore Molecular Diversity.
    Hepatology. 2021;73 Suppl 1:14-26.
    PubMed    


  532. LU X, Paliogiannis P, Calvisi DF, Chen X, et al
    Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies.
    Hepatology. 2021;73 Suppl 1:49-61.
    PubMed     Abstract available


  533. PEA A, Jamieson NB, Braconi C
    Biology and Clinical Application of Regulatory RNAs in Hepatocellular Carcinoma.
    Hepatology. 2021;73 Suppl 1:38-48.
    PubMed     Abstract available


    December 2020
  534. PINATO DJ, Fessas P, Sapisochin G, Marron TU, et al
    Perspectives on the neoadjuvant use of immunotherapy in hepatocellular carcinoma.
    Hepatology. 2020 Dec 28. doi: 10.1002/hep.31697.
    PubMed     Abstract available


  535. ELKRIEF L, Lazareth M, Chevret S, Paradis V, et al
    Liver stiffness by transient elastography to detect porto-sinusoidal vascular liver disease with portal hypertension.
    Hepatology. 2020 Dec 21. doi: 10.1002/hep.31688.
    PubMed     Abstract available


  536. ANANIA FA, Dimick-Santos L, Mehta R, Toerner J, et al
    Nonalcoholic Steatohepatitis: Current Thinking from the Division of Hepatology and Nutrition at the Food and Drug Administration.
    Hepatology. 2020 Dec 19. doi: 10.1002/hep.31687.
    PubMed     Abstract available


  537. VIVEIROS A, Beliveau V, Panzer M, Schaefer B, et al
    Neurodegeneration in Hepatic and Neurologic Wilson Disease.
    Hepatology. 2020 Dec 14. doi: 10.1002/hep.31681.
    PubMed     Abstract available


  538. LIOU H, Mody K, Boyle AW, Keaveny AP, et al
    Neoadjuvant Radiation Lobectomy and Immunotherapy for Angioinvasive Hepatocellular Carcinoma Resulting in Complete Pathologic Response.
    Hepatology. 2020 Dec 7. doi: 10.1002/hep.31675.
    PubMed     Abstract available


  539. KOUKOULIOTI E, Ziagaki A, Weber SN, Lammert F, et al
    Long-term colestyramine treatment prevents cholestatic attacks in refractory benign recurrent intrahepatic cholestasis type 1 disease.
    Hepatology. 2020 Dec 5. doi: 10.1002/hep.31671.
    PubMed     Abstract available


  540. KEISHAM A, Taneja S, Roy A, Singh V, et al
    ABIDE in NAFLD: A potential game changer in a select cohort of cirrhosis.
    Hepatology. 2020 Dec 4. doi: 10.1002/hep.31667.
    PubMed     Abstract available


  541. ANAND A, Pathak P, Shalimar
    Letter to the editor: ABIDE model for predicting decompensation in non-alcoholic fatty liver disease-related cirrhosis.
    Hepatology. 2020 Dec 3. doi: 10.1002/hep.31668.
    PubMed     Abstract available


  542. BUCKHOLZ A, Brown RS Jr, Trivedi H, Khan MM, et al
    Hepatology Highlights.
    Hepatology. 2020;72:1893-1896.
    PubMed    


  543. NOUREDDIN N, Alkhouri N, Brown KA, Noureddin M, et al
    Driving Nonalcoholic Steatohepatitis Forward Using the FibroScan Aspartate Aminotransferase Score, But Obey the Traffic Lights.
    Hepatology. 2020;72:2228-2230.
    PubMed    


  544. MEHTA N, Yao FY
    Reply.
    Hepatology. 2020;72:2243-2244.
    PubMed    


  545. SELCK TJ, Bok J, Amintavakoli R
    Letter to the Editor: Do Weather and Sunlight Really Affect Alcohol Consumption?
    Hepatology. 2020;72:2239.
    PubMed    


  546. VENTURA-COTS M, Abraldes JG, Bataller R
    Reply.
    Hepatology. 2020;72:2239-2240.
    PubMed    


    November 2020
  547. SIMON TG, Chan AT, Huttenhower C
    Microbiome Biomarkers: One Step Closer in NAFLD-Cirrhosis.
    Hepatology. 2020 Nov 29. doi: 10.1002/hep.31660.
    PubMed     Abstract available


  548. KWON HM, Moon YJ, Kim KS, Shin WJ, et al
    Prognostic value of B-type natriuretic peptide in liver transplant patients: Implication in post-transplant mortality.
    Hepatology. 2020 Nov 28. doi: 10.1002/hep.31661.
    PubMed     Abstract available


  549. HERNANDEZ-MEZA G, von Felden J, Gonzalez-Kozlova EE, Garcia-Lezana T, et al
    DNA methylation profiling of human hepatocarcinogenesis.
    Hepatology. 2020 Nov 25. doi: 10.1002/hep.31659.
    PubMed     Abstract available


  550. KHATUN M, Sur S, Steele R, Ray R, et al
    Inhibition of long noncoding RNA Linc-Pint by hepatitis C virus in infected hepatocytes enhances lipogenesis.
    Hepatology. 2020 Nov 24. doi: 10.1002/hep.31656.
    PubMed     Abstract available


  551. MOUSA OY, Juran BD, McCauley BM, Vesterhus MN, et al
    Bile Acid Profiles in Primary Sclerosing Cholangitis and their Ability to Predict Hepatic Decompensation.
    Hepatology. 2020 Nov 23. doi: 10.1002/hep.31652.
    PubMed     Abstract available


  552. SIMONETTO DA, Shah VH, Kamath PS
    Surgery in patients with cirrhosis: as much an art as science.
    Hepatology. 2020 Nov 21. doi: 10.1002/hep.31643.
    PubMed     Abstract available


  553. IOANNOU GN, Liang PS, Locke E, Green P, et al
    Cirrhosis and SARS-CoV-2 infection in US Veterans: risk of infection, hospitalization, ventilation and mortality.
    Hepatology. 2020 Nov 21. doi: 10.1002/hep.31649.
    PubMed     Abstract available


  554. BARMAN PM, VanWagner LB
    Cardiac Risk Assessment in Liver Transplant Candidates: Current Controversies and Future Directions.
    Hepatology. 2020 Nov 20. doi: 10.1002/hep.31647.
    PubMed     Abstract available


  555. LI S, Liu Y, Bai Y, Chen M, et al
    RHOF promotes hepatocellular carcinoma metastasis by altering the metabolic status of cancer cells via RAB3D.
    Hepatology. 2020 Nov 18. doi: 10.1002/hep.31641.
    PubMed     Abstract available


  556. RICH NE, Marrero JA, Singal AG
    Reply: Wang et al, "Should growth pattern of hepatocellular carcinoma be constant and homogenous?"
    Hepatology. 2020 Nov 18. doi: 10.1002/hep.31638.
    PubMed     Abstract available


  557. WANG H, Mao Y, Huang M
    Letter to the Editors: should growth pattern of hepatocellular carcinoma be constant and homogenous?
    Hepatology. 2020 Nov 18. doi: 10.1002/hep.31640.
    PubMed     Abstract available


  558. SETIAWAN VW, Rosen HR
    Stratification of residual risk of hepatocellular carcinoma following HCV clearance with DAA in patients with advanced fibrosis and cirrhosis.
    Hepatology. 2020 Nov 18. doi: 10.1002/hep.31639.
    PubMed     Abstract available


  559. GU X, Sun R, Chen L, Chu S, et al
    Neutral ceramidase mediates nonalcoholic steatohepatitis by regulating monounsaturated fatty acids and gut IgA(+) B cells.
    Hepatology. 2020 Nov 13. doi: 10.1002/hep.31628.
    PubMed     Abstract available


  560. KOKUDO T
    Evaluating Liver Function in Patients With Cirrhosis.
    Hepatology. 2020 Nov 13. doi: 10.1002/hep.31626.
    PubMed     Abstract available


  561. LOUSTAUD-RATTI V, Anneraud A, Carrier P, Debette-Gratien M, et al
    Letter to the Editor: Post-Liver Transplantation Sinusoidal Obstruction Syndrome and immunosuppressive drugs: causality of MMF or tacrolimus?
    Hepatology. 2020 Nov 13. doi: 10.1002/hep.31633.
    PubMed     Abstract available


  562. LOOMBA R
    MRI-PDFF treatment response criteria in nonalcoholic steatohepatitis.
    Hepatology. 2020 Nov 11. doi: 10.1002/hep.31624.
    PubMed     Abstract available


  563. HUO TI, Liu PH, Hsu CY
    Using circulating biomarkers to stage hepatocellular carcinoma: Pitfalls and limitations.
    Hepatology. 2020 Nov 10. doi: 10.1002/hep.31618.
    PubMed     Abstract available


  564. SUN L, Guan A, Liu M, Mao Y, et al
    Letter to the editor: Comment on "HepatoScore-14: Measures of biological heterogeneity significantly improve prediction of hepatocellular carcinoma risk".
    Hepatology. 2020 Nov 10. doi: 10.1002/hep.31621.
    PubMed     Abstract available


  565. LOOMBA R, Noureddin M, Kowdley KV, Kohli A, et al
    Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis due to NASH.
    Hepatology. 2020 Nov 10. doi: 10.1002/hep.31622.
    PubMed     Abstract available


  566. GAO J, Wei B, Liu M, Hirsova P, et al
    Endothelial p300 promotes portal hypertension and hepatic fibrosis through CCL2-mediated angiocrine signaling.
    Hepatology. 2020 Nov 7. doi: 10.1002/hep.31617.
    PubMed     Abstract available


  567. KURODA H, Abe T, Fujiwara Y, Nagasawa T, et al
    Contrast-enhanced ultrasonography-based hepatic perfusion for early prediction of prognosis in acute liver failure.
    Hepatology. 2020 Nov 5. doi: 10.1002/hep.31615.
    PubMed     Abstract available


  568. KRISHNAN MS, Rajan Kd A, Park J, Arjunan V, et al
    Genomic analysis of Vascular Invasion in Hepatocellular Carcinoma (HCC) Reveals Molecular Drivers and Predictive Biomarkers.
    Hepatology. 2020 Nov 3. doi: 10.1002/hep.31614.
    PubMed     Abstract available


  569. SMETS L, Verbeek J, Korf H, van der Merwe S, et al
    Improved markers of cholestatic liver injury in patients with primary biliary cholangitis treated with obeticholic acid and bezafibrate.
    Hepatology. 2020 Nov 3. doi: 10.1002/hep.31613.
    PubMed     Abstract available


  570. RUSSO NW, Brown RS Jr, Parthasarathy G, Schwartz RE, et al
    Hepatology Highlights.
    Hepatology. 2020;72:1505-1508.
    PubMed    


  571. BANINI BA, P Kumar D, Cazanave S, Seneshaw M, et al
    Identification of a metabolic, transcriptomic and molecular signature of PNPLA3-mediated acceleration of steatohepatitis.
    Hepatology. 2020 Nov 1. doi: 10.1002/hep.31609.
    PubMed     Abstract available


  572. ALKHOURI N, Kohli A, Loomba R, Harrison SA, et al
    Maintaining Patient Safety and Data Integrity of Nonalcoholic Steatohepatitis Clinical Trials During the Severe Acute Respiratory Syndrome-Coronavirus 2 Pandemic.
    Hepatology. 2020;72:1509-1513.
    PubMed    


  573. BERTOLINI A, van de Peppel IP, Bodewes FAJA, Moshage H, et al
    Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis.
    Hepatology. 2020;72:1864-1872.
    PubMed    


  574. CAVE MC
    Environmental Pollution and the Developmental Origins of Childhood Liver Disease.
    Hepatology. 2020;72:1518-1521.
    PubMed    


  575. JAESCHKE H, Ramachandran A
    Pleiotropic Roles of Platelets and Neutrophils in Cell Death and Recovery During Acetaminophen Hepatotoxicity.
    Hepatology. 2020;72:1873-1876.
    PubMed    


  576. SINGH S, Verma N, Singh V
    Letter to the Editor: MELD-Lactate-the New Kid on the Block.
    Hepatology. 2020;72:1883.
    PubMed    


    October 2020
  577. LONG MT, Zhang X, Xu H, Liu CT, et al
    Hepatic fibrosis associates with multiple cardiometabolic disease risk factors: The Framingham Heart Study.
    Hepatology. 2020 Oct 30. doi: 10.1002/hep.31608.
    PubMed     Abstract available


  578. XU Y, Zhu Y, Hu S, Xu Y, et al
    Hepatocyte nuclear factor 4alpha prevents the steatosis-to-NASH progression by regulating p53 and bile acid signaling.
    Hepatology. 2020 Oct 23. doi: 10.1002/hep.31604.
    PubMed     Abstract available


  579. STARLINGER P, Pereyra D, Hackl H, Ortmayr G, et al
    Consequences of Perioperative Serotonin Reuptake Inhibitor Treatment during Hepatic Surgery.
    Hepatology. 2020 Oct 20. doi: 10.1002/hep.31601.
    PubMed     Abstract available


  580. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
    Liver metastases of intrahepatic cholangiocarcinoma: implications for a potential new staging system.
    Hepatology. 2020 Oct 18. doi: 10.1002/hep.31598.
    PubMed     Abstract available


  581. TAN HY, Wang N, Zhang C, Chan YT, et al
    LOXL4 Fosters an Immunosuppressive Microenvironment During Hepatocarcinogenesis.
    Hepatology. 2020 Oct 17. doi: 10.1002/hep.31600.
    PubMed     Abstract available


  582. LI XJ, Li QL, Ju LG, Zhao C, et al
    Deficiency of histone methyltransferase SETD2 in liver leads to abnormal lipid metabolism and hepatocarcinoma.
    Hepatology. 2020 Oct 15. doi: 10.1002/hep.31594.
    PubMed     Abstract available


  583. BROWN SA, Izzy M, Watt KD
    Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underutilized Potential.
    Hepatology. 2020 Oct 12. doi: 10.1002/hep.31595.
    PubMed     Abstract available


  584. ALONSO S, Manzano ML, Gea F, Gutierrez ML, et al
    A model based on non-invasive markers predicts very low hepatocellular carcinoma risk after viral response in HCV-advanced fibrosis.
    Hepatology. 2020 Oct 6. doi: 10.1002/hep.31588.
    PubMed     Abstract available


  585. YUAN G, Yao J, Yu J, Xie X, et al
    Letter to the Editors: Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
    Hepatology. 2020 Oct 5. doi: 10.1002/hep.31590.
    PubMed     Abstract available


  586. WONG TC, Yan-Yue Fung J, Pang HH, Leung CK, et al
    Analysis of survival benefits of living vs. deceased donor liver transplant in high MELD and hepatorenal syndrome.
    Hepatology. 2020 Oct 2. doi: 10.1002/hep.31584.
    PubMed     Abstract available


  587. ANTKOWIAK M, Green RM
    Telomeres, p53, Hepatocyte Nuclear Factor 4alpha, and Liver Disease.
    Hepatology. 2020;72:1166-1168.
    PubMed    


  588. LA MURA V, Villanueva C, Abraldes JG, Bosch J, et al
    Reply.
    Hepatology. 2020;72:1494-1495.
    PubMed    


  589. KUNZMANN LK, Schoknecht T, Poch T, Henze L, et al
    Monocytes as Potential Mediators of Pathogen-Induced T-Helper 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC).
    Hepatology. 2020;72:1310-1326.
    PubMed     Abstract available


    September 2020
  590. CALZADILLA-BERTOT L, Vilar-Gomez E, Wong VW, Romero-Gomez M, et al
    ABIDE: an accurate predictive model of liver decompensation in patients with non-alcoholic fatty liver-related cirrhosis.
    Hepatology. 2020 Sep 25. doi: 10.1002/hep.31576.
    PubMed     Abstract available


  591. CHANDLER RJ, Venturoni LE, Liao J, Hubbard BT, et al
    Promoterless, nuclease-free genome editing confers a growth advantage for corrected hepatocytes in mice with methylmalonic acidemia.
    Hepatology. 2020 Sep 25. doi: 10.1002/hep.31570.
    PubMed     Abstract available


  592. OOSHIO T, Yamamoto M, Fujii K, Xin B, et al
    Hepatocyte MKK7 Contributes to Restoration of the Liver Parenchyma Following Injury.
    Hepatology. 2020 Sep 23. doi: 10.1002/hep.31565.
    PubMed     Abstract available


  593. ZHANG BH, Cai YS, Song JL, Lyu T, et al
    Letter to the Editor: Statin Reduces the Risk of Hepatocellular Carcinoma Development in CHB Patients.
    Hepatology. 2020 Sep 23. doi: 10.1002/hep.31563.
    PubMed     Abstract available


  594. GOH MJ, Sinn DH, Woo SY, Kim S, et al
    Statins and reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: Author's Reply.
    Hepatology. 2020 Sep 22. doi: 10.1002/hep.31567.
    PubMed     Abstract available


  595. CHEN D, Wu H, Feng X, Chen Y, et al
    DNA Methylation of CNRIP1 Promotes Pathogenesis of Intrahepatic Cholangiocarcinoma Through Suppressing Parkin-Dependent PKM2 Ubiquitination.
    Hepatology. 2020 Sep 21. doi: 10.1002/hep.31561.
    PubMed     Abstract available


  596. MAHMUD N, Fricker Z, Hubbard RA, Ioannou GN, et al
    Novel Risk Prediction Models for Post-Operative Mortality in Patients with Cirrhosis.
    Hepatology. 2020 Sep 16. doi: 10.1002/hep.31558.
    PubMed     Abstract available


  597. JASPER S, Hakeem AR, Vij M, Sachan D, et al
    First report of toxin-induced graft injury following liver transplantation for Yellow Phosphorus Poisoning.
    Hepatology. 2020 Sep 16. doi: 10.1002/hep.31553.
    PubMed     Abstract available


  598. MARTIN N, Ziegler DV, Parent R, Bernard D, et al
    Hepatic Stellate Cell Senescence in Liver Tumorigenesis.
    Hepatology. 2020 Sep 15. doi: 10.1002/hep.31556.
    PubMed     Abstract available


  599. MORRIS JS, Hassan MM, Zohner YE, Wang Z, et al
    HepatoScore-14: Measures of biological heterogeneity significantly improve prediction of hepatocellular carcinoma risk.
    Hepatology. 2020 Sep 15. doi: 10.1002/hep.31555.
    PubMed     Abstract available


  600. YAZDANI HO, Kaltenmeier C, Morder K, Moon J, et al
    Exercise training decreases hepatic injury via changes in immune response to liver ischemia/reperfusion in mice.
    Hepatology. 2020 Sep 14. doi: 10.1002/hep.31552.
    PubMed     Abstract available


  601. VERMA M, Younossi Z
    Integrating Patient Reported Outcomes within Routine Hepatology Care: A Prompt to Action.
    Hepatology. 2020 Sep 12. doi: 10.1002/hep.31550.
    PubMed     Abstract available


  602. THOMSON MJ, Lok AS, Tapper EB
    Appropriate and Potentially Inappropriate Medication Use in Decompensated Cirrhosis.
    Hepatology. 2020 Sep 10. doi: 10.1002/hep.31548.
    PubMed     Abstract available


  603. ZHEN S, Cai X
    Letter to Editor: Predicting survival after hepatocellular carcinoma resection using deep-learning on histological slides.
    Hepatology. 2020 Sep 7. doi: 10.1002/hep.31543.
    PubMed     Abstract available


  604. CHEN L, Zhou T, White T, O'Brien A, et al
    The apelin-apelin receptor axis triggers cholangiocyte proliferation and liver fibrosis during mouse models of cholestasis.
    Hepatology. 2020 Sep 7. doi: 10.1002/hep.31545.
    PubMed     Abstract available


  605. PIANO S, Gambino C, Vettore E, Calvino V, et al
    Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome.
    Hepatology. 2020 Sep 1. doi: 10.1002/hep.31529.
    PubMed     Abstract available


  606. PHIPPS MM, Barraza LH, LaSota ED, Sobieszczyk ME, et al
    Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort.
    Hepatology. 2020;72:807-817.
    PubMed     Abstract available


  607. DA BL, Im GY, Schiano TD
    Coronavirus Disease 2019 Hangover: A Rising Tide of Alcohol Use Disorder and Alcohol-Associated Liver Disease.
    Hepatology. 2020;72:1102-1108.
    PubMed     Abstract available


  608. KAPLAN A, Rosenblatt R, Buckholz A, Kumar S, et al
    Hepatology Highlights.
    Hepatology. 2020;72:791-793.
    PubMed    


  609. JIANG X, Ding WX
    Acyl Coenzyme A Thioesterase 9: A Novel Target for Nonalcoholic Fatty Liver Disease by Shuttling Mitochondrial Short-Chain Fatty Acids?
    Hepatology. 2020;72:797-800.
    PubMed    


  610. GUICCIARDI ME, Nakao Y, Gores GJ
    The Metabolic Sensor Adenosine Monophosphate-Activated Protein Kinase Regulates Apoptosis in Nonalcoholic Steatohepatitis.
    Hepatology. 2020;72:1139-1141.
    PubMed    


  611. KUMAR M
    Reply.
    Hepatology. 2020;72:1160.
    PubMed    


  612. WEISS TS, Melter M, Dayoub R
    Letter to the Editor: Does Augmenter of Liver Regeneration Deficiency Pave the Way for Nonalcoholic Steatohepatitis Progression?
    Hepatology. 2020;72:1156-1157.
    PubMed    


  613. VERMA AK, Gandhi CR
    Reply.
    Hepatology. 2020;72:1157-1158.
    PubMed    


    August 2020
  614. SCHWANTES-AN TH, Darlay R, Mathurin P, Masson S, et al
    Genome-wide association study and meta-analysis on alcohol-related liver cirrhosis identifies novel genetic risk factors.
    Hepatology. 2020 Aug 27. doi: 10.1002/hep.31535.
    PubMed     Abstract available


  615. LOOMBA R, Ling L, Dinh DM, DePaoli AM, et al
    The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in Nonalcoholic Steatohepatitis.
    Hepatology. 2020 Aug 13. doi: 10.1002/hep.31523.
    PubMed     Abstract available


  616. BHUSHAN B, Molina L, Koral K, Stoops JW, et al
    Yap is crucial for CAR-driven hepatocyte proliferation, but not for induction of drug metabolism genes in mice.
    Hepatology. 2020 Aug 13. doi: 10.1002/hep.31521.
    PubMed     Abstract available


  617. LEUNG KK, James PD, Jaberi A, Hirschfield GM, et al
    Esophageal Stenting as Bridge Therapy to Direct Intrahepatic Portocaval Shunt for Refractory Variceal Bleeding.
    Hepatology. 2020 Aug 11. doi: 10.1002/hep.31519.
    PubMed     Abstract available


  618. KULKARNI AV, Sharma M, Kumar P, Gupta R, et al
    Midodrine for Hepatic Hydrothorax.
    Hepatology. 2020 Aug 8. doi: 10.1002/hep.31513.
    PubMed     Abstract available


  619. BANINI BA, Alwatari Y, Ogden N, Gershman E, et al
    Letter to Editor: Response to Commentary "Midodrine for Hepatic Hydrothorax".
    Hepatology. 2020 Aug 7. doi: 10.1002/hep.31512.
    PubMed     Abstract available


  620. LU L, Jiang J, Zhan M, Zhang H, et al
    Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies.
    Hepatology. 2020 Aug 7. doi: 10.1002/hep.31502.
    PubMed     Abstract available


  621. DEGASPERI E, Galmozzi E, Pelusi S, D'Ambrosio R, et al
    Hepatic fat - genetic risk score predicts hepatocellular carcinoma in HCV cirrhotic patients treated with DAAs.
    Hepatology. 2020 Aug 6. doi: 10.1002/hep.31500.
    PubMed     Abstract available


  622. FRISSEN M, Liao L, Schneider KM, Djudjaj S, et al
    Bidirectional role of NLRP3 during acute and chronic cholestatic liver injury.
    Hepatology. 2020 Aug 4. doi: 10.1002/hep.31494.
    PubMed     Abstract available


  623. GINDIN Y, Chung C, Jiang Z, Zhou JZ, et al
    A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Novel Drivers of Disease Progression in Primary Sclerosing Cholangitis.
    Hepatology. 2020 Aug 3. doi: 10.1002/hep.31488.
    PubMed     Abstract available


  624. VERNA EC, Serper M, Chu J, Corey K, et al
    Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation.
    Hepatology. 2020 Aug 2. doi: 10.1002/hep.31491.
    PubMed     Abstract available


  625. WANGENSTEEN KJ, Chang KM
    Multiple roles for hepatitis B and C viruses and the host in the development of hepatocellular carcinoma.
    Hepatology. 2020 Aug 1. doi: 10.1002/hep.31481.
    PubMed     Abstract available


  626. TALAT A, Shah PA, Lau DTY, Russo NW, et al
    Hepatology Highlights.
    Hepatology. 2020;72:369-370.
    PubMed    


  627. SERPER M, Cubell AW, Deleener ME, Casher TK, et al
    Telemedicine in Liver Disease and Beyond: Can the COVID-19 Crisis Lead to Action?
    Hepatology. 2020;72:723-728.
    PubMed     Abstract available


  628. WEN Y, Ju C
    MER Proto-Oncogene Tyrosine Kinase: A Novel Potential Target to Treat Nonalcoholic Steatohepatitis Fibrosis.
    Hepatology. 2020;72:772-774.
    PubMed    


  629. SINHA RA, Bruinstroop E, Singh BK, Yen PM, et al
    Thyroid Hormones and Thyromimetics: A New Approach to Nonalcoholic Steatohepatitis?
    Hepatology. 2020;72:770-771.
    PubMed    


  630. GAWRIEH S, Kleiner DE, Chalasani N, Vanderbeck S, et al
    Letter to the Editor: Quantitative Histological Assessment in Nonalcoholic Fatty Liver Disease.
    Hepatology. 2020;72:785.
    PubMed    


  631. WEI L, Chang PEJ, Anstee QM
    Reply.
    Hepatology. 2020;72:786.
    PubMed    


  632. KWON HM, Hwang GS
    Reply.
    Hepatology. 2020;72:784.
    PubMed    


  633. HUANG JF, Dai CY, Yu ML, Chuang WL, et al
    Letter to the Editor: Regional Epidemics of Nonalcoholic Fatty Liver Disease: Timing of Westernization and Ethnicity Matter.
    Hepatology. 2020;72:781.
    PubMed    


    July 2020
  634. LV Y, Wang Z, Li K, Wang Q, et al
    Risk Stratification based on CLIF Consortium Acute Decompensation score in Patients with Child-Pugh B Cirrhosis and Acute Variceal Bleeding.
    Hepatology. 2020 Jul 24. doi: 10.1002/hep.31478.
    PubMed     Abstract available


  635. AMZAL R, Thebaut A, Lapalus M, Almes M, et al
    Pharmacological premature termination codon readthrough of ABCB11 in bile salt export pump deficiency: an in vitro study.
    Hepatology. 2020 Jul 23. doi: 10.1002/hep.31476.
    PubMed     Abstract available


  636. SABERI B, Naik H, Overbey JR, Erwin AL, et al
    Hepatocellular Carcinoma in Acute Hepatic Porphyrias: Results from the Longitudinal Study of the U.S. Porphyrias Consortium.
    Hepatology. 2020 Jul 18. doi: 10.1002/hep.31460.
    PubMed     Abstract available


  637. LISMAN T
    Hemostatic Changes of Acute Kidney Injury in Patients With Cirrhosis: What Do They Mean?
    Hepatology. 2020 Jul 4. doi: 10.1002/hep.31451.
    PubMed     Abstract available


  638. ZANETTO A, Rinder HM, Campello E, Saggiorato G, et al
    Acute kidney injury in decompensated cirrhosis is associated with both hypo- and hyper-coagulable features.
    Hepatology. 2020 Jul 2. doi: 10.1002/hep.31443.
    PubMed     Abstract available


  639. WEI X, Zhao L, Ren R, Ji F, et al
    MiR-125b Loss Activated HIF1alpha/pAKT Loop, Leading to Trans-Arterial Chemoembolization Resistance in Hepatocellular Carcinoma.
    Hepatology. 2020 Jul 1. doi: 10.1002/hep.31448.
    PubMed     Abstract available


  640. WANG Y
    Letter to the Editor: Issues of Circular RNAs as MicroRNA Sponges.
    Hepatology. 2020;72:365.
    PubMed    


  641. LI L, Wei Y, Wang H
    REPLY.
    Hepatology. 2020;72:366.
    PubMed    


  642. HOOFNAGLE JH
    FXR Agonists as Therapy for Liver Disease.
    Hepatology. 2020;72:1-3.
    PubMed    


  643. MALLAT A, Lotersztajn S
    Glutamate Signaling in Alcohol-associated Fatty Liver: "Pas de Deux".
    Hepatology. 2020;72:350-352.
    PubMed    


  644. SU T, Iwakiri Y
    Endothelial Leukocyte Cell-Derived Chemotaxin 2/Tyrosine Kinase With Immunoglobulin-Like and Epidermal Growth Factor-Like Domains 1 Signaling in Liver Fibrosis.
    Hepatology. 2020;72:347-349.
    PubMed    


  645. YANG JD, Mara KC, Gores GJ, Roberts LR, et al
    Reply.
    Hepatology. 2020;72:364-365.
    PubMed    


  646. YANG JD, Mara KC, Gores GJ, Roberts LR, et al
    REPLY.
    Hepatology. 2020;72:362-363.
    PubMed    


  647. ARASE Y, Kagawa T, Tanaka A
    Reply.
    Hepatology. 2020;72:360-361.
    PubMed    


  648. LLEO A, Ma X, Gershwin ME, Invernizzi P, et al
    Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?
    Hepatology. 2020;72:359-360.
    PubMed    


    June 2020
  649. PAPATHEODORIDIS GV, Voulgaris T, Papatheodoridi M, Kim WR, et al
    Risk Scores for Hepatocellular Carcinoma in Chronic Hepatitis B: A Promise for Precision Medicine.
    Hepatology. 2020 Jun 30. doi: 10.1002/hep.31440.
    PubMed     Abstract available


  650. KIM BK, Kim SU
    Re: Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma after Surgical Resection.
    Hepatology. 2020 Jun 29. doi: 10.1002/hep.31439.
    PubMed     Abstract available


  651. WU J, Gao W, Tang Q, Yu Y, et al
    M2 macrophage-derived exosomes facilitate hepatocarcinoma metastasis by transferring alphaM beta2 integrin to tumor cells.
    Hepatology. 2020 Jun 28. doi: 10.1002/hep.31432.
    PubMed     Abstract available


  652. XU M, Ge C, Zhu L, Qin Y, et al
    iRhom2 promotes hepatic steatosis by activating MAP3K7-dependent pathway.
    Hepatology. 2020 Jun 26. doi: 10.1002/hep.31436.
    PubMed     Abstract available


  653. BANINI BA, Alwatari Y, Stovall M, Ogden N, et al
    Multidisciplinary Management of Hepatic Hydrothorax in 2020: An Evidence-Based Review and Guidance.
    Hepatology. 2020 Jun 25. doi: 10.1002/hep.31434.
    PubMed     Abstract available


  654. AKBULUT S, Sahin TT, Yilmaz S
    Comment on Alpha-Fetoprotein Decrease from > 1.000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes.
    Hepatology. 2020 Jun 24. doi: 10.1002/hep.31433.
    PubMed     Abstract available


  655. KLOECKNER R, Galle PR, Bruix J
    Local and Regional Therapies for Hepatocellular Carcinoma.
    Hepatology. 2020 Jun 18. doi: 10.1002/hep.31424.
    PubMed     Abstract available


  656. KIM YS, Nam HJ, Han CY, Joo MS, et al
    LXRalpha activation inhibits autophagy and lipophagy in hepatocytes by dysregulating ATG4B and Rab-8B, reducing mitochondrial fuel oxidation.
    Hepatology. 2020 Jun 17. doi: 10.1002/hep.31423.
    PubMed     Abstract available


  657. RUSSO MW, Fix OK, Koteish AA, Duggan K, et al
    Modeling the Hepatology Workforce in the United States: A Predicted Critical Shortage.
    Hepatology. 2020 Jun 17. doi: 10.1002/hep.31425.
    PubMed     Abstract available


  658. ZHANG J, Li Y, Liu Q, Huang Y, et al
    Sirt6 alleviated liver fibrosis by deacetylating conserved lysine 54 on Smad2 in hepatic stellate cells.
    Hepatology. 2020 Jun 14. doi: 10.1002/hep.31418.
    PubMed     Abstract available


  659. ALFERINK LJ, Radjabzadeh D, Erler NS, Vojinovic D, et al
    Microbiomics, metabolomics, predicted metagenomics and hepatic steatosis in a population-based study of 1355 adults.
    Hepatology. 2020 Jun 12. doi: 10.1002/hep.31417.
    PubMed     Abstract available


  660. XIE C, Fang JH, Zhuang SM
    Reply to: Letter to the editor, "PDIA3P1 level could predict recurrence-free survival in hepatocellular carcinoma: reliable?" (HEP-20-0942).
    Hepatology. 2020 Jun 11. doi: 10.1002/hep.31300.
    PubMed     Abstract available


  661. MUNROE M, Niero EL, Fok WC, Vessoni AT, et al
    Telomere dysfunction activates p53 and represses HNF4alpha expression leading to impaired human hepatocyte development and function.
    Hepatology. 2020 Jun 9. doi: 10.1002/hep.31414.
    PubMed     Abstract available


  662. PFEIFFER RM, Rotman Y, O'Brien TR
    Genetic Determinants of Cirrhosis and Hepatocellular Carcinoma Due to Fatty Liver Disease: What's the Score?
    Hepatology. 2020 Jun 7. doi: 10.1002/hep.31413.
    PubMed     Abstract available


  663. ZHAO N, Dang H, Ma L, Martin SP, et al
    Intratumoral gammadelta T-cell infiltrates, CCL4/5 protein expression and survival in patients with hepatocellular carcinoma.
    Hepatology. 2020 Jun 5. doi: 10.1002/hep.31412.
    PubMed     Abstract available


  664. ABUD A, Maddur H, Salem R
    Management of symptomatic portal cavernoma cholangiopathy via transplenic portal vein recanalization and TIPS.
    Hepatology. 2020 Jun 5. doi: 10.1002/hep.31411.
    PubMed     Abstract available


  665. PRABHU A, Cargill T, Roberts N, Ryan JD, et al
    Systematic review of the clinical outcomes of iron reduction in Hereditary Hemochromatosis.
    Hepatology. 2020 Jun 4. doi: 10.1002/hep.31405.
    PubMed     Abstract available


  666. KUMAR K, Kulkarni AV
    Sodium-Glucose Cotransporter-2(SGLT2-I) inhibitor are not the magic pills for control of ascites in cirrhosis and diabetes.
    Hepatology. 2020 Jun 3. doi: 10.1002/hep.31399.
    PubMed     Abstract available


  667. PATEL K, Chung C, Myers RP
    Reply to HEP-20-0871 Letter to the Editors: Cilofexor in patients with non-alcoholic steatohepatitis (NASH): Is it really effective?
    Hepatology. 2020 Jun 3. doi: 10.1002/hep.31402.
    PubMed     Abstract available


  668. PATOULIAS D, Katsimardou A, Papadopoulos C, Doumas M, et al
    Letter to the Editor: Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes.
    Hepatology. 2020 Jun 3. doi: 10.1002/hep.31398.
    PubMed     Abstract available


  669. KARDASHIAN A, Ge J, McCulloch CE, Kappus MR, et al
    Identifying an Optimal Liver Frailty Index Cutoff to Predict Waitlist Mortality in Liver Transplant Candidates.
    Hepatology. 2020 Jun 3. doi: 10.1002/hep.31406.
    PubMed     Abstract available


  670. JINDAL A, Sarin SK
    Letter to the Editors: Cilofexor in Patients With Nonalcoholic Steatohepatitis (NASH): Is It Really Effective?
    Hepatology. 2020 Jun 2. doi: 10.1002/hep.31400.
    PubMed     Abstract available


  671. THALJI L, Thalji NM, Heimbach JK, Ibrahim SH, et al
    Renal Function Parameters and Serum Sodium Enhance Prediction of Waitlist Outcomes in Pediatric Liver Transplantation.
    Hepatology. 2020 Jun 2. doi: 10.1002/hep.31397.
    PubMed     Abstract available


  672. LUCEY MR, Singal AK
    Integrated Treatment of Alcohol Use Disorder in Patients With Alcohol-Associated Liver Disease: An Evolving Story.
    Hepatology. 2020;71:1891-1893.
    PubMed    


    May 2020
  673. CALVISI DF
    Schistoma mansoni and Hepatocellular Carcinoma: is it all about c-Jun and STAT3?
    Hepatology. 2020 May 28. doi: 10.1002/hep.31392.
    PubMed     Abstract available


  674. HALL Z, Chiarugi D, Charidemou E, Leslie J, et al
    Lipid remodelling in hepatocyte proliferation and hepatocellular carcinoma.
    Hepatology. 2020 May 27. doi: 10.1002/hep.31391.
    PubMed     Abstract available


  675. SMITH JL, Rodriguez TC, Mou H, Kwan SY, et al
    YAP1 withdrawal in hepatoblastoma drives therapeutic differentiation of tumor cells to functional hepatocyte-like cells.
    Hepatology. 2020 May 26. doi: 10.1002/hep.31389.
    PubMed     Abstract available


  676. GUNASEKARAN G, Bekki Y, Lourdusamy V, Schwartz M, et al
    Surgical Treatments of Hepatobiliary Cancers.
    Hepatology. 2020 May 21. doi: 10.1002/hep.31325.
    PubMed     Abstract available


  677. LLOVET JM, Villanueva A, Marrero JA, Schwartz M, et al
    Trial Design and Endpoints in hepatocellular carcinoma: AASLD Consensus Conference.
    Hepatology. 2020 May 20. doi: 10.1002/hep.31327.
    PubMed     Abstract available


  678. DEVARBHAVI H
    RE: Acute Liver Failure (ALF) in Pregnancy: How Much Is Pregnancy-Related? Casey et al. Hepatology 2020 Jan 28[Online ahead of print DOI: 10.1002/hep.31144.
    Hepatology. 2020 May 17. doi: 10.1002/hep.31323.
    PubMed     Abstract available


  679. CHU S, Sun R, Gu X, Chen L, et al
    Inhibition of sphingosine-1-phosphate-induced Th17 cells ameliorates alcoholic steatohepatitis in mice.
    Hepatology. 2020 May 17. doi: 10.1002/hep.31321.
    PubMed     Abstract available


  680. NEWTON KP, Lavine JE, Wilson L, Behling C, et al
    Alanine Aminotransferase and Gamma Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis.
    Hepatology. 2020 May 16. doi: 10.1002/hep.31317.
    PubMed     Abstract available


  681. GABR A, Kulik L, Mouli S, Riaz A, et al
    Liver Transplantation Following Yttrium-90 Radioembolization: 15-year Experience in 207-Patient Cohort.
    Hepatology. 2020 May 16. doi: 10.1002/hep.31318.
    PubMed     Abstract available


  682. VANDEL J, Dubois-Chevalier J, Gheeraert C, Derudas B, et al
    Hepatic molecular signatures highlight the sexual dimorphism of Non-Alcoholic SteatoHepatitis (NASH).
    Hepatology. 2020 May 11. doi: 10.1002/hep.31312.
    PubMed     Abstract available


  683. WOLF E, Rich NE, Marrero JA, Parikh N, et al
    Utilization of hepatocellular carcinoma surveillance in patients with cirrhosis: A systematic review and meta-analysis.
    Hepatology. 2020 May 8. doi: 10.1002/hep.31309.
    PubMed     Abstract available


  684. FINN RS, Zhu AX
    Evolution of Systemic Therapy for Hepatocellular Carcinoma.
    Hepatology. 2020 May 7. doi: 10.1002/hep.31306.
    PubMed     Abstract available


  685. LI W
    Letter to the Editor: PDIA3P1 level could predict recurrence-free survival in hepatocellular carcinoma: reliable?
    Hepatology. 2020 May 7. doi: 10.1002/hep.31299.
    PubMed     Abstract available


  686. PISA JF, Brown RS Jr, Hirsova P, Schwartz RE, et al
    Hepatology Highlights.
    Hepatology. 2020;71:1527-1529.
    PubMed    


  687. KAPLOWITZ N, Than TA, Win S
    Acetaminophen Hepatotoxicity: Strong Offense and Weakened Defense.
    Hepatology. 2020;71:1530-1532.
    PubMed    


  688. RAEVENS S, Fallon MB
    PORTICO: First Randomized Controlled Trial of Vasomodulator Therapy in Portopulmonary Hypertension.
    Hepatology. 2020;71:1870-1872.
    PubMed    


  689. HENSON JB, Roden M, Targher G, Corey KE, et al
    Is Nonalcoholic Fatty Liver Disease Not a Risk Factor for Cardiovascular Disease: Not Yet Time for a Change of Heart.
    Hepatology. 2020;71:1867-1869.
    PubMed    


  690. ABERG F, Farkkila M, Salomaa V, Jula A, et al
    REPLY.
    Hepatology. 2020;71:1888-1889.
    PubMed    


  691. GOW P, Testro AG, Hey P, Sinclair M, et al
    Letter to the Editor: Moderate Alcohol Use in Fatty Liver Disease: Don't Throw the Cabernet Out With the Bathwater.
    Hepatology. 2020;71:1887-1888.
    PubMed    


  692. MA Y, Brown PM, Rotman Y
    REPLY.
    Hepatology. 2020;71:1886-1887.
    PubMed    


  693. GALMOZZI E
    Letter to the Editor: Does the HSD17B13 rs72613567 Splice Variant Actually Yield a New Type of Alternative Splicing?
    Hepatology. 2020;71:1885-1886.
    PubMed    


  694. IZZY M, VanWagner LB, Lin G, Altieri M, et al
    Reply.
    Hepatology. 2020;71:1884-1885.
    PubMed    


  695. ZHOU J, Zhou F, Wang W, Zhang XJ, et al
    Epidemiological Features of NAFLD From 1999 to 2018 in China.
    Hepatology. 2020;71:1851-1864.
    PubMed     Abstract available


  696. CHEN Y, Liu K, Zhang J, Hai Y, et al
    c-Jun NH2 -Terminal Protein Kinase Phosphorylates the Nrf2-ECH Homology 6 Domain of Nuclear Factor Erythroid 2-Related Factor 2 and Downregulates Cytoprotective Genes in Acetaminophen-Induced Liver Injury in Mice.
    Hepatology. 2020;71:1787-1801.
    PubMed     Abstract available


  697. GAO W, Jia Z, Tian Y, Yang P, et al
    HBx Protein Contributes to Liver Carcinogenesis by H3K4me3 Modification Through Stabilizing WD Repeat Domain 5 Protein.
    Hepatology. 2020;71:1678-1695.
    PubMed     Abstract available


  698. FLEMING BD, Urban DJ, Hall MD, Longerich T, et al
    Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.
    Hepatology. 2020;71:1696-1711.
    PubMed     Abstract available


  699. XIE C, Zhang LZ, Chen ZL, Zhong WJ, et al
    A hMTR4-PDIA3P1-miR-125/124-TRAF6 Regulatory Axis and Its Function in NF kappa B Signaling and Chemoresistance.
    Hepatology. 2020;71:1660-1677.
    PubMed     Abstract available


    April 2020
  700. BEYLS C, Haustermans K, Deroose CM, Pans S, et al
    Could autoimmune disease contribute to the abscopal effect in metastatic hepatocellular carcinoma?
    Hepatology. 2020 Apr 29. doi: 10.1002/hep.31186.
    PubMed     Abstract available


  701. FONDEVILA MF, Fernandez U, Gonzalez-Rellan MJ, Da Silva Lima N, et al
    The L-alpha-lysophosphatidylinositol/GPR55 system induces the development of non-alcoholic steatosis and steatohepatitis.
    Hepatology. 2020 Apr 23. doi: 10.1002/hep.31290.
    PubMed     Abstract available


  702. CHOI J, Jo C, Lim YS
    Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma after Surgical Resection.
    Hepatology. 2020 Apr 23. doi: 10.1002/hep.31289.
    PubMed     Abstract available


  703. MCGLYNN KA, Petrick JL, El-Serag HB
    Epidemiology of Hepatocellular Carcinoma.
    Hepatology. 2020 Apr 22. doi: 10.1002/hep.31288.
    PubMed     Abstract available


  704. KUMAR A
    Letter to the Editor: Role of Sorafenib in Liver Transplantation Outcomes of Patients with Hepatocellular Carcinoma Presenting Beyond Milan Criteria?
    Hepatology. 2020 Apr 22. doi: 10.1002/hep.31285.
    PubMed     Abstract available


  705. KARDASHIAN A, Agopian V
    Reply to: "Role of Sorafenib in Liver Transplantation Outcomes of Patients with Hepatocellular Carcinoma Presenting Beyond Milan Criteria?"
    Hepatology. 2020 Apr 20. doi: 10.1002/hep.31283.
    PubMed     Abstract available


  706. MAHMUD N, Asrani SK
    Defining (and refining) the role of the Model for End Stage Liver Disease-Lactate (MELD-LA) score in cirrhosis.
    Hepatology. 2020 Apr 20. doi: 10.1002/hep.31287.
    PubMed     Abstract available


  707. LU L, Jiang J, Zhan M, Zhang H, et al
    Targeting Neoantigens in Hepatocellular Carcinoma for Immunotherapy: A Futile Strategy?
    Hepatology. 2020 Apr 16. doi: 10.1002/hep.31279.
    PubMed     Abstract available


  708. FIX OK, Hameed B, Fontana RJ, Kwok RM, et al
    Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement.
    Hepatology. 2020 Apr 16. doi: 10.1002/hep.31281.
    PubMed     Abstract available


  709. ZHANG L, Tian R, Yao X, Zhang XJ, et al
    Milk Fat Globule-EGF Factor 8 improves Hepatic Steatosis and Inflammation.
    Hepatology. 2020 Apr 15. doi: 10.1002/hep.31277.
    PubMed     Abstract available


  710. MONTALVO-GORDON I, Chi-Cervera LA, Garcia-Tsao G
    Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes.
    Hepatology. 2020 Apr 15. doi: 10.1002/hep.31270.
    PubMed     Abstract available


  711. DAVE S, Park S, Murad MH, Barnard A, et al
    Comparative Effectiveness of Entecavir vs Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: a Systematic Review and Meta-analysis.
    Hepatology. 2020 Apr 10. doi: 10.1002/hep.31267.
    PubMed     Abstract available


  712. SERPER M, Weinberg EM, Cohen JB, Reese PP, et al
    Mortality and hepatic decompensation in patients with cirrhosis and atrial fibrillation treated with anticoagulation.
    Hepatology. 2020 Apr 8. doi: 10.1002/hep.31264.
    PubMed     Abstract available


  713. PRIMIGNANI M, Tosetti G, Tripodi A
    Thromboelastography guided blood product transfusion in cirrhosis with coagulopathy: real saving or just less waste?
    Hepatology. 2020 Apr 8. doi: 10.1002/hep.31263.
    PubMed     Abstract available


  714. KUMAR A, Sharma P, Arora A
    A new prognostic algorithm based on stage of cirrhosis and HVPG to improve risk-stratification after variceal bleeding.
    Hepatology. 2020 Apr 4. doi: 10.1002/hep.31254.
    PubMed     Abstract available


  715. LAPUMNUAYPOL K, Danford CJ, Lau DTY, Pisa JF, et al
    Hepatology Highlights.
    Hepatology. 2020;71:1143-1145.
    PubMed    


  716. RATZIU V
    Timing Is Everything: Improving NASH Histology in Clinical Trials Should Not Be Rushed.
    Hepatology. 2020;71:1146-1149.
    PubMed    


  717. WANG S, Friedman SL
    Taming the Savage Breast From Within: Transcription Factor 21, a Regulator of Stellate Cell Deactivation.
    Hepatology. 2020;71:1150-1153.
    PubMed    


  718. HILSCHER MB, Shah VH
    Small but Mighty: Platelets in NASH and Other Chronic Liver Diseases.
    Hepatology. 2020;71:1501-1504.
    PubMed    


  719. YKI-JARVINEN H
    Ceramides: A Cause of Insulin Resistance in Nonalcoholic Fatty Liver Disease in Both Murine Models and Humans.
    Hepatology. 2020;71:1499-1501.
    PubMed    


  720. HAJIFATHALIAN K, Torabi Sagvand B, McCullough A
    Reply.
    Hepatology. 2020;71:1526.
    PubMed    


  721. BRAILLON A
    Letter to the Editor: Modest Alcohol Consumption and Nonalcoholic Fatty Liver Disease: An Oxymoron?
    Hepatology. 2020;71:1525.
    PubMed    


  722. CARVAO J, Jasmins L
    Letter to the Editor: Glomerular Filtration Rate Assessment in Liver Disease (GRAIL): Are We There Yet?
    Hepatology. 2020;71:1522-1523.
    PubMed    


  723. KHALAF RT, Sokol RJ
    New Insights Into Intestinal Failure-Associated Liver Disease in Children.
    Hepatology. 2020;71:1486-1498.
    PubMed     Abstract available


  724. XIONG X, Kuang H, Liu T, Lin JD, et al
    A Single-Cell Perspective of the Mammalian Liver in Health and Disease.
    Hepatology. 2020;71:1467-1473.
    PubMed    


  725. IBRAHIM SH, Jonas MM, Taylor SA, Gutierrez Sanchez LH, et al
    Liver Diseases in the Perinatal Period: Interactions Between Mother and Infant.
    Hepatology. 2020;71:1474-1485.
    PubMed     Abstract available


  726. XIONG J, Liu T, Mi L, Kuang H, et al
    hnRNPU/TrkB Defines a Chromatin Accessibility Checkpoint for Liver Injury and Nonalcoholic Steatohepatitis Pathogenesis.
    Hepatology. 2020;71:1228-1246.
    PubMed     Abstract available


  727. LIU J, Wu Z, Han D, Wei C, et al
    Mesencephalic Astrocyte-Derived Neurotrophic Factor Inhibits Liver Cancer Through Small Ubiquitin-Related Modifier (SUMO)ylation-Related Suppression of NF-kappaB/Snail Signaling Pathway and Epithelial-Mesenchymal Transition.
    Hepatology. 2020;71:1262-1278.
    PubMed     Abstract available


  728. ADAMS JM, Huppert KA, Castro EC, Lopez MF, et al
    Sox9 Is a Modifier of the Liver Disease Severity in a Mouse Model of Alagille Syndrome.
    Hepatology. 2020;71:1331-1349.
    PubMed     Abstract available


  729. CHEN F, Esmaili S, Rogers GB, Bugianesi E, et al
    Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation.
    Hepatology. 2020;71:1213-1227.
    PubMed     Abstract available


  730. ZHANG C, Lin R, Li Z, Yang S, et al
    Immune Exhaustion of T Cells in Alveolar Echinococcosis Patients and Its Reversal by Blocking Checkpoint Receptor TIGIT in a Murine Model.
    Hepatology. 2020;71:1297-1315.
    PubMed     Abstract available


  731. SHIGETA K, Datta M, Hato T, Kitahara S, et al
    Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.
    Hepatology. 2020;71:1247-1261.
    PubMed     Abstract available


    March 2020
  732. LIU Y, Yang W, VoPham T, Ma Y, et al
    Plant-based and animal-based low-carbohydrate diets and risk of hepatocellular carcinoma among US men and women.
    Hepatology. 2020 Mar 29. doi: 10.1002/hep.31251.
    PubMed     Abstract available


  733. QIN J, Wang H, Qin X, Zhang P, et al
    Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient.
    Hepatology. 2020 Mar 27. doi: 10.1002/hep.31257.
    PubMed     Abstract available


  734. SCHWACHA-EIPPER B, Minciuna I, Banz V, Dufour JF, et al
    Immunotherapy as a downstaging therapy for liver transplantation.
    Hepatology. 2020 Mar 14. doi: 10.1002/hep.31234.
    PubMed     Abstract available


  735. ISAACS-TEN A, Echeandia M, Moreno-Gonzalez M, Brion A, et al
    Intestinal microbiome-macrophage crosstalk contributes to cholestatic liver disease by promoting intestinal permeability.
    Hepatology. 2020 Mar 13. doi: 10.1002/hep.31228.
    PubMed     Abstract available


  736. STENDER S, Loomba R
    PNPLA3 Genotype and Risk of Liver and All-Cause Mortality.
    Hepatology. 2020;71:777-779.
    PubMed    


  737. TANER T, Heimbach JK
    Something Wicked this Way Comes.
    Hepatology. 2020;71:1119-1121.
    PubMed    


  738. WONG GL, Wong VW
    Reply.
    Hepatology. 2020;71:1134.
    PubMed    


  739. LO GH
    Letter to the Editor: Could Variceal Screening Stratified by Liver/Spleen Stiffness Replace the Role of Endoscopy?
    Hepatology. 2020;71:1133.
    PubMed    


  740. RIZVI S, Gores GJ
    The Two Faces of Relaxin in Cancer: Antitumor or Protumor?
    Hepatology. 2020;71:1117-1119.
    PubMed    


  741. SUGIYAMA T
    Letter to the Editor: Bone Health and Denosumab Treatment in Autoimmune Liver Diseases: A Possible Involvement of Physical Activity.
    Hepatology. 2020;71:1131-1132.
    PubMed    


  742. ARASE Y, Kagawa T
    Reply.
    Hepatology. 2020;71:1132-1133.
    PubMed    


  743. YANG D, Yan J, Weng J
    Reply.
    Hepatology. 2020;71:1129.
    PubMed    


  744. LU ZN, Han ZG
    Reply.
    Hepatology. 2020;71:1130-1131.
    PubMed    


  745. WANG JB, Bai ZF, Xiao XH
    Letter to the Editor: Is Aristolochic Acid the Major Cause of Liver Cancer in China and Asia?
    Hepatology. 2020;71:1130.
    PubMed    


  746. SPANN A, Yasodhara A, Kang J, Watt K, et al
    Applying Machine Learning in Liver Disease and Transplantation: A Comprehensive Review.
    Hepatology. 2020;71:1093-1105.
    PubMed     Abstract available


  747. UNALP-ARIDA A, Ruhl CE
    Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population.
    Hepatology. 2020;71:820-834.
    PubMed     Abstract available


  748. LU ZN, Luo Q, Zhao LN, Shi Y, et al
    The Mutational Features of Aristolochic Acid-Induced Mouse and Human Liver Cancers.
    Hepatology. 2020;71:929-942.
    PubMed     Abstract available


  749. AJMERA VH, Liu A, Singh S, Yachoa G, et al
    Clinical Utility of an Increase in Magnetic Resonance Elastography in Predicting Fibrosis Progression in Nonalcoholic Fatty Liver Disease.
    Hepatology. 2020;71:849-860.
    PubMed     Abstract available


  750. DE CHIARA F, Thomsen KL, Habtesion A, Jones H, et al
    Ammonia Scavenging Prevents Progression of Fibrosis in Experimental Nonalcoholic Fatty Liver Disease.
    Hepatology. 2020;71:874-892.
    PubMed     Abstract available


  751. CHANG Y, Ryu S, Kim Y, Cho YK, et al
    Low Levels of Alcohol Consumption, Obesity, and Development of Fatty Liver With and Without Evidence of Advanced Fibrosis.
    Hepatology. 2020;71:861-873.
    PubMed     Abstract available


  752. ABERG F, Puukka P, Salomaa V, Mannisto S, et al
    Risks of Light and Moderate Alcohol Use in Fatty Liver Disease: Follow-Up of Population Cohorts.
    Hepatology. 2020;71:835-848.
    PubMed     Abstract available


    February 2020
  753. NAULT JC, Villanueva A
    Biomarkers for hepatobiliary cancers.
    Hepatology. 2020 Feb 11. doi: 10.1002/hep.31175.
    PubMed     Abstract available


  754. DEROO R, Trepo E, Holvoet T, De Pauw M, et al
    Vasomodulators and liver transplantation for portopulmonary hypertension: evidence from a systematic review and meta-analysis.
    Hepatology. 2020 Feb 4. doi: 10.1002/hep.31164.
    PubMed     Abstract available


  755. GUILLOT A, Tacke F
    The Unexpected Role of Neutrophils for Resolving Liver Inflammation by Transmitting MicroRNA-223 to Macrophages.
    Hepatology. 2020;71:749-751.
    PubMed    


  756. PANDEY S
    Letter to the Editor: Re: Noninvasive Tests in Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Critical Insights from STELLAR Trials.
    Hepatology. 2020;71:763-764.
    PubMed    


  757. HASSAN S, Sebastian S, Maharjan S, Lesha A, et al
    Liver-on-a-Chip Models of Fatty Liver Disease.
    Hepatology. 2020;71:733-740.
    PubMed    


  758. SANDAHL TD, Laursen TL, Munk DE, Vilstrup H, et al
    The Prevalence of Wilson's Disease: An Update.
    Hepatology. 2020;71:722-732.
    PubMed     Abstract available


  759. ARASE Y, Tsuruya K, Hirose S, Ogiwara N, et al
    Efficacy and Safety of 3-Year Denosumab Therapy for Osteoporosis in Patients With Autoimmune Liver Diseases.
    Hepatology. 2020;71:757-759.
    PubMed    


  760. PENRICE D, Simonetto DA
    Nodular Regenerative Hyperplasia Associated With Primary Liver Malignancies.
    Hepatology. 2020;71:760-761.
    PubMed    


  761. BAIGES A, Turon F, Simon-Talero M, Tasayco S, et al
    Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation): An International Observational Study.
    Hepatology. 2020;71:658-669.
    PubMed     Abstract available


  762. SCHUMACHER JD, Kong B, Wu J, Rizzolo D, et al
    Direct and Indirect Effects of Fibroblast Growth Factor (FGF) 15 and FGF19 on Liver Fibrosis Development.
    Hepatology. 2020;71:670-685.
    PubMed     Abstract available


  763. ALLEN AM, Shah VH, Therneau TM, Venkatesh SK, et al
    The Role of Three-Dimensional Magnetic Resonance Elastography in the Diagnosis of Nonalcoholic Steatohepatitis in Obese Patients Undergoing Bariatric Surgery.
    Hepatology. 2020;71:510-521.
    PubMed     Abstract available


  764. ARORA V, Maiwall R, Rajan V, Jindal A, et al
    Terlipressin Is Superior to Noradrenaline in the Management of Acute Kidney Injury in Acute on Chronic Liver Failure.
    Hepatology. 2020;71:600-610.
    PubMed     Abstract available


    January 2020
  765. WALLACE D, Cowling T, PcPhail MJ, Brown SE, et al
    Assessing the time-dependent impact of performance status on outcomes after liver transplantation.
    Hepatology. 2020 Jan 22. doi: 10.1002/hep.31124.
    PubMed     Abstract available


  766. NEUSCHWANDER-TETRI BA
    Too Much Sugar-The Not-So-Sweet Reality of Its Impact on Our Health.
    Hepatology. 2020;71:377-379.
    PubMed    


  767. THALHEIMER U
    Letter to the Editor: The Obsolescence of Sclerotherapy.
    Hepatology. 2020;71:393.
    PubMed    


  768. CHEUNG AC, Walker DI, Juran BD, Miller GW, et al
    Studying the Exposome to Understand the Environmental Determinants of Complex Liver Diseases.
    Hepatology. 2020;71:352-362.
    PubMed    


  769. SHANG L, Mashek DG
    The Underpinnings of PNPLA3-Mediated Fatty Liver Emerge.
    Hepatology. 2020;71:375-377.
    PubMed    


  770. JANSSON-KNODELL CL, Gawrieh S, McIntyre AD, Liang T, et al
    Apolipoprotein B and PNPLA3 Double Heterozygosity in a Father-Son Pair With Advanced Nonalcoholic Fatty Liver Disease.
    Hepatology. 2020;71:383-385.
    PubMed    


  771. BALOG S, Li Y, Ogawa T, Miki T, et al
    Development of Capsular Fibrosis Beneath the Liver Surface in Humans and Mice.
    Hepatology. 2020;71:291-305.
    PubMed     Abstract available


  772. KWAN SY, Sheel A, Song CQ, Zhang XO, et al
    Depletion of TRRAP Induces p53-Independent Senescence in Liver Cancer by Down-Regulating Mitotic Genes.
    Hepatology. 2020;71:275-290.
    PubMed     Abstract available


  773. LAITINEN TT, Vahtera J, Pahkala K, Magnussen CG, et al
    Childhood Socioeconomic Disadvantage and Risk of Fatty Liver in Adulthood: The Cardiovascular Risk in Young Finns Study.
    Hepatology. 2020;71:67-75.
    PubMed     Abstract available


  774. GELLERT-KRISTENSEN H, Nordestgaard BG, Tybjaerg-Hansen A, Stender S, et al
    High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase-Lowering Effect of a HSD17B13 Variant.
    Hepatology. 2020;71:56-66.
    PubMed     Abstract available


    December 2019
  775. GAO E, Cheema H, Waheed N, Mushtaq I, et al
    OSTalpha deficiency: A disorder with cholestasis, liver fibrosis and congenital diarrhea.
    Hepatology. 2019 Dec 21. doi: 10.1002/hep.31087.
    PubMed     Abstract available


    November 2019
  776. GYORI GP, Pereyra D, Rumpf B, Hackl H, et al
    Von Willebrand factor facilitates MELD-independent risk stratification on the waiting list for liver transplantation.
    Hepatology. 2019 Nov 27. doi: 10.1002/hep.31047.
    PubMed     Abstract available


  777. LEE BP, Vittinghoff E, Pletcher MJ, Dodge JL, et al
    Medicaid Policy and Liver Transplant for Alcohol-Related Liver Disease.
    Hepatology. 2019 Nov 8. doi: 10.1002/hep.31027.
    PubMed     Abstract available


  778. KUTKUT I, Rachwan RJ, Timsina LR, Ghabril MS, et al
    Pre-Liver Transplant Cardiac Catheterization is Associated with Low Rate of Myocardial Infarction and Cardiac Mortality.
    Hepatology. 2019 Nov 7. doi: 10.1002/hep.31023.
    PubMed     Abstract available


  779. EATON JE, Vuppalanchi R, Reddy R, Sathapathy S, et al
    Liver Injury in Patients with Cholestatic Liver Disease Treated with Obeticholic Acid.
    Hepatology. 2019 Nov 4. doi: 10.1002/hep.31017.
    PubMed     Abstract available


    October 2019
  780. POLI E, Kounis I, Guettier C, Verstuyft C, et al
    Post-Liver Transplantation Sinusoidal Obstruction Syndrome With Refractory Ascites Induced by Mycophenolate Mofetil.
    Hepatology. 2019 Oct 9. doi: 10.1002/hep.30984.
    PubMed     Abstract available


  781. SHAHEEN R, Alsahli S, Ewida N, Alzahrani F, et al
    Biallelic mutations in TTC26 (IFT56) cause severe biliary ciliopathy in humans.
    Hepatology. 2019 Oct 8. doi: 10.1002/hep.30982.
    PubMed     Abstract available


    September 2019
  782. KIM YC, Jung H, Seok S, Zhang Y, et al
    MicroRNA-210 promotes bile acid-induced cholestatic liver injury by targeting mixed-lineage leukemia-4 methyltransferase in mice.
    Hepatology. 2019 Sep 24. doi: 10.1002/hep.30966.
    PubMed     Abstract available


  783. DUSZYNSKI CC, Avati V, Lapointe AP, Scholkmann F, et al
    Near infrared spectroscopy reveals brain hypoxia and cerebrovascular dysregulation in primary biliary cholangitis.
    Hepatology. 2019 Sep 19. doi: 10.1002/hep.30920.
    PubMed     Abstract available


  784. ASRANI SK, Jennings LW, Kim WR, Kamath P, et al
    MELD-GRAIL-Na: Glomerular filtration rate and mortality on Liver-Transplant Waiting List.
    Hepatology. 2019 Sep 16. doi: 10.1002/hep.30932.
    PubMed     Abstract available


  785. BI X, Deising A, Frenette C
    Acute Liver Failure from Exertional Heatstroke Can Result in Excellent Long-term Survival with Liver Transplantation.
    Hepatology. 2019 Sep 11. doi: 10.1002/hep.30938.
    PubMed     Abstract available


  786. TARDELLI M, Bruschi FV, Fuchs CD, Claudel T, et al
    Monoacylglycerol lipase inhibition protects from liver injury in mouse models of sclerosing cholangitis.
    Hepatology. 2019 Sep 10. doi: 10.1002/hep.30929.
    PubMed     Abstract available


    August 2019
  787. KWON HM, Moon YJ, Jung KW, Park YS, et al
    Appraisal of cardiac ejection fraction with liver disease severity: Implication in post-liver transplantation mortality.
    Hepatology. 2019 Aug 28. doi: 10.1002/hep.30913.
    PubMed     Abstract available


  788. BEUERS U, Hohenester S
    Fatigue in Primary Biliary Cholangitis: no Place for Rituximab.
    Hepatology. 2019 Aug 23. doi: 10.1002/hep.30906.
    PubMed     Abstract available


  789. MOHANTY SK, Lobeck I, Donnelly B, Dupree P, et al
    Rotavirus reassortant induced murine model of liver fibrosis parallels human biliary atresia.
    Hepatology. 2019 Aug 23. doi: 10.1002/hep.30907.
    PubMed     Abstract available


    July 2019
  790. KYRITSI K, Chen L, O'Brien A, Francis H, et al
    Modulation of the TPH1/MAO-A/5HT/5HTR2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis.
    Hepatology. 2019 Jul 25. doi: 10.1002/hep.30880.
    PubMed     Abstract available


  791. CHOUDHARY NS, Saigal S, Soin AS
    Liver transplantation for Acute Liver Failure due to Dengue fever: first successful reported case worldwide.
    Hepatology. 2019 Jul 22. doi: 10.1002/hep.30869.
    PubMed     Abstract available


  792. MARRERO JA
    Obesity and Liver Disease: The New Era of Liver Transplantation.
    Hepatology. 2019 Jul 13. doi: 10.1002/hep.30854.
    PubMed     Abstract available


    June 2019
  793. FIRL DJ, Sasaki K, Agopian VG, Gorgen A, et al
    Charting the Path Forward for Risk Prediction in Liver Transplant for HCC: International Validation of HALTHCC amongst 4,089 patients.
    Hepatology. 2019 Jun 27. doi: 10.1002/hep.30838.
    PubMed     Abstract available


  794. CAREY EJ, Lai JC, Sonnenday C, Tapper EB, et al
    A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation.
    Hepatology. 2019 Jun 20. doi: 10.1002/hep.30828.
    PubMed     Abstract available


  795. GALANTE A, Adeyi O, Lau L, Humar A, et al
    Liver transplantation for Acute Liver Failure due to Dengue fever: first successful reported case worldwide.
    Hepatology. 2019 Jun 4. doi: 10.1002/hep.30803.
    PubMed     Abstract available


    May 2019
  796. TERZIROLI BERETTA-PICCOLI B, Thompson R, Foskett P, Cerny A, et al
    A novel heterozygous ABCB4, RUNDC3B and ABCB1 deletion associated with severe cholestatic liver disease in adulthood.
    Hepatology. 2019 May 24. doi: 10.1002/hep.30783.
    PubMed     Abstract available


  797. SIEW SM, Cunningham SC, Zhu E, Tay SS, et al
    Prevention of cholestatic liver disease and reduced tumorigenicity in a murine model of PFIC type 3 using hybrid AAV-piggyBac gene therapy.
    Hepatology. 2019 May 17. doi: 10.1002/hep.30773.
    PubMed     Abstract available


  798. XIAO Y, Liu R, Li X, Gurley EC, et al
    Long non-coding RNA H19 contributes to cholangiocyte proliferation and cholestatic liver fibrosis in biliary atresia.
    Hepatology. 2019 May 7. doi: 10.1002/hep.30698.
    PubMed     Abstract available


    April 2019
  799. LEVITSKY J, Asrani SK, Abecassis M, Ruiz R, et al
    External Validation of a Pre-Transplant Biomarker Model (REVERSE) Predictive of Renal Recovery after Liver Transplantation.
    Hepatology. 2019 Apr 19. doi: 10.1002/hep.30667.
    PubMed     Abstract available


    March 2019
  800. WANG C, Zheng X, Jiang P, Tang R, et al
    Genome Wide Association Studies of Specific Antinuclear Autoantibody Sub-phenotypes in Primary Biliary Cholangitis.
    Hepatology. 2019 Mar 10. doi: 10.1002/hep.30604.
    PubMed     Abstract available


    February 2019
  801. SINHA J, Mehta N, Dodge JL, Poltavskiy E, et al
    Are There Upper Limits in Tumor Burden for Down-staging of HCC to Liver Transplant? Analysis of the All-comers Protocol.
    Hepatology. 2019 Feb 19. doi: 10.1002/hep.30570.
    PubMed     Abstract available


    January 2019
  802. HEERKENS M, Dedden S, Scheepers H, Van Paassen P, et al
    Effect of plasmapheresis on cholestatic pruritus and autotaxin activity during pregnancy.
    Hepatology. 2019 Jan 7. doi: 10.1002/hep.30496.
    PubMed     Abstract available


    December 2018
  803. FUNKE K, Rockey DC
    Cholestatic drug induced liver injury caused by mifepristone.
    Hepatology. 2018 Dec 18. doi: 10.1002/hep.30465.
    PubMed     Abstract available


  804. GONG S, Yan Z, Liu Z, Niu M, et al
    Intestinal microbiota mediates the susceptibility to polymicrobial sepsis-induced liver injury by granisetron generation in mice.
    Hepatology. 2018 Dec 1. doi: 10.1002/hep.30361.
    PubMed     Abstract available


    November 2018
  805. SANTAMARIA E, Rodriguez-Ortigosa CM, Uriarte I, Latasa MU, et al
    The epidermal growth factor receptor ligand amphiregulin protects from cholestatic liver injury and regulates bile acids synthesis.
    Hepatology. 2018 Nov 8. doi: 10.1002/hep.30348.
    PubMed     Abstract available


    September 2018
  806. SONG ATW, Abdala E, de Martino RB, Malbouisson LMS, et al
    Liver transplantation for fulminant hepatitis due to yellow fever.
    Hepatology. 2018 Sep 15. doi: 10.1002/hep.30273.
    PubMed     Abstract available


    August 2018
  807. GORGIS NM, Kennedy C, Lam F, Thompson K, et al
    Clinical Consequences of Cardiomyopathy in Children with Biliary Atresia Requiring Liver Transplantation.
    Hepatology. 2018 Aug 3. doi: 10.1002/hep.30204.
    PubMed     Abstract available


  808. LINDOR KD, Bowlus CL, Boyer J, Levy C, et al
    Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30145.
    PubMed     Abstract available


    July 2018
  809. LOOMES KM, Spino C, Goodrich NP, Hangartner TN, et al
    Bone Density in Children with Chronic Liver Disease Correlates with Growth and Cholestasis.
    Hepatology. 2018 Jul 31. doi: 10.1002/hep.30196.
    PubMed     Abstract available


  810. SAYINER M, Golabi P, Stepanova M, Younossi I, et al
    Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Utilization.
    Hepatology. 2018 Jul 17. doi: 10.1002/hep.30174.
    PubMed     Abstract available


    May 2018
  811. KHANNA A, Jopson L, Howel D, Bryant A, et al
    Rituximab is Ineffective for Treatment of Fatigue in Primary Biliary Cholangitis: A phase-2 Randomised Controlled Trial.
    Hepatology. 2018 May 23. doi: 10.1002/hep.30099.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: